

---

# **CASEIN PHOSPHOPEPTIDES AS POSSIBLE NUTRACEUTICALS FOR FUNCTIONAL FOODS**

---

**Gabriella Pinto**

Dottorato in Scienze Biotechnologiche – XXII ciclo  
Indirizzo Biotechnologie industriale  
Università di Napoli Federico II





Dottorato in Scienze Biotecnologiche – XXII ciclo  
Indirizzo Biotecnologie industriale  
Università di Napoli Federico II



---

# **CASEIN PHOSHOPEPTIDES AS POSSIBLE NUTRACEUTICALS FOR FUNCTIONAL FOODS**

---

**Gabriella Pinto**

Dottoranda: Gabriella Pinto

Relatore: Prof. Francesco Addeo

Coordinatore: Prof. Ettore Benedetti



*"La scienza deve abbandonare il terreno dell'incontrollata genialità individuale, del caso, dell'arbitrario, della sintesi affrettata e procedere sulla base di uno sperimentalismo fondato sulla consapevolezza della natura strumentale delle facoltà conoscitive...la conquista di verità nuove non può essere opera del singolo, ma solo di una collettività di scienziati organizzata a questo scopo".*

Francis Bacon



## INDICE

<b>1. Riassunto</b>	pag.	1
<b>2. Summary</b>	pag.	6
<b>3. Introduction</b>	pag.	7
<b>4. Bioactive Peptides</b>	pag.	8
4.1 Antithrombotic peptides	pag.	8
4.2 Antihypertensive peptides	pag.	9
4.3 Opioid peptides	pag.	11
4.4 Immunomodulating peptides	pag.	12
4.5 Antimicrobial peptides	pag.	13
4.6 Glycomacropeptide	pag.	14
<b>5. The object of study of this PhD work. Bioactive casein phosphopeptides</b>	pag.	15
<b>6. Possible use of CPP for industrial applications</b>	pag.	17
<b>7. Techniques for phosphopeptide enrichment for industrial applications</b>	pag.	19
<b>8. Development of a new enrichment technique</b>	pag.	22
<b>9. Experimental procedure 1</b>	pag.	23
<b>10. Results and discussion</b>	pag.	25
<b>11. Formulation of a functional drink in semi-industrial scale</b>	pag.	35
<b>12. Experimental procedure 2</b>	pag.	36
<b>13. Results and discussion</b>	pag.	37
<b>14. Quantification of CPP in HAS-CPP preparation to be added to milk</b>	pag.	43
<b>15. Evaluation of the quality of used milk for CPP preparation</b>	pag.	49
<b>16. Experimental procedure 3</b>	pag.	50
<b>17 Results and discussions</b>	pag.	51
17.1 Dephosphorylation kinetic	pag.	51
17.2. Analysis of proteins and CPP occurring in mastitic milk	pag.	58
<b>18. Use of CPP as process markers</b>	pag.	68
<b>19. Experimental procedure 4</b>	pag.	69
<b>20. Results and discussion</b>	pag.	69
<b>21. Conclusions</b>	pag.	73
<b>22. References</b>	pag.	74





## 1. Riassunto

Nella sequenza delle proteine del latte sono criptati peptidi cosiddetti 'bioattivi', di lunghezza variabile tra 3 e 20 residui amminoacidici, rilasciati per digestione enzimatica *in vivo* od *in vitro*.

È stato dimostrato che, a seconda della sequenza amminoacidica, essi possono esplicare attività specifiche in diverse classi di prodotti naturali o sintetici del tipo antitrombotico, antiipertensivo, oppioide, immunomodulante ed antimicrobico (1).

Oggetto della tesi di dottorato è la preparazione, a livello di laboratorio ed a livello di impianto pilota, di una classe di peptidi bioattivi, suscettibili di utilizzazione industriale come ingrediente nutraceutico. Nutraceutico è un termine, derivante dalla unione di "nutrizione" e "farmaceutico", col quale si designano alimenti o nutrienti estratti dagli alimenti che svolgono sia azione di prevenzione di patologie sia azione benefica sulla salute umana. Questa categoria di peptidi bioattivi comprende i fosfopeptidi della caseina bovina.

I fosfopeptidi (CaseinoPhosphoPeptides, CPP) sono rilasciati dalla caseina, a seguito di idrolisi enzimatica delle frazioni caseiniche  $\kappa$ -,  $\alpha_{s1}$ -,  $\alpha_{s2}$ -, e  $\beta$ -CN (2). Essi sono caratterizzati da una sequenza consenso del tipo SerP-X-SerP/ThrP/Glu/Asp, dove X è un qualsiasi residuo amminoacidico eccetto Pro e non contengono residui di tirosina e di istidina fosforilati. Una sequenza comune alle frazioni  $\alpha_{s1}$ -,  $\alpha_{s2}$ -, e  $\beta$ -CN è -Ser(P)-Ser(P)-Ser(P)-Glu-Glu- (3). I CPP sono interessanti perché sopravvivono al passaggio gastrointestinale (4) e si ritrovano nello stomaco, nel duodeno e nell'ileo distale dopo ingestione di latte (5). Fungono da trasportatori di cationi minerali di- o trivalenti, aumentandone la biodisponibilità per l'assorbimento nel piccolo intestino (6). È stato, infatti, dimostrato che i CPP, in particolare i peptidi (1-25)4P della  $\beta$ -caseina e (59-79)5P dell' $\alpha_{s1}$ -caseina, aumentano l'*uptake* di calcio in cellule tumorali umane differenziate in senso enterocitico (HT-29) (7), nelle cellule Caco2 (8), e negli osteoblasti (9). Questi dati ci hanno suggerito la possibilità di utilizzare i CPP come vettori di  $\text{Ca}^{2+}$  in alimenti funzionali per aumentarne la biodisponibilità nello sviluppo dell'organismo, nella calcificazione delle ossa e nella prevenzione dell'osteoporosi.

E' stato poi dimostrato che i CPP sono capaci di stabilizzare le soluzioni di fosfato di calcio amorfo (ACP), formando piccoli *cluster* del tipo CPP-ACP, fino ad una taglia-limite, oltrepassata la quale il fosfato di calcio comincia a precipitare con formazione di nuclei cristallini (10). Il meccanismo di azione sarebbe il seguente: i CPP trasportano l'ACP sulla superficie del dente, inibendo la demineralizzazione dello smalto dentale e promuovono la rimineralizzazione delle lesioni superficiali (11). Essi svolgono anche un ruolo indiretto nel contrasto alla carie, impedendo l'adesione alla superficie del dente di *Streptococcus mutans* o di altri streptococchi (12).

Il complesso CPP-ACP, ideato da Eric Reynolds dell'Università di Melbourne, è commercializzato come prodotto per la cura orale (Recaldent<sup>TM</sup>) e viene aggiunto come ingrediente nutraceutico in gomma masticante (Trident White Gum), paste dentifriche (GC Tooth Mousse) ed in altri prodotti.

Esistendo sul mercato preparazioni commerciali di CPP (Arla, Danimarca, Tatu, Nuova Zelanda), è stata fatta un'indagine conoscitiva tesa a stabilirne la composizione in CPP. L'analisi mediante MALDI ha rivelato che i due prodotti commerciale sono costituiti in effetti da una miscela di CPP e di peptidi non fosforilati. Non essendo conosciuto il sistema di preparazione di questi prodotti, è probabile che l'innovazione operata da queste industrie a livello di prodotto sia stata

l'utilizzazione di uno o più enzimi in sequenza per generare CPP. Le preparazioni commerciali contengono infatti peptidi a diversa taglia molecolare cosa che indica una procedura differente di preparazione. Non esistendo sul mercato un preparazione di CPP esente da peptidi non fosforilati, l'obiettivo della tesi è stato quello di elaborare un procedimento per ottenere CPP ad elevata concentrazione, cioè peptidi a diverso grado di fosforilazione, presenti nella caseina nativa, esenti da peptidi non fosforilati.

La prima parte del lavoro è stata, quindi, focalizzata sull'individuazione di una metodologia di frazionamento degli idrolizzati enzimatici di caseina per il raggiungimento dell'obiettivo prefissato. Sono stati considerati diversi procedimenti di arricchimento dei CPP: a) precipitazione come sali di bario insolubili (13); b) derivatizzazione chimica (14); c) cromatografia di affinità su c1) ioni metallici immobilizzati (IMAC) (15); c2) su ossidi di metallo (MOC) (16).

La derivatizzazione chimica dà basse rese di prodotto ed un prodotto finale più complesso di quello iniziale (17). Le tecniche cromatografiche IMAC e MOC consentono di arricchire la preparazione in CPP, ma recuperano anche peptidi non fosforilati di natura acida (18). L'accoppiamento di resine con ossidi di metallo modificati da idrossiacidi alifatici (19), l'impiego di tamponi di caricamento su  $\text{TiO}_2$  contenenti acido 2,5-p-idrossibenzoico (DHB) (18), la precipitazione con fosfato di calcio accoppiato all'arricchimento IMAC (20), la combinazione di cromatografia a scambio cationico (SCX) e scambio anionico (SAX) (21) si sono dimostrati capaci di arricchire, su base analitica, le preparazioni di CPP, ma non sono scalabili allo stato industriale. Tuttavia, nessuno dei sistemi analitici sperimentati potrebbe trovare applicazione alimentare, sostanzialmente per tre ragioni: a) la matrice a cui sono legati i CPP non è edibile; b) l'eluizione di CPP dalla matrice richiede sistemi di purificazione molto lunghi e costosi; c) l'aggiunta all'alimento dei CPP eluiti altera il gusto conferendo una marcata nota di amaro, anche per la capacità dei CPP di chelare gli ioni minerali con cui viene a contatto.

La seconda parte del lavoro è stata rivolta alla messa a punto di una tecnica di arricchimento specifica per fosfoproteine e peptidi fosforilati, allo scopo di disporre di un procedimento preparativo di CPP da utilizzare successivamente come ingrediente in alimenti funzionali. L'idea è stata quella di sviluppare una tecnica analitica da adattare successivamente a fini preparativi. Essa prevede l'impiego come matrice cromatografica dell'idrossiapatite (HA), una forma cristallina di fosfato di calcio  $[\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2]$ , rinvenibile nel tessuto osseo e dentale, largamente impiegata in medicina per protesi ortopediche e dentali, per favorire la completa integrazione del metallo nel tessuto osseo umano. Il meccanismo di funzionamento dell'HA prevede che i gruppi carichi negativamente delle proteine (gruppi carbossilici e fosfato) interagiscano con gli ioni  $\text{Ca}^{2+}$  (C-sites) del reticolo cristallino formando legami di tipo elettrostatico (22). Le proteine fosforilate vengono in tal modo immobilizzate sulla resina, mentre quelle non fosforilate vengono allontanate mediante lavaggio con tamponi di opportuna composizione. L'affinità delle frazioni caseiniche per l'adsorbente è tanto maggiore quanto maggiore è il grado di fosforilazione della proteina (22). Abbiamo dimostrato che l'affinità dei CPP nei riguardi dell'HA è simile a quella esibita dalle fosfoproteine. In dettaglio, si è trovato che l'HA lega i fosfopeptidi presenti, in quantità anche sub-stechiometrica, in miscele complesse di peptidi. Se si dispone di fosfoproteine genitrici legate all'HA, si possono generare *in situ*, a mezzo di un'opportuna idrolisi enzimatica, i corrispondenti fosfopeptidi. I CPP rimangono legati alla resina, mentre tutti quelli non fosforilati, ad esempio  $\alpha_{s1}$ -CN (f91-100) (m/z 1266.7) e  $\alpha_{s1}$ -CN (f8-22) (m/z 1758.9), presi come esempi di peptidi

acidi non fosforilati, vengono allontanati con i tamponi di lavaggio. Per sviluppare il corrispondente procedimento industriale è stato ideato un metodo a livello di laboratorio. Si produce un'idrolisi triptica della caseina fresca legata all'HA. I CPP rimangono legati all'HA, mentre i peptidi non fosforilati vengono allontanati con lavaggi, fino ad ottenere un prodotto lavato con acqua distillata. Il prodotto viene, poi, essiccato per la conservazione della polvere per tempi dell'ordine di anni a temperatura ambiente.

È stato, poi, affrontato il problema di stabilire quali peptidi rimangano legati alla resina. Per questo è stato elaborato un sistema di controllo di qualità della preparazione, utilizzando tecniche di spettrometria di massa quali MALDI-TOF, LC-ESI/MS e LC-ESI-MS/MS. Abbiamo dimostrato che ognuna di queste tecniche consente di caratterizzare i CPP legati alla resina. Dallo studio è risultato che la resina immobilizza una pletora di peptidi, tra cui i CPP con fosforilazione multipla del tipo  $\alpha_{s1}$ -CN (f59-79)5P (2720.91 Da),  $\beta$ -CN (f1-25)4P (3122.26 Da) e  $\alpha_{s2}$ -CN (f46-70)5P (3087.99 Da), ognuno caratterizzato dalla sequenza *cluster* (Ser(P)-Ser(P)-Ser(P)-Glu-Glu), funzionale al trasporto di ioni metallici.

La preparazione del complesso HA-CPP, in scala semi-industriale, ha suggerito di sintetizzare l'HA, a causa degli elevati costi di questo materiale, invece che utilizzare il costoso prodotto commerciale. Pertanto, l'HA è stata sintetizzata per via umida a partire da  $\text{Ca}(\text{OH})_2$  e  $\text{H}_3\text{PO}_4$ , utilizzando condizioni di temperatura e pH ottimali, per l'ottenimento di cristalli di apatite pura. La capacità legante della resina sintetizzata è stata valutata confrontando la capacità legante dei CPP in 3 diverse miscele proteiche: caseina isoelettrica, proteine del latte (caseine + sieroproteine non fosforilate) e latte. L'analisi MALDI-TOF ha evidenziato la cattura, da parte dell'HA sintetica, degli stessi CPP, in quantità simili, nonostante la diversa complessità della matrice di partenza. La prova ha, quindi, dimostrato che il procedimento è scalabile per fini industriali. Una volta ottenuto il complesso HA-CPP su scala pilota, si è passati alla progettazione di un alimento funzionale. È stato scelto come alimento funzionale il latte poiché l'aggiunta al latte di quantità variabili tra 2.0 e 5.0g del complesso CPP-ACP/itro aumenta la capacità dei CPP a ripristinare la mineralizzazione delle lesioni dello smalto dentale (23), facendo aumentare rispettivamente dell' 81% e del 164% il contenuto in minerali (calcio e fosfato) del latte "nativo" (24). Naturalmente, data la maggiore densità, i granuli di HA-CPP, prima dell'aggiunta al latte, sono stati finemente triturati per evitare l'immediata sedimentazione nel latte. Tuttavia, prima del consumo, la bevanda deve essere agitata, per rendere omogenea la sospensione. Una volta agitata, la bevanda arricchita di CPP ha mostrato le stesse caratteristiche sensoriali del latte di partenza, in quanto i gruppi fosfato dei CPP sono neutralizzati dagli ioni calcio dei cristalli di HA. Il complesso HA-CPP è inodore ed insapore. Nelle prove di recupero dei granuli di HA aggiunti al latte mediante centrifugazione, l'analisi MALDI dei granuli ha mostrato che l'HA è capace di legare i CPP liberi e la caseina solubile del latte. In altre prove, i granuli di HA-CPP aggiunti al latte si sono rivelati capaci di mantenere legati i CPP della preparazione e di chelare anche i CPP liberi del latte.

Per stabilire la quantità di CPP aggiunta nel latte, è stato affrontato il problema di un dosaggio quantitativo applicabile ad una qualsiasi matrice alimentare. Sono stati scelti come modello per la valutazione quantitativa i CPP del tipo monofosforilato,  $\alpha_{s1}$ -CN (f106-119)1P con sequenza VPQLEIVPNpSAEER, e difosforilato,  $\alpha_{s1}$ -CN (f43-58)2P con sequenza DIGpSEpSTEDQAMEDIK. Il metodo quantitativo si basa sull'utilizzo di standard interni a base di fosfopeptidi sintetici analoghi a quelli naturali. E' stato verificato che il peptide naturale e quello analogo

sintetico, modificato in un solo sito amminoacidico, ionizzano allo stesso modo. I peptidi sintetici utilizzati si sono rivelati, dunque, idonei a fungere da standard interno per l'analisi quantitativa dei CPP monofosforilati e difosforilati. La misura delle aree sottese dalle coppie di picchi MALDI/MS dei peptidi monoP e diP ha consentito di costruire delle rette di calibrazione. Utilizzando tale sistema analitico si è potuto stabilire sia la quantità di CPP presente nel complesso HA-CPP, sia quella aggiunta nel latte da rendere funzionale.

Nella terza parte del lavoro di tesi, è stato affrontato il problema della valutazione della qualità della preparazione sperimentale a base di CPP. Com'è noto, la presenza di proteasi attive nel latte, a seguito di stati patologici della ghiandola mammaria, si riflette sia sulla integrità (proteolisi) sia sul livello di fosforilazione della caseina. La defosforilazione è una delle modifiche post-traslazionali più rilevanti dal punto di vista biologico perché, tra l'altro, altera la funzionalità della caseina, rendendola meno adatta a caseificazione ed a fungere da ingrediente per la preparazione di CPP. In un latte con elevato numero di cellule somatiche, è stata dimostrata una spinta degradazione proteolitica ad opera degli enzimi idrolitici sia endogeni che derivati dalle stesse cellule somatiche. Abbiamo potuto stabilire su base molecolare che latte proveniente da animali affetti da mastite è caratterizzato da un profilo caseinico alterato per l'aumento di attività della fosfatasi (25) e della plasmina (26), responsabili rispettivamente della defosforilazione e dell'idrolisi delle frazioni caseiniche. Questi tipi di alterazione delle micelle di caseina abbassano la qualità del latte alimentare e la resa casearia. Per valutare la qualità della caseina in un latte mastitico, abbiamo utilizzato l'HA per valutare la chelazione delle fosfoproteine e dei CPP da parte dell'adsorbente. Lo studio con tecniche MALDI-MS ed ESI-Q-TOF ha messo in evidenza la comparsa di frazioni caseiniche con un ampio intervallo di fosforilazione. Ad esempio, la  $\beta$ -CN 6P e 5P, allo stato nativo, si trasformava in proteina con grado di fosforilazione variabile da 6 a 3P. Inoltre, è stata rilevata la comparsa di frammenti proteici prodotti dall'azione della plasmina e da altri enzimi associati con le cellule somatiche (cathepsine, elastasi, etc).

I CPP possono essere anche fungere da marcatori di processo. In prodotti stagionati come il formaggio Grana Padano, infatti, i CPP subiscono una degradazione più o meno spinta ad opera di proteinasi/peptidasi e fosfatasi alcalina ed acida, a seconda della zona in cui il campione analizzato è stato prelevato, parte esterna o parte interna della forma. La parte centrale del formaggio, durante la lavorazione, subisce un'auto-pastorizzazione, mentre la parte esterna, raffreddandosi più velocemente dalla temperatura di lavorazione (circa 55° C), contiene livelli di fosfatasi residua di circa 10-100 volte superiori. Poiché il Disciplinare di produzione del formaggio prevede l'uso di latte crudo, ogni lavorazione con latte pastorizzato (attività fosfatasica negativa) produrrà un'attività di fosfatasi uguale, indipendentemente dalla zona di prelievo del campione nella forma. In un lavoro precedente si era messo in evidenza che nel Grana Padano DOP, le fosfatasi, aminopeptidasi e carbossipeptidasi del formaggio producono una progressiva defosforilazione e idrolisi dei CPP derivati dall'azione idrolitica della plasmina, fino a fornire peptidi contenenti il cluster Ser(P)-Ser(P)-Ser(P)-Glu-Glu, più resistente alla digestione enzimatica *in vivo* di altri peptidi mono-P e di-P (27). La nostra tecnica di arricchimento dei CPP mediante l'utilizzazione di HA per lo studio dei CPP nella frazione solubile a pH 4.6, ha confermato l'esistenza di un profilo dipendente da una diversa attività enzimatica tra parti interne ed zona esterna nelle forme di formaggio Grana Padano (28). Abbiamo trovato che il profilo dei CPP riflette il gradiente termico centripeto con differenza di raffreddamento tra zone esterne ed interne della forma,

con inattivazione centripeta degli enzimi del formaggio. Nella parte esterna della forma abbiamo dimostrato che i CPP subiscono una defosforilazione più spinta che nelle zone interne.

In conclusione, nel corso del dottorato, è stata sviluppata una selettiva tecnica di arricchimento di componenti fosforilati, a partire da miscele complesse di proteine e peptidi. I peptidi fosforilati della caseina sonostati, poi, utilizzati per la formulazione di un latte funzionale contenente microgranuli di HA-CPP, utili per la cura della carie dentaria e per veicolare microelementi (ioni rame, ferro, selenio, etc.). La tecnica analitica elaborata è suscettibile di applicazione generale per lo studio del fosfoproteoma. Lo studio della fosforilazione proteica ha consentito, inoltre, di affrontare uno degli aspetti della qualità delle proteine, sulla base del loro grado di fosforilazione. In questa direzione, il metodo analitico si presta a fornire informazioni dettagliate sulla valutazione della genuinità di latte alimentare e di formaggio.

## Bibliografia

1. FitzGerald, R. J., *et al.* 2003 In: P.F. Fox, & P.L.H. McSweeney (Eds.), *Advanced dairy chemistry*, Vol. 1: Proteins (3rd ed.), 675–698.
2. Kitts, D. *et al.* 1994 *J. Physiol. Pharmacol.* 72, 423–434
3. Meisel, H. *et al.* 1995 *Nahrung* 39, 1-20
4. Chabance, B. *et al.* 1998 *Biochimie* 80(2), 155–16
5. Meisel, H., *et al.* 2003 *British Journal of Nutrition* 89(3), 351–359
6. FitzGerald, R. J. *et al.* 1998 *Int. Dairy J.* 8, 451–457
7. Ferraretto, A. *et al.* 2001 *Journal of Nutrition* 131(6), 1655–1661.
8. Ferraretto A. *et al.* 2009 *Journal of Nutritional Biochemistry*, article in press.
9. Ferraretto A. *et al.* 2009 *Peptides*, article in Press.
10. Holt, C. *et al.* 1998 *J. Dairy Sci.* 81, 2994-3003.
11. Reynolds, E.C. *et al.* 1997 *J. Dent. Res.* 76, 1587-1595.
12. Rose, R. K. *et al.* 2000 *Arch. Oral. Biol.* 45, 569-57.
13. Manson, W. *et al.* 1971 *Archives of Biochemistry and Biophysics* 145, 16-26.
14. Oda Y. *et al.* 2001 *Nat. Biotechnol.* 19, 379–382.
15. Posewitz, M. C. *et al.* 1999 *Anal. Chem.* 71, 2883–2892.
16. Pinkse, M. W. *et al.* 2004 *Anal. Chem.* 76, 3935–3943.
17. Zhou, H. *et al.* 2001 *Nat. Biotechnol.* 19, 375–378.
18. Roepstorff P. *et al.* 2005 *Mol Cell Proteomics* 4(7), 873-86.
19. Sugiyama N. *et al.* 2007 *Mol Cell Proteomics* 6(6), 1103-1109.
20. Roepstorff P. *et al.* 2007 *Mol Cell Proteomics* 6(11), 2032-2042.
21. Guanghui Han *et al.* 2008 *Analyst.* 133, 1128–1138.
22. Schmidt S. R. *et al.* 2007 *Journal of Chrom. B* 849, 154–162.
23. Walker G, *et al.* 2006 *J. Dairy Res.* 73, 74–78.
24. Walker GD *et al.* 2009 *Australian Dental J.* 54, 245–249.
25. Babaei H. *et al.* 2007 *Veterinary Research Communications* 31, 419-425.
26. Leitner G. *et al.* 2004 *J. Dairy Sci.* 87, 46-52.
27. Addeo *et al.* 1997 *J. Dairy Res.* 64, 601-615
28. Addeo *et al.* 1997 *Lait* 77, 217-228.

## 2. Summary

In the present PhD work, the results affording the formulation of a new functional drink are presented using as nutraceutical component a preparation of caseinophosphopeptides (CPP). CPP as well as other source bioactive peptides are encrypted within the sequence of a protein. The CPP, produced in vivo or in vitro by enzymatic hydrolysis of casein, are phosphopeptides containing SerP or ThrP residues occurring mainly in the SerP-X-SerP/ThrP/Glu/Asp clusters where X is any amino acid residue except Pro. The phosphorylated cluster sequence Ser(P)-Ser(P)-Ser(P)-Glu-Glu occurs in most of the CPP, serving as the binding site for di- or trivalent minerals.

We were interested to CPP for their ability to form soluble organophosphate salts and may function as mineral carriers, especially for calcium, preventing calcium precipitation as insoluble calcium phosphate. This suggests the possibility that CPP, increasing solubility of calcium, may enhance absorption of calcium. It has been demonstrated that CPP play a key role in bone mineralization and dental enamel recalcification.

In the first part of PhD work, various chromatographic adsorbents for immobilizing metal ion (IMAC) and metal oxide affinity chromatography (MOAC) have been evaluated for obtaining phosphorylated peptides in mixtures. However, none of the above indicated analytical system is suitable for milk fortification with CPP.

In the second part of the thesis, a new selective technique for CPP enrichment based on hydroxyapatite (HA) chromatography has been developed for obtaining functional milk. This technique is the most appropriate for CPP enrichment using casein as source of highly phosphorylated protein. Therefore, casein is particularly suitable for the CPP extraction from complex mixtures of phosphocaseins. The structure of CPP was determined by MALDI-TOF and LC-MS analysis and confirmed by LC-ESI-MS/MS sequencing. Once confirmed the purity of the mixture, CPP in semi-industrial scale preparation was realized. In order to reduce production costs, HA (HAS) was synthesized and used for the enrichment of CPP using 3 different protein mixtures as substrate. The selection of casein, milk proteins or raw milk was chosen on the basis of the specific industrial needs. In any case, the HAS-CPP complex needed to be finely ground for milk fortifying. Whatever the source of casein, the sensory properties of CCP-complex were compatible with the use of the novel formulation as functional ingredient. To know the amount of CPP produced in various experimental different sources of casein, some CPP were used as internal standards. The latter included one-site modified synthetic monophosphorylated  $\alpha_{s1}$ -CN (106-119) and diphosphorylated,  $\alpha_{s1}$ -CN (43-58)2P peptides. Using these internal standards, the two natural phosphopeptide counterparts were quantified.

In the third part of this PhD thesis, the quality of CPP preparation has been evaluated. The study has been focused on the casein phosphorylation as index of the protein quality. The phosphoproteomic approach has allowed to detect anomalous milk such as the mastitic milk and mechanisms of dephosphorylation in Protected Denomination of Origin Grana Padano (GP) cheese. In both the cases, the composition of pH 4.6 soluble CPP or pH 4.6 insoluble caseins was suitable to provide information on milk and cheese genuineness. The phosphoproteomics in the presented version should be applicable to a variety of biological systems mainly in medicine and biology.

### 3. Introduction

Milk is rich in a variety of essential nutrients and is considered as a basic food. The major bovine milk proteins are classified into two classes: *casein* and *whey proteins*. The main group of milk proteins are the caseins accounting for ca. 80% total proteins milk subdivided into four families named  $\alpha_{s1}$ -casein (34%),  $\beta$ -casein (34%),  $\alpha_{s2}$ -casein (15%), and  $\kappa$ -casein (14%). Each fractions show genetic polymorphism and post-translational modification with phosphorylation and/or glycosylation (only  $\kappa$ -casein). All the other milk proteins (ca. 20%) are grouped under the name of whey proteins. The major bovine whey proteins are  $\beta$ -lactoglobulin and  $\alpha$ -lactalbumin. Whey, the pH 4.6 soluble fraction of milk, also contains substantial amounts of immunoglobulins (IgGs), serum albumin, which are filtered by the mammary gland and secreted into milk. Due to the presence of plasmin, an indigenous endopeptidase of milk,  $\beta$ -casein is processed throughout the *N*- and *C*-terminal end. The *C*-terminal peptides, designed in the nomenclature as  $\gamma$ -casein, co-precipitate with native casein by lowering milk pH to 4.6. The *N*-terminal peptides, called proteose-peptones are heat-stable to heat treatments at variance with whey proteins which are very sensitive to heating. Moreover, they are acid-insensitive being the proteose-peptones for the main part phosphorylated peptides.

Milk has long been considered only as food protein source for young mammals because milk proteins are the principal source of amino acids. However, milk proteins, in addition to a nutritional role have physiological importance and source of biologically active peptides. Bioactive peptides are defined those peptides produced *in vivo* or *in vitro* by enzymatic hydrolysis exerting *in vivo* biological functions or physiological effects. During the last two decades, the presence of peptides with biological activity has been demonstrated. These peptides, which are inactive within the sequence of the parent protein, can be released by enzymatic hydrolysis, for example, during the gastrointestinal digestion or in the food manufacturing. In fermented milk or ripened cheese, proteolysis leads to the formation of various peptides, some of which can exhibit themselves a biological activity or as precursors can release active forms of biological peptides. Once they are liberated in the body, bioactive peptides may act as regulatory compounds with hormone-like activity. These peptides usually contain 3-20 amino acid residues per molecule and their function is generated by their particular primary sequence. Thus, these peptides represent health enhancer nutraceuticals potentially functional to foods. Although other animal, as well as plant, protein contain potential bioactive sequences, milk proteins are currently the main source of a range of biologically active peptides<sup>1</sup>. Each milk proteins can be degraded into numerous peptide fragments by enzymatic proteolysis and serve as source of bioactive peptides.

Increased awareness of the diet-health relationship in many countries has stimulated a trend in nutrition science whereby more attention is given to the health effects of individual foods. The role of diet and specific foods in the prevention and treatment of diseases and improved body functions has become more prominent and active. With today's sophisticated analytical, and biochemical research tools, the presence of many other compounds with biological activity has been demonstrated. Improvements in separation techniques, in the dairy industry and enzyme technology, offer the opportunity to isolate, concentrate or modify biologically active compounds (or others), so that their application in functional, dietary supplements, nutraceuticals and medical foods has become possible. Potentially, the addition of bioactive peptides to the food products could improve consumer's safety as a result

of the antimicrobial property, for example. Lastly, bioactive peptides may function as health care products, providing therapeutic value for either treatment of infection or prevention of disease<sup>2</sup>.

Biologically active peptides are recommended as constituents of the so-called 'functional food' (i.e., food designed in order to obtain the desired functional and biological properties)<sup>3,4</sup>. Functional foodstuffs are a source of nutrients responsible for the physiological aspects of the proper functioning of the body.

#### 4. Bioactive peptides

It is now well established that physiologically active peptides are produced during gastrointestinal digestion and fermentation of food proteins by lactic acid bacteria. Bioactive peptides have been defined as specific protein fragments that have a positive impact on body functions or conditions and may ultimately influence health<sup>5</sup>. Protein-derived peptides can affect a decrease in blood pressure, inhibit the activity of proline endopeptidases, stimulate the functions of the immune system, demonstrate opioid agonist and antagonistic activity, induce contractions of smooth muscles, inhibit the process of thrombocyte aggregation, exhibit antibacterial, fungicidal and surface activity, bind metal ions and participate in mineral transport, determine the sensory properties, and improve the nutritive value of foods. A growing interest has been observed recently in the use of bioactive peptides for therapeutic purposes, especially in treatment with antibiotics and antimycotic agents, as well as in therapy of the following pathological states: neoplasms, viral inflammations (infections), disorders of the immune systems, neurological and cardiologic disorders<sup>6</sup>. Structural motifs occurring in peptides may serve as a source of information to be used while designing new compounds, the so-called 'peptidemimetics' with a similar mechanism of interactions with receptors<sup>7</sup>. For this reason, the potential of distinct dietary peptide sequences to promote human health by reducing the risk of chronic diseases or boosting natural immune protection has aroused a lot of scientific interest over the past few years. The beneficial health effects may be attributed to numerous known peptide sequences exhibiting, e.g., antimicrobial, antioxidative, antithrombotic, antihypertensive and immunomodulatory activities<sup>8,9,10</sup>.

##### 4.1 Antithrombotic peptides


It was discovered that the mechanisms involved in milk clotting, defined by the interaction of  $\kappa$ -CN with chymosin and blood clotting processes, defined by the interaction of fibrinogen with thrombin, are for several aspects comparable. A large number of molecular similarities have been previously reported between these two clotting phenomena<sup>11</sup>. In addition, structural homologies between the undecapeptide (residues 106-116, with MAIPPKKNQDK sequence) from bovine  $\kappa$ -casein, and the C-terminal dodecapeptide (residues 400-411 with HHLGGAKQAGDV sequence) of human fibrinogen  $\gamma$ -chain have been reported<sup>12</sup>. Three amino acid residues (Ile<sup>108</sup>, Lys<sup>112</sup>, Asp<sup>115</sup>) of the undecapeptide of  $\kappa$ -casein are in homologous positions as compared with the  $\gamma$ -chain sequence of human fibrinogen<sup>13</sup>. Fibrinogen has a bifunctional role in the blood clotting: it participates both in platelet aggregation [fibrinogen binds to a specific receptor on the platelet surface: the glycoprotein IIb-IIIa complex (GP IIb-IIIa)] and in fibrin formation<sup>14</sup>. Casoplatelins, which are  $\kappa$ -casein



derived peptides such as f106–116 but also the smaller fragments such as f106–112, f112–116, f113–116<sup>15</sup>, are inhibitors of both the aggregation of ADP-activated platelets and the binding of human fibrinogen  $\gamma$ -chain to a specific receptor region on the platelet surface<sup>16</sup>. Furthermore, the  $\kappa$ -casein fragment f103–111 can also prevent blood clotting through inhibition of platelet aggregation, but it is ineffective in the fibrinogen binding to ADP-treated platelets<sup>17</sup>. These residues seem to be important for the inhibitory effect which is due to the competition between antithrombotic peptides and the  $\gamma$ -chain for the platelet receptors. The potential physiological effects of these antithrombotic peptides have not been established, but such peptides have been detected in the plasma of newborn children after breastfeeding or ingestion of cow milk-based infant formulae<sup>18</sup>.

## 4.2 Antihypertensive peptides

Blood pressure regulation is partially dependent on the renin–angiotensin system; renin acts on angiotensinogen and releases angiotensin I, an inactive decapeptide that is further converted into the hormone angiotensin II, an active octapeptide with a potent vasoconstrictor action<sup>19</sup>, by the angiotensin-converting enzyme (peptidyl dipeptide hydrolase, ACE) action which removes two amino acids from the inactive form. Furthermore this enzyme inactivates bradykinin, which has hypotensive activity. (Figure1).



**Figure 1.** The renin–angiotensin system

Angiotensin II has a central role in the regulation of blood pressure and vascular structure. Reducing the levels of angiotensin II by ACE inhibition results in decreased vasoconstriction, as well as diminished aldosterone secretion which decreases the renal output while increasing water retention<sup>20</sup>. Therefore, inhibition of ACE is considered a useful therapeutic approach in the treatment of high blood pressure. Much research has been done related to bioactive peptides, and some of these studies have been focused on ACE-inhibitory peptides. Several food protein sources contain ACE-inhibitory peptides but the main ACE inhibitory peptides derive from milk proteins. The peptides obtained from casein are known as casokinins while those peptides derived from whey proteins termed lactokinins. The first observation about their activity is that the peptides being studied have little or no effect on blood pressure of normotensive subjects suggesting that they exert no acute hypotensive

effect. Therefore, ACE inhibitory peptides could be applied as initial treatment in mildly hypertensive individuals or as supplemental treatment. Another important consideration resulted by several *in vitro* and *in vivo* assays that is peptides with an ACE-inhibitory activity *in vitro* do not necessarily possess an antihypertensive effect after ingestion; the results of these tests have highlighted an important lack of correlation between the *in vitro* ACE inhibitory activity and the *in vivo* action. In order to produce antihypertensive effects *in vivo* the peptides have to be able to survive gastrointestinal digestion, be absorbed intact through the intestine and finally reach the cardiovascular system in an active form. It has been reported an increase in ACE inhibitory activity by the action of digestive enzymes on fermented casein solution<sup>21,22</sup>. In fact it was found that the sequence KVLPVPE ( $\beta$ -casein f169-175), with a low *in vitro* ACE-inhibitory activity was hydrolysed *in vivo* by pancreatic digestion to the potent ACE inhibitor KVLPVP, which was probably responsible for the high antihypertensive activity of KVLPVPE in spontaneously hypertensive rats (SHR)<sup>23</sup>. On the contrary, peptides that apparently exhibit *in vitro* ACE-inhibitory activity can fail to show *in vivo* antihypertensive activity as they are hydrolysed during the gastrointestinal digestion. Most of the ACE inhibitory peptides are short sized formed by only two to nine amino acid residues. It has been demonstrated that di- or tripeptides, especially those with C-terminal proline or hydroxyproline, are generally resistant to degradation by digestive enzymes<sup>24,25</sup>. Proline is known to be actually resistant to degradation by digestive enzymes<sup>26</sup>.

In addition, short peptides consisting of two or three amino acids are absorbed more rapidly than free amino acids<sup>27</sup>. These peptides can pass the intestinal tract, and after absorption, inhibit the production of angiotensin-II in blood. The ACE inhibitory tripeptides Val-Pro-Pro (VPP) or Ile-Pro-Pro (IPP), for example, were detected in the aorta of SHR, following oral administration of fermented milk<sup>28</sup>. Nakamura *et al.*<sup>29</sup> studied the antihypertensive effect of orally administered doses of Calpis sour milk. Calpis (Calpis Food Industry Co., Ltd., Tokyo, Japan) is a Japanese soft drink made from skim milk fermented by Calpis sour milk starter containing *Lactobacillus helveticus* and *Saccharomyces cerevisiae*. From this sour milk two tripeptides (VPP or IPP) were purified having each a antihypertensive activity in SHR rats. The sour milk or tripeptides decreased systolic blood pressure 6–8h postadministration.

Gobbetti *et al.*<sup>30</sup> demonstrated the formation of ACE-inhibitory peptides with two dairy strains, *Lb. delbrueckii* ssp. *bulgaricus* and *Lc. lactis* ssp. *cremoris*, after fermentation of milk separately with each strain for 72h. The most inhibitory fractions of the fermented milk mainly contained  $\beta$ -casein derived peptides. The milk fermented by *L. delbrueckii* subsp. *bulgaricus* SS1 contained the fragments of  $\beta$ -casein f6-14, f7-14, f73-82, f74-82, and f75-82 while the milk fermented by *L. lactis* subsp. *cremoris* FT4 contained the sequences of  $\beta$ -CN f7-14, f47-52, and f169-175 and  $\kappa$ -CN f155-160 and f152-160.

The structure-activity relationships of the ACE inhibitory peptides has not well studied. However, some general features have been highlighted<sup>31,32,33</sup>. The binding to ACE is strongly influenced by the C-terminal sequence. In fact ACE appears to prefer substrates or competitive inhibitors containing hydrophobic (aromatic or branched side chains) amino acid residues at each of the three C-terminal positions. It is known that the presence of Pro or lysine or arginine as a C-terminal or antepenultimate residue appears to enhance binding. In contrast, ACE binds only weakly competitive peptide inhibitors that have penultimate Pro residues<sup>34,35</sup>. In

addition, the presence of the positive charge of Lys ( $\epsilon$ -amino group) and Arg (guanidine group) as the C-terminal residue may contribute to the inhibitory potency.

Furthermore, it has been postulated that the mechanism of ACE inhibition may involve the interaction of the inhibitor with subsites not normally occupied by substrates or with an anionic inhibitor binding site that is different from the catalytic site of the enzyme<sup>32</sup>. Peptides can adopt different configurations depending on the environmental conditions, which determine their bioactivity. Gómez-Ruiz J. A. *et al* have reported the relevance of the conformational structure of the peptide on the interaction with the active site of ACE. It seems that peptides containing *trans*-Pro in the C-terminal position are substrate for ACE better than those carrying *cis*-Pro. The carboxyl groups of both *trans*-Pro and the penultimate residue lie on the same side of the peptide chain. In contrast, if proline is in the *cis*-configuration, these two groups are forced to move to opposite sides of the chain. This could lead to the loss of interactions with the active site and, in consequence, to a decreased (if any) binding to the enzyme and inhibitory activity<sup>36</sup>.

Recently, three novel casein-derived peptides, obtained by pepsin hydrolysis of the isoelectric casein have been identified. They corresponded to  $\alpha_{s1}$ -CN (f90–94) (RYLGY),  $\alpha_{s1}$ -CN (f143–149) (AYFYPEL), and  $\alpha_{s2}$ -CN (f89–95) (YQKFPQY). They showed both potent ACE-inhibitory and antioxidant activity; in particular two of them exerted high antihypertensive activity in SHR and their activity was similar to that of tripeptide VPP when orally administered at the same dose<sup>37</sup>.

#### 4.3 Opioid peptides

The first, most studied, biologically active casein peptides were the opioid peptides with opiate activity. The major opioid peptides are fragments of  $\beta$ -CN, called  $\beta$ -casomorphins, due to their exogenous origin and morphine-like properties<sup>38</sup>. They are fragments of  $\beta$ -casein between the 60th and the 70th residues, mainly f60–63, f60–64, f60–65, f60–66 and f60–70<sup>39</sup>. They possess the same N-terminal sequence (Tyr-Pro-Phe-Pro) and are characterized as  $\mu$ -type ligands<sup>40</sup>. They have been obtained from pepsin hydrolysis of bovine  $\alpha_{s1}$ -CN<sup>41,42,43</sup>. Similar peptides have been reported from human  $\beta$ -CN fractions<sup>44</sup> and the Y-P-F sequence, which is common to bovine  $\beta$ -casomorphin, was also found to be present in the primary structure of human  $\beta$ -CN. In general, the  $\alpha_s$ - and  $\beta$ -CN fragments produce agonist responses, while those derived from  $\kappa$ -CN, called casoxins, elicit antagonist effects. In fact they suppress the agonistic activity of opioid peptides like enkephalin. Casoxins, found in both bovine and human  $\kappa$ -casein as well as in  $\alpha_{s1}$ -casein<sup>45</sup>, act as specific ligands of  $\mu$ - and  $\kappa$ -receptor.

The common structural feature among endogenous and exogenous opioid peptide (except  $\alpha_s$ -casein opioids) is the presence of a Tyr residue at the N-terminus, and the presence of another aromatic residue, e.g. Phe or Tyr, in the third or fourth position. This is an important structural feature, that ensure that the peptide fits into the binding site of opioid receptors. The negative potential, localized in the vicinity of the phenolic hydroxyl group of Tyr, seem to be essential for opioid activity. Lack of the Tyr residue results in a total absence of bioactivity<sup>46</sup> while the Pro in the second N-terminal position seems to maintain the proper orientation of Tyr and Phe chains<sup>47</sup>.

Chabance *et al.*<sup>48</sup> showed that many peptides from  $\alpha_{s1}$ -,  $\beta$ -,  $\kappa$ -casein and  $\kappa$ -caseinomacropptide exist in the stomach of adults following consumption of milk or

yoghurt, and some casein fragments were also found in the duodenum. Studies have suggested that opioid peptide are formed in the gut as a result of *in vivo* hydrolysis of milk after ingesting of this but, once they are liberated, they are resistant to enzymes of the gastrointestinal tract and have been detected *in vivo* in the intestinal chyme of minipigs<sup>49</sup> and human small intestines<sup>50</sup>. Because their absorption in the gut has not been observed in adults, it is generally concluded that the physiological influences are limited to the gastrointestinal tract with important effects on intestinal transit time, amino acid uptake, and water balance<sup>51</sup>.

Thus, orally administered opioid peptides may modulate absorption processes in the gut and influence the gastrointestinal function in two ways: first, by affecting smooth muscles, which reduces the transit time, and second, by affecting the intestinal transport of electrolytes, which explains their anti-secretory properties<sup>52</sup>. In contrast, passive transport of  $\beta$ -caseinomorphins across intestinal mucosal membranes does occur in neonates, which may experience physiological responses such as an analgesic effect on the nervous system resulting in calmness and sleep in infants after breast or bottle feeding<sup>53</sup>.

#### 4.4 Immunomodulating peptides

Milk protein hydrolysates and peptides derived from caseins and major whey proteins can enhance immune cell functions, measured as lymphocyte proliferation, antibody synthesis and cytokine regulation<sup>54</sup>. Breast feeding facilitates physical transmission of passive immunity via a number of multifunctional factors, which have a direct effect on the neonate's resistance to bacterial and viral infections. The most important compounds are immunoglobulins, but, in addition, casein are included among these factors. In fact, during enzymatic digestion of human and bovine milk caseins, peptides with immunomodulating capacities are released. Jolles *et al.*<sup>55</sup> were the first to report that trypsinised human milk possesses immunostimulating activity; in particular, the human milk hexapeptide Val-Glu-Pro-Ile-Pro-Tyr, corresponding to  $\beta$ -casein (f54-59) was isolated from its tryptic hydrolyzate<sup>56</sup> and proven to account for such an activity. It is noteworthy that the hexapeptide represents the C-terminal part of  $\beta$ -casomorphin-11. Casein-derived immunopeptides including fragments of  $\alpha_{s1}$ -casein (residues 194-199; Thr-Thr-Met-Pro-Leu-Trp) and  $\beta$ -casein (residues 63-68; Pro-Gly-Pro-Ile-Pro-Asn and 191-193; Leu-Leu-Tyr) stimulate phagocytic activity of murine and human macrophages *in vitro*. Then, the pH 4.6-soluble products from the hydrolysis of whole bovine casein by chymosin encompass peptides possessing immunomodulatory activity, i.e.  $\alpha_{s1}$ -casein f1-23 and  $\beta$ -casein f193-209<sup>57</sup>.

Furthermore, immunopeptides formed during milk fermentation have been shown to contribute to the antitumor effects observed in many studies with fermented milks. The peptides released by bacterial proteolysis might have important implications in modulation of the host's immune response and have an impact on inhibition of tumor development.<sup>58</sup>

In addition to this, a commercially available caseinophosphopeptide preparation (CPP-III), mainly consisting of  $\alpha_{s2}$ -casein f1-32 and  $\beta$ -casein f1-28, which exert an immunostimulatory action, attributed to the *o*-phospho-L-serine residue has been described, hence suggesting that such a bioactivity is relatively stable to proteinase action in the intestinal tract<sup>59</sup>.

Nowadays, mechanism, structure and activity of the immunomodulating peptides is still debated. However, an Arg residue at the *N*- or *C*- terminal region of a

peptide has been suggested to be the leading motif recognizable by specific surface membrane receptors<sup>60</sup>.

#### 4.5 Antimicrobial peptides

The antibacterial properties of milk have been known for a long time. In fact, the incidence of disease like diarrhoea or respiratory infections are significantly lower in breast-fed infants than in formula-fed infants and a variety of protective factors in human milk have been claimed to be responsible for this effect. In addition to the naturally occurring antimicrobial proteins present in milk, there are also a variety of antibacterial peptides encrypted within the sequence of milk proteins that are released upon suitable hydrolysis of the parent protein.

Lahov *et al.* (1971) isolated antibacterial glycopeptides released upon cow's milk heating. They showed that milk heating followed by chymosin digestion produced similar, basic high molecular weight polypeptides called casecidins which inhibited the growth of pathogenic bacteria as well as of lactobacilli. Casecidin was among the first amongst purified defense peptides and exhibited *in vitro* activity against *Staphylococcus*, *Sarcina*, *Bacillus subtilis*, *Diplococcus pneumoniae*, and *Streptococcus pyogenes*<sup>61</sup>. The peptide consisted of the  $\alpha_{s1}$ -casein (f1-23) segment, named 'isracidin', and was significantly effective *in vivo* at concentrations that were competitive with known antibiotics, as seen in the protection of mice against lethal infection by *Staphylococcus aureus* Smith strain. Field trials showed that injection of isracidin into the udder gave protection against mastitis in sheep and cows. Isracidin was both therapeutic and prophylactic and produced long-term immune resistance.

Casocidin-I (bovine milk), a cationic  $\alpha_{s2}$ -CN derived peptide, inhibited *Escherichia coli* and *Staphylococcus carnosus*<sup>62</sup> growth. Two other peptides were in the meantime isolated from a peptic hydrolysate of  $\alpha_{s2}$ -casein, namely f183–207 and f164–179; the former exhibited higher antimicrobial activity than the latter, although both possessed comparable hemolytic effects<sup>63</sup>. The search for antibacterial activity from  $\alpha_{s2}$ -casein has been extended to milk from other species.

Recently, McCann *et al.*<sup>64</sup> have isolated and identified a novel fragment from bovine  $\alpha_{s1}$ -casein. This cationic peptide (with a theoretical pI 10.46) corresponded to residues 99–109 of bovine  $\alpha_{s1}$ -casein. This peptide was obtained by submitting casein to pepsin hydrolysis and subsequent purification by several steps of preparative RP-HPLC. The latter peptide showed activity against the Gram-positive bacteria *Bacillus subtilis* and *Listeria innocua*. With respect to Gram-negative bacteria, (f99–109) presented activity against *Salmonella typhimurium*, *E. coli*, *Sal. enteritidis* and *Citrobacter freundii*.

The  $\kappa$ -casein fraction also originated several antibacterial fragments, such as kappacin. It is another example of an antimicrobial peptide derived from  $\kappa$ -casein<sup>65</sup>. Kappacin corresponds to the nonglycosylated, phosphorylated form of caseinmacropeptide (CMP). In order to characterize the active region of kappacin, the peptide was subjected to hydrolysis with endoproteinase Glu-C, seeing that the peptide  $\kappa$ -casein A (f138-158) Ser(P)149 was the active form with antimicrobial activity against *Str. mutans*, *E. coli* and *Porphyromonas gingivalis*. It is important to emphasize that the active form is the phosphorylated and non-glycosylated form, since it has been demonstrated that non phosphorylated and glycosylated forms do not have any activity against *Str. mutans*. Other small peptide fragments from  $\kappa$ -casein have also demonstrated antibacterial activity.

A peptide, called  $\kappa$ -casecidin, has been identified in  $\kappa$ -casein tryptic digests and corresponded to  $\kappa$ -casein (f17-21). Chemically synthesized  $\kappa$ -casecidin inhibited growth of some pathogenic bacteria such as *S. aureus*, *E. coli* and *Sal. typhimurium*<sup>66</sup>.

In addition to these antimicrobial peptides, several human and rabbit  $\beta$ -casein sequences have been reported to elicit antimicrobial activity. A peptide raising from human  $\beta$ -casein was obtained after hydrolysis of human milk with a purified proteinase of *Lactobacillus helveticus* PR4<sup>67</sup>. The peptide corresponded to human  $\beta$ -casein f(184-210) and showed a large inhibition spectrum against Gram-positive and Gram-negative bacteria, including species of potential clinical interest.

Trypsin digestion of rabbit casein yielded several peptide fragments with antibacterial activity against Gram-positive bacteria<sup>68</sup>. Of the peptides identified, rabbit  $\beta$ -casein (f64-77) was the most active.

In general, the mechanisms of action of this kind of peptides is not well known. An amphiphilic and a positive net charge are recognised as major structural motifs determining the interaction with bacterial membranes, which has been accepted as a common target in their mechanism of action. It is recognized that the antibacterial activity starts with the electrostatic interaction of cationic peptide with the anionic molecules orientated toward the exterior of the cell. This would provide a ready explanation for their specificity for bacterial membranes. However, there is uncertainty about how these peptides perturb the membrane and whether this membrane perturbation is related to their antimicrobial activity<sup>69</sup>.

#### 4.6 Glycomacropeptide

The glycomacropeptide (GMP) is formed during the enzymatic cheesemaking process. In fact, it is released from casein during the enzymatic (rennin or chymosin)  $\kappa$ -casein clotting. Chymosin is an aspartyl protease that is secreted in the fourth stomach of young mammals having the function of coagulating milk. This enzyme hydrolyses the  $\kappa$ -casein at the Phe<sub>105</sub>-Met<sub>106</sub> bond into two fragments, e.g para- $\kappa$ -casein (CMT, residues 1-105) and glycomacropeptide (GMP, residues 106-169). Since the C-terminal portion of glycosylated  $\kappa$ -casein molecules is more hydrophilic, for O-linked threonine and serine oligosaccharides, GMP is lost in the whey.

Many studies over the last 10 years have attempted to establish the potential role of GMP and its non glycosylated form, CMP, in regulating the intestinal functions<sup>70</sup>.

GMP is known to have many biological functions such as promoting bifidobacterium growth<sup>71</sup>, modulating immune responses<sup>72</sup>, inhibiting gastric secretions and slow down stomach contractions<sup>73</sup>.

It has been suggested that CMP stimulates the release of cholecystokinin (CKK), the satiety hormone involved in controlling food intake and digestion in the duodenum of animals and humans<sup>74</sup>. In fact some peptides obtained from pepsin hydrolysis induce a satiety effect<sup>75</sup> when administered to starving animals; the latter effect was similar to that exhibited following cholecystokinin injection.

Intact CMP has been detected in the stomach during digestion<sup>76</sup> but, on the other hand, it has also been observed that GMP can be absorbed as intact and partially digested into the circulating blood of human adults after milk or yoghurt ingestion<sup>77</sup>. Based on the above studies, commercial products containing GMP have

been launched on the market claiming appetite control and weight management effect.

Moreover, in the recent years the preventive effects of GMP against intestinal infection have been also investigated. It is known that specific oligosaccharides are involved when infections of patients with bacteria, bacterial toxins and viruses. The initial phase of infection is brought about by the adhesion of lectins on the surface of bacteria to specific receptors on the intestinal epithelial cells. Mannose and sialic acids have been found to be involved in specific receptors<sup>78</sup>. Hence, such infection could be prevented by blocking the adhesion of pathogenic bacteria to the intestinal epithelial cells with food components. Since GMP contains sialic acid, it has been shown that GMP would be able to bind to pathogenic bacteria thus preventing intestinal infection<sup>79</sup>

## **5. The object of study of this PhD thesis. Bioactive casein phosphopeptides**


The term phosphopeptide was pioneered by Mellander (1950)<sup>80</sup> and it means a casein-derived phosphorylated peptide which enhances vitamin D-independent bone calcification in rachitic infants.

The CPP, produced *in vivo* or *in vitro* by enzymatic hydrolysis of casein, are casein-derived phosphopeptides containing SerP or ThrP residues that occur mainly in the SerP-X-SerP/ThrP/Glu/Asp clusters where X is any amino acid residue except Pro. They have different molecular size and most of them contain a common cluster sequence of three phosphoseryl groups followed by two residues of glutamic acid, Ser(P)-Ser(P)-Ser(P)-Glu-Glu, serving as binding sites for di- or trivalent mineral ions. The phosphate residues, corresponding to ca. 30% of the phosphorus content in milk, is present as Ser monoesters and the high concentration of negative charges of phosphorylated peptides makes them resistant to further proteolysis<sup>81</sup>. Chabance *et al.*<sup>82</sup> have proven the occurrence of CPP in the stomach and duodenum following milk ingestion. Certain CPP were for the first time detected in ileostomy fluid by Meisel *et al.* which confirms the ability of such peptides to survive gastrointestinal passage to the human distal ileum<sup>83</sup>. It is also proved that the *in vivo* formation of CPP derived from bovine casein occurred in small intestine chyme of minipigs after ingestion of a diet containing casein<sup>84</sup>.

Furthermore, the negatively charged phosphate groups of CPP represent the binding site for different minerals. CPP have been shown to bind to different macroelements and oligoelements. Phosphopeptides can form soluble organophosphate salts and may function as carriers for these minerals, especially calcium<sup>85</sup>. *In vitro* studies demonstrated that CPP can prevent the precipitation of calcium ions as insoluble salts like calcium phosphate<sup>86</sup>. According to Meisel<sup>87</sup>, binding of Ca involves Ser-bound phosphate groups, as well as the free carboxyl groups of Glu; the hydrophobic tail protects this complex from further interactions, and hence prevents formation of insoluble calcium phosphate. This suggested the possibility that CPP may enhance the soluble calcium amount in the intestinal lumen, thereby increasing the mineral availability for absorption in the small intestine<sup>88,89,90</sup>.

The possible influence of CPP on calcium uptake by cultured HT-29 tumor cells was assessed by Ferraretto, *et al.*<sup>91</sup> that directly measured the intracellular free calcium concentration,  $[Ca^{2+}]_i$ , after exposure to different CPP preparations. Chemically synthesized CPP,  $\beta$ -casein (f1-25)4P and  $\alpha_{s1}$ -CN(f59-79)5P, carrying the characteristic 'cluster SerP motif Ser(P)-Ser(P)-Ser(P)-Glu-Glu, were found to cause

an increase of  $\text{Ca}^{2+}$  concentration, due to influx of extracellular  $\text{Ca}^{2+}$ . Moreover, the CPP-promoting effect on calcium concentration was proven to depend on the structural conformation conferred by both the phosphorylated “acidic motif” and the preceding *N*-terminal portion<sup>92</sup>. Notably, calcium binding to  $\beta\text{-CN}(\text{f1-25})4\text{P}$  was reported to cause conformational changes to the peptide backbone resulting in a loop-type structure of the residues 1-4 ( $\text{Arg}_1$  to  $\text{Glu}_4$ ) and  $\beta$ -turn structure of residues 8-11 ( $\text{Val}_8$  to  $\text{Glu}_{11}$ ), 17-20 ( $\text{Ser}(\text{P})_{17}$  to  $\text{Glu}_{20}$ , the ‘acidic motif’), and 21-24 ( $\text{Glu}_{21}$  to  $\text{Thr}_{24}$ )<sup>93</sup>. In the case of  $\alpha_{\text{s1}}\text{-CN}(\text{59-79})5\text{P}$  calcium association leads to a  $\beta$ -turn structure of residues  $\text{Pro}_{73}$  to  $\text{Val}_{76}$ , and a loop-like structure of residues  $\text{Glu}_{61}$  to  $\text{Ser}(\text{P})_{67}$ <sup>94</sup> (Figure 2).



**Figure 2.** Primary structure of casein phosphopeptides

Here, it was demonstrated that the rise of intracellular  $[\text{Ca}^{2+}]$ , is more pronounced with the  $\beta$ -casein-derived peptide than with those from  $\alpha_{\text{s1}}$ -casein. Presumably, steric factors due to the amino acids flanking the ‘acidic motif’ contribute to the calcium binding ability, as well as other biological properties of CPP, like the  $[\text{Ca}^{2+}]$  intracellular rise effect and immunogenicity<sup>95</sup>. This tends to suggest that the interaction between CPP and the plasma membrane of HT-29 cells, presumably instrumental to favour a  $\text{Ca}^{2+}$  influx inside the cells, requires a precise peptide structure and conformation, where not only the ‘acidic motif’ but also some additional polypeptide portions could play pivotal roles<sup>96</sup>.

Moreover, a recent work by Farrell *et al.*<sup>97</sup> showed that the dephosphorylated form of  $\beta\text{-CN}(\text{1-25})4\text{P}$  assumes a much more flexible and dynamic structure, which facilitates self-aggregation of the peptide. As a consequence, some motifs on the casein phosphopeptide might become cryptic, compromising the functionality of the peptide itself. It has been shown by Ferrarretto *et al* that the ability to take up extracellular calcium ions under CPP stimulation is exhibited also by both HT-29 and Caco2 cells, but only upon cell differentiation. This evidence adds novel support to the notion that CPP favour calcium absorption.<sup>98</sup>

Furthermore CPP are also capable to effectively bind Mg and Fe, as well as as Zn, Ba, Cr, Ni, Co and Se. Iron deficiency, a major worldwide nutritional problem, can be reduced by CPP; in fact, binding of Fe to phosphopeptides prevents formation of high-molecular weight ferric hydroxides, which are poorly absorbed. *In vitro* studies with rats<sup>99</sup> have demonstrated that Fe bound to the phosphoserine residues of low-molecular weight CPP, as  $\beta$ -casein (f1–25), improved their ability to treat anaemia and restore Fe storage tissues, when compared with Fe bound to whole casein and inorganic salts. Zinc absorption can also be enhanced if that metal is bound to CCPs, in particular  $\beta$ -casein (f1–25)<sup>100</sup>.

CPP have also the ability to stabilize calcium phosphate in solution through binding amorphous calcium phosphate with their multiple phosphoserine residues. This allows the formation of small CPP-ACP clusters, but without allowing growth to the critical size required for nucleation of crystals and subsequent precipitation of



calcium phosphate<sup>101,102</sup>. CPP-ACP have been demonstrated to have anticariogenic potential in laboratory, animal, and human *in situ* experiments<sup>103</sup>.

The complex CPP-ACP can significantly enhance the availability of calcium in plaque; in fact CPP localize ACP at the tooth surface, inhibiting enamel demineralization and promoting enamel remineralization. Tooth enamel is a polymeric substance consisting of crystalline calcium phosphate, embedded in a protein matrix. Dental caries is initiated via the demineralization of tooth hard tissue by organic acids directly assumed with the diet or produced from fermentable carbohydrate by dental plaque cariogenic bacteria. Fluoride ions, in the presence of calcium and phosphate ions, can help to replace the lost minerals of early caries lesions by remineralization. In the development of teeth and bone, it has also been shown that phosphopeptides act as nucleators of hydroxyapatite and control the growth of the crystals, resulting in a unique crystal morphology characteristic of the biological systems.

A new calcium phosphate remineralization technology has been developed by Reynolds<sup>104</sup> based on CPP-ACP [Recaldent™ CASRN691364-49-5]. This CPP preparation is claimed to stabilize high concentrations of calcium and phosphate ions, together with fluoride ions, at the tooth surface by binding to pellicle and plaque. Reynolds (1997) has demonstrated that the complex CPP-ACP can remineralize sub-surface lesions in human enamel. In several different studies, the CPP-ACP technology has been demonstrated to increase the levels of calcium and phosphate ions in supragingival plaque significantly when delivered in a mouthrinse and to promote the remineralization of enamel subsurface lesions *in situ*<sup>105</sup>. Then, it has been also shown that CPP-ACP inhibited the adhesion of cariogenic streptococci as *Streptococcus mutans* to the tooth surface and produced a copious reservoir of bioavailable calcium ions<sup>106,107</sup>.

Moreover, it been revealed that yogurt and cheese are also a consistent source of bioavailable CPP. Shaw *et al.*<sup>108</sup> observed that ice cream, and cheese lowered incidence of dental caries in rats. Elderly people that eat cheese several times per week had a lower incidence of root surface caries development<sup>109</sup>. Interestingly, the concentration of CPP in yogurt is higher than that in milk due to the proteolytic activity of enzyme micro-organisms.<sup>110</sup> Recently, it has demonstrated that CPP of yogurt have an inhibitory effect on demineralization and promote the remineralization of dental enamel<sup>111</sup>.

Since CPP can be incorporated into foodstuffs as well as therapeutic agents and demonstrate none of the adverse effects of fluoride overuse (fluorosis at moderate doses and toxicity at higher doses), it is possible to exploit CPP as powerful anticaries agents. Hence, it comes our interest for these products as nutraceutical ingredients for the formulation of 'functional foods'.

## 6. Possible use of CPP for industrial applications

The "nutraceutical" term is a portmanteau of nutrition and pharmaceuticals and it has been coined the first time by Dr. Stephen De Felice (the founder and chairman of Foundation for Innovation in Medicine) in 1989. He defined nutraceuticals as "food, or parts of food, that provide medical or health benefits including the prevention and treatment of diseases". The term functional food is also used to refer nutraceuticals. In the states of Canada and Great Britain, a functional food is essentially a food, but a nutraceutic is an isolated form or concentrated form. Achievements in separation

techniques in the dairy industry and enzyme technology offer the opportunity to isolate, concentrate or modify these compounds, so that their application in functional foods, dietary supplements, nutraceuticals and medical foods became possible.

CPP represent functional substances or bioactive milk components that are potential ingredients of functional foods in conjunction with a certain “health claim”. These peptides are potential health-enhancing nutraceuticals for food and pharmaceutical applications. Numerous claims have been made with respect to the application of CPP to enhance mineral bioavailability. For examples, an adequate  $\text{Ca}^{2+}$  supply is required for development or ricalcification following bone fracturing, in the prevention of osteoporosis and during the treatment of rickets. Recent studies have confirmed the possibility that CPP play a role as modulator of bone cell activity, probably sustained by the ability as calcium carriers, for their stimulatory activity on osteoblast differentiation and matrix mineralization<sup>112</sup>. Inadequate  $\text{Ca}^{2+}$  levels are also implicated in the development of hypertension, colon cancer and kidney stones. Lack of adequate dietary  $\text{Fe}^{2+}$  can, for example, lead to anaemia.

Currently, several multinational companies, particularly in Europe and Japan, market CPP containing products aimed at enhancing the bioavailability of mineral functional foods.

Moreover, calcium CPP are palatable and can be used as an anticariogenic additive<sup>113</sup>. The addition of CPP to toothpaste formulas has been suggested to have anticariogenic effects and prevent enamel demineralization<sup>114</sup>. Laboratory, animal and human in situ experiments have demonstrated that synthetic CPP-ACP nanocomplexes contained in mouthrinses and sugar-free chewing gums are anticariogenic<sup>115,116</sup>. In fact, CPP have been incorporated into a wide range of products such as toothpaste, toothpowder, topical gels, dental filling material, mouthwashed, chewing gum, lozenges, tablets, mineral drinks, nutritional supplements for children, confectionery, and products for dental care<sup>117</sup>.

CPP-ACP is already being used commercially as an ingredient (Recaldent™) (Table 1) in oral care products. Recaldent is the first product that has been claimed to strengthen teeth by increasing remineralisation and protect against decay (dental caries). It is an invention by Professor Eric Reynolds from the University of Melbourne, Australia and contains CPP and ACP.

The complex (CPP-ACP) has been incorporated into sugar-free chewing gum as Trident White Gum that was marketed in the USA, Japan and four European countries. Apart from gums, Recaldent™ (CPP-ACP) is used in paste. In fact the GC Corporation has developed a concentrated paste, containing Recaldent™ (CPP-ACP) that is known as GC Tooth Mousse in most parts of the world and as MI (Minimum Intervention™) Paste in the USA and Japan.

**Table 1** Commercial dairy products and ingredients with health or function claims based on bioactive peptides, in particular CPP.

<b>Table 2 – Commercial dairy products and ingredients with health or function claims based on bioactive peptides (modified from Korhonen and Pihlanto, 2006).</b>				
Brand name	Type of product	Claimed functional bioactive peptides	Health/function claims	Manufacturer
Calpis	Sour milk	Val-Pro-Pro, Ile-Pro-Pro, derived from $\beta$ -casein and $\kappa$ -casein	Reduction of blood pressure	Calpis Co., Japan
Evolus	Calcium enriched fermented milk drink	Val-Pro-Pro, Ile-Pro-Pro, derived from $\beta$ -casein and $\kappa$ -casein	Reduction of blood pressure	Valio Oy, Finland
BioZate	Hydrolysed whey protein isolate	$\beta$ -Lactoglobulin fragments	Reduction of blood pressure	Davisco, USA
BioPURE-GMP	Whey protein isolate	$\kappa$ -Casein f(106–169) (Glycomacropeptide)	Prevention of dental caries, influence the clotting of blood, protection against viruses and bacteria	Davisco, USA
PRODIET F200/Lactium	Flavoured milk drink, confectionery, capsules	$\alpha_{s1}$ -Casein f(91–100) (Tyr-Leu-Gly-Tyr-Leu- Glu-Gln-Leu-Leu-Arg)	Reduction of stress effects	Ingredia, France
Festivo	Fermented low-fat hard cheese	$\alpha_{s1}$ -casein f(1–6), (1–7), (1–9)	No health claim	MTT Agrifood Research Finland
Cysteine Peptide	Ingredient/hydrolysate	Milk protein-derived peptide	Aids to raise energy level and sleep	DMV International, the Netherlands
C12	Ingredient/hydrolysate	Casein derived peptide	Reduction of blood pressure	DMV International, the Netherlands
Capolac	Ingredient	Caseinophosphopeptide	Helps mineral absorption	Arla Foods Ingredients, Sweden
PeptoPro	Ingredient/hydrolysate	Casein derived peptide	Improves athletic performance and muscle recovery	DSM Food Specialties, the Netherlands
Vivinal Alpha	Ingredient/hydrolysate	Whey derived peptide	Aids relaxation and sleep	Borculo Domo Ingredients (BDI), the Netherlands
Recaldent	Chewing gum	Calcium casein peptone-calcium phosphate	Anticariogenic	Cadbury Adams, USA


## 7. Techniques for phosphopeptide enrichment for industrial applications

The first part of PhD thesis was focused on finding a methodology for obtaining from the casein hydrolysate a enriched CPP preparation on semi-industrial scale. Most commercial CPP preparations contain low quantities of CPP. The product HCP 102 (Hydrolyzed casein protein 102) obtained from Tatua Cooperative Dairy Co. (Ltd, Morrinsville, New Zealand) has been analyzed using mass spectrometry. The product is indicated as “an ideal ingredient for products at increased mineral solubility, boosted protein levels for quicker nitrogen digestion”. We showed that in a product labelled as enriched-CPP preparation, no signal in the MALDI spectrum was attributable to phosphorylated peptides as only 16% CPP was present after enrichment. Detection problems of CPP might be caused by suppression effects of the nonphosphorylated peptides during the ionization process. The ionization of phosphorylated peptides is often suppressed in the presence of non-phosphorylated peptides as in the normal proteolytic digest of a phosphoprotein<sup>118</sup>. For matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS), desorption/ionization efficiency for phosphopeptides were reported to be an order of magnitude lower than those of their nonphosphorylated counterparts, and ionization of phosphorylated peptides can become more difficult as the number of phosphorylation sites increases. Moreover, these commercial preparations are obtained by hydrolysis of different enzymes and not all peptides have Lys and Arg residues as C-terminal residue which would increase the ionization efficiency. In fact, it has been

demonstrated that the peptides that contain C-terminal lysine, with respect to arginine-containing peptides give 4- to 18-fold more intense ions. This could possibly be due to the higher basicity of the arginine residue, increasing retention of charge<sup>119</sup>. Therefore, selective enrichment techniques were searched for separating phosphopeptides from nonphosphorylated peptides.

The first techniques of enrichment consisted in the precipitation of CPP as insoluble barium salts and recovery by centrifugation, according to the procedure of Manson & Annan<sup>120</sup>. Current available high-throughput phosphoproteome technologies rely on the protein separation by one- or two-dimensional gels according to the isoelectric point, digestion with trypsin and analysis of the resulting peptides by MALDI-TOF mass spectrometry<sup>121</sup>. This procedure combines the very high resolving power of gel electrophoresis with the sensitivity of mass spectrometry.


Recently, methods have been developed for the selective enrichment of phosphopeptides based on chemical derivatization and affinity chromatography-methods. In the derivatization technique,  $\beta$ -elimination chemistry provides a considerably simpler method to enrich phosphopeptides. In this chemistry, strong bases such as NaOH or Ba(OH)<sub>2</sub> are used to cleave the phosphoester bonds of phosphoserine and phosphothreonine to form the respective dehydroalanine or dehydroaminobutyric acid analogs, which can react with different nucleophiles, such as ethanedithiol, or EDT and can be linked to a biotin affinity tag or a polymer support<sup>122</sup> (Scheme 1).



**Scheme 1.** Chemical conversion of a phosphoserine residue to a biotinylated residue. Indicated by the dashed line is the position of the facile cleavage (see text) that produces the ion observed at  $m/z = 446$  in the MS/MS spectra.

Although the chemical derivatization methods are highly selective, they are not widely applied in the phosphoproteome studies for sample loss caused by the multiple reaction steps and increased sample complexity by unavoidable side reactions<sup>123</sup>.

Several affinity based methods such as immobilized metal ion affinity chromatography (IMAC) (with  $Fe^{3+}$ ,  $Ga^{3+}$ ,  $Ni^{2+}$  and  $Zr^{4+}$  metal ions) and metal oxide affinity chromatography (MOAC) (with  $TiO_2$ ,  $ZrO_2$ ,  $Al_2O_3$  and  $Nb_2O_5$ ) have been developed for selective enrichment of phosphopeptides (Figure 3).



**Figure 3.** Schematic diagram of phosphopeptide isolation by IMAC or MOAC.

IMAC beads immobilized with Fe(III) or Ga(III) are commonly used for the purification of phosphopeptides<sup>124,125</sup>. In this technique, iminodiacetic acid (IDA, a tridentate metal-chelator) and nitrilotriacetic acid (NTA, a quadridentate metal-chelator) are often used as functional reagent that reacts with multivalent metal ions to form chelated ions with positive charges. Phosphate groups of phosphopeptides with negative charges are attracted by the chelated ions owing to static interaction, leading to phosphopeptides retained on the immobilized chelated ions. The phosphate group interacts through nonbonding ion pair electron coordination with metal ions which have been chelated to a multidentate ligand immobilized onto a support material. There is a number of challenges associated to IMAC. First, because of the metal ions are not covalently bound to the substrate, there is a possibility to leach these ions from the column, during the enrichment steps, which might lead to loss of phosphopeptides or to a contamination of peptides with metal ions. A second challenge is nonspecific binding of peptides that contain the acidic glutamic and aspartic acid residues. Methyl esterification of carboxyl groups has been demonstrated to decrease the nonspecific adsorption of acidic peptides on IMAC<sup>126</sup>.

Instead of using IMAC with Fe<sup>3+</sup>, higher specificity and lower sample loss was observed for MOAC, using some metal oxides such as TiO<sub>2</sub> and ZrO<sub>2</sub>. The negatively charged phosphopeptides selectively interact with titansphere via bidentate binding at the dioxide surface<sup>127,128,129</sup>. However, the selectivity of this method was somewhat compromised by the detection of several acidic non-phosphorylated peptides that were also retained by their TiO<sub>2</sub> column.

Considerable efforts have been made to improve this technique. Significant improvement was obtained in MOC with titania when benzoic acid derivatives such as 2,5-dihydroxybenzoic acid (DHB)<sup>130</sup> and phthalic acid<sup>131</sup> were used in the sample loading buffer to eliminate acidic nonphosphorylated peptides. Recently, it has been found that aliphatic hydroxyl acid-modified metal oxide works more efficiently and more specifically than aromatic modifiers such as DHB and phthalic acid in titania and zirconia MOC<sup>132</sup>.


In several studies the combination of different enrichment methods has been found to be advantageous for selective phosphopeptide enrichment as the coupling of two complementary enrichment methods as calcium phosphate precipitation and

IMAC<sup>133</sup>, or as SCX and SAC where protein digests were first loaded on an SCX column, and the flow-through peptides from SCX were collected and further loaded onto a SAX column<sup>134</sup>.

However, none of the tested analytical systems could be applied in industrial field for three reasons: a) the resin to which CPP are linked is not edible and barium chloride, in the procedure of Manson & Annan, is hazardous reagent and large quantity of expensive ethyl alcohol makes the procedure unreliable, b) the elution of CPP from the resin requires very long and expensive purification systems, c) fortification of foods with eluted CPP alter the taste, making it more bitter. This is principally due to the ability by CPP to chelate mineral ions from contacting matrix.

## 8. Development of a new enrichment technique

In the second part of the PhD work, a new technique for specific phosphoproteins and phosphopeptides enrichment from complex mixtures have been developed. The objective is to set out an analytical method for CPP enrichment to use for preparative purpose of nutraceuticals in functional foods. Using inexpensive, raw materials free of harmful Ba, Fe, Ga, Ni, Zr and Ti compounds, a large scale CPP isolation was obtained. Chromatography on industrial scale is based on ion exchange columns separation of great diameter or, to avoid the problems of clogging, on batch processes. The used material consists of a resin having the capacity of binding anion compounds such as CPP carrying negative charges in a wide pH range. This high selectivity technique is based on hydroxyapatite (HA) chromatography. HA is a form of calcium phosphate with the formula  $[\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2]$  which can be used as chromatographic matrix. HA chromatography is considered to work as a “mixed mode” ion exchange or a “pseudo-affinity” chromatography. The functional groups comprise positively charged pairs of crystal calcium ions (*C*-sites) and clusters of six negatively charged oxygen atoms associated with triplets of crystal phosphates (*P*-sites). The hydroxyapatite/biomolecule interactions are complex. Generally, it is thought that amino groups are attracted to negatively charged *P*-sites and repelled by positively charged *C*-sites. The opposite is true for negatively charged, phosphorylated residues of proteins. (Figure 4)



**Figure 4.** Protein binding to hydroxyapatite. Double parentheses indicate repulsion. Dotted lines indicate ionic bonds. Triangular linkages indicate coordination bonds.

The more phosphates are present, the more dominating is the calcium site binding and thus the tighter is the binding of the protein to the matrix<sup>135</sup>

Phosphorylated groups on proteins and other solutes interact even more strongly with C-sites than do carboxyls<sup>136</sup>. This is reflected in extremely strong binding by proteins and peptide with high degree of phosphorylation. Then several studies demonstrated that phosphorylated proteins bind more strongly to HAP than their unphosphorylated counterparts<sup>137</sup>.

The developed method employs ceramic hydroxyapatite (HA) as solid-phase adsorbent to separate nonphosphorylated from resin-bound phosphorylated components. Casein was chosen as phosphorylated protein model. Phosphopeptide was obtained by tryptic digestion *in situ* on HA-casein complexes.

## **9. Experimental procedure 1**

### ***Materials***

Raw whole milk was collected from local dairy farms. Milk was skimmed by centrifugation at 4,000 rpm at 4° C for 30 min. Isoelectric casein was prepared by adding to skim milk 10% (v/v) acetic acid, allowing to stand 30 min at 35° C and then adding 1M NaOAc to 4.6 final pH. After standing for 30 min, suspension was centrifuged (4,000 rpm, 5° C for 30min), the supernatant discarded, casein washed twice with buffer diluted 1:4, twice with water Milli-Q, and subsequently freeze dried. HA (Macro-Prep Ceramic Hydroxyapatite TYPE I, catalog number 157-0040) was purchased from Bio-Rad (Milan, Italy). Tris (hydroxymethyl) aminomethane hydrochloride (Tris-HCl), potassium chloride (KCl), urea, trifluoroacetic acid (TFA), acetonitrile (ACN) for HPLC Plus, orthophosphoric acid 85% were from Carlo Erba (Milan, Italy). Trypsin TPCK treated from bovine pancreas was from Sigma (St. Louis, MO, USA). Sodium acetate trihydrate, 2,5-dihydroxybenzoic acid (DHB) were from Fluka (St. Louis, MO, USA). Acetic acid was purchased from Baker Chemicals B.V. (Deventer, The Netherlands). Dithiothreitol (DTT) was from Applichem (Darmstadt, Germany). Water was prepared using a Milli-Q system (Millipore, Bedford, MA, USA).

### ***HA-based phosphoprotein/peptide enrichment***

Casein (10 mg) was dissolved in 80µl buffer at pH 8.0 containing TrisHCl 50 mM, KCl 0.2 M, urea 4.5 M, DTT 10 mM. The casein solution was loaded on HA (10 mg), previously equilibrated in the loading buffer. The HA-bound casein was incubated for 15 min at room temperature and centrifuged for 5 min at 4,000 rpm. The resin was washed in succession with three buffers, i.e. the loading buffer (1ml); washing buffer at pH 7.8 containing Tris-HCl 50mM (1 ml); and 20mM Tris-HCl (pH 7.8) buffer containing 20% ACN (v/v)(1ml). The resin washed with water Milli-Q (1ml) and finally freeze-dried with a SpeedVac concentrator system (Thermo Electron, Milford, MA).

### ***HA-based CPP enrichment***

The HA-bound phosphoproteins were hydrolyzed *in situ* with trypsin added to the suspension at an enzyme/substrate ratio of 1:50 (w/w) in 50mM Tris-HCl buffer, pH 8.0, containing 0.2 M KCl, 4.5M urea, and 10 mM DTT. The reaction was carried out at 37° C overnight and stopped by centrifuging the HA-CPP microgranules for 5 min at 4,000 rpm. Then, the microgranules were washed as described above for



phosphoproteins. After washing with water Milli-Q, they were dried by using a SpeedVac apparatus.

### **MALDI-TOF MS Analysis**

MALDI-TOF mass spectra were recorded using a Voyager DE-PRO mass spectrometer (Applied Biosystem, Framingham, USA), in positive linear mode. All spectra were acquired in the range of 15–30 kDa (for proteins) and 1–5 kDa (for peptides) with the following settings: an accelerating voltage 25 kV (for proteins), and 20 kV (for peptides) and grid voltage 93% (for proteins) and 95% (for peptides) of accelerating voltage, a guide wire of 0.15% (for proteins) and 0.05% (for peptides), delayed ion extraction time of 485 (for proteins) and 175 ns (for peptides). The laser power was set just above the ion generation threshold to obtain peaks with highest possible signal to noise ratio. All spectra were acquired with 200 shots in 3 replicate. Two different matrix solutions were freshly made each day using stocks of the required solvents and sonicated for 15 min in an ultrasonic water bath prior to use. The sample/wash (SW) method was based on the sample/matrix/wash (SMW) method described by Zhang *et al.*<sup>138</sup> with the exclusion of the wash step. The matrix for phosphoprotein analysis was constituted by sinapinic acid (SA) solution at 10 mg/mL in 50% ACN and 0.1% TFA. 1  $\mu$ L of sample was added to spot and allowed to dry. The matrix for phosphopeptides contained 2,5-dihydroxybenzoic acid (2,5-DHB), 10 mg/mL in 1 ml of H<sub>2</sub>O/ACN/PA (49/50/1). 1  $\mu$ L of sample was added to spot and allowed to dry. The HA-phosphoprotein microgranules were deposited onto the MALDI plate and covered with the SA matrix (10 mg/ml in 50% ACN) to promote analyte/matrix co-crystallization in presence of increasing TFA concentration (0.01%, 0.05%, 0.1% and 0.5%) for proteins. For CPP, 1% phosphoric acid (PA) was included in the DHB solution (10 mg/ml SA in 50% ACN)<sup>139</sup>.

### **Microscopic observation**

The HA-CPP microgranules deposited onto a 96-well MALDI target were observed by stereomicroscopy before and after co-crystallization with the DHB matrix. The microscope (PBI International, Milan, Italy) was equipped with a binocular head illuminated with a 6 V, 20 W halogen lamp and 100-230 V, 50/60 Hz power supply

### **LC/MS Analysis**

LC/MS spectra were obtained by means of an Agilent 1100LC/MSD single quadrupole instrument. HA-CPP complexes (1 mg) were solubilized with 120  $\mu$ L of solution containing 0.5% PA and 100  $\mu$ L of this solution were then injected. For this analysis, HA-CPP complexes of caseins were fractionated using a Vydac C18 218TP52 column (250mm-2.1mm i.d.), at a constant flow rate of 0.2 mL/min. Elution was carried out with a linear gradient from 5% to 90% of solvent B (0.1% TFA in acetonitrile, v/v) over 100 min after 15 min of isocratic elution at 5% B; solvent A was 0.1% TFA in water (v/v). Liquid effluents from the column were directly injected into the source of a LC/MSD SL (Agilent Technologies) single quadrupole mass spectrometer. The mass spectra were scanned from m/z 1600 to 400 at a scan cycle of 4.90 s/scan and 0.1 s inter-scan delay. The source temperature was 180°C. Spectra were acquired in positive ion mode, where the capillary voltage and the cone




voltage were 3.6 kV and 40 V, respectively. N<sub>2</sub> was used as both the drying and nebulising gas.

### LC-ESI-MS/MS Analysis

HA-CPP complexes (1 mg) were solubilized with 120 µl of 0.5% PA and analyzed by a CapLC nano-flow high-pressure pump system (Waters) interfaced with a QTOF Micro mass spectrometer (Waters/Micromass) operating in the positive ion mode. Chromatographic separations were performed on a reverse phase Atlantis dC18 capillary column (75 µm i.d.). The mobile phase was water (A) and ACN (B) with 0.1% FA. A linear gradient from 5 to 70% of B was applied over 45 min at a flow-rate of approximately 300 nL/min using a precolumn split with a pump operating at 5 µl min<sup>-1</sup>. The source conditions were as follows: capillary voltage, 2.6 kV; cone voltage, 100 V; and RF1 lens, 40 V. In the ESI-MS/MS experiments for peptide sequencing, argon was used as the collision gas. Raw data were processed using MassLynx 3.5 ProteinLynx software.

## 10. Results and discussion

The analytical method which finally was adopted can be summarized in the following six consecutive steps: (1) selective enrichment of the phosphoproteins/phosphopeptides on HA microgranules (resin:protein 1:1, w/w) from protein mixtures, (2) flow-through of the unphosphorylated components using the dilution/washing buffer, (3) drying the protein/peptide-HA microgranules, (4) loading a few dried HA microgranules (~1000) on the MALDI target plate; (5) covering with the sinapinic acid or DHB matrix with acid solution (TFA) or (PA) respectively which co-crystallise with HA microgranules and (6) *in situ* desorption of the bound HA-phosphoproteins/phosphopeptides by direct MALDI/MS analysis (Figure 5).





**Figure 5.** Schematic representation of the technique of HAP-based phosphoproteins/peptides enrichment. Phosphoproteins/peptides were bound to the HAP through their phosphate groups, the non phosphorylated components were removed using washing buffers. The dried HAP-phosphoproteins were analysed directly by MALDI-TOF after co-crystallization of the sinapinic acid with an appropriate quantity of trifluoroacetic acid.

It resulted a highly sensitive and selective method with good reproducibility for extraction and enrichment of phosphorylated proteins and peptides. The unphosphorylated components including  $\gamma$ -CN and nonphosphorylated peptide like  $\alpha_{s1}$ -CN (f91-100) (m/z 1267), and  $\alpha_{s1}$ -CN (f8-22) (m/z 1759) were removed from the resin in the washing buffer. Inclusion of 20% ACN in the Tris-HCl buffers greatly


weakened ionic interaction between peptides and HA, which facilitated their release from the adsorbent resin. Moreover, using the Tris-HCl buffer at pH 7.8, the positively charged amino group of Tris was protonated and it competed with the peptides for binding to the negatively charged phosphate groups of the resin in order to weaken the bond between the amino groups of peptides and phosphate groups of the resin.

Therefore, some experiments were directed to optimize the separation of mono-phosphorylated and multiply phosphorylated proteins in separate pools. The HA-phosphoprotein microgranules were deposited onto MALDI plate and covered with sinapinic acid matrix (10 mg/ml in 50% ACN) to promote analyte/matrix co-crystallization, in presence of 0.01-0.5% TFA (Figure 6). It has been observed that the inclusion of 0.01% TFA in the MALDI matrix resulted in the ionization of phosphoproteins with a lower degree of phosphorylation as  $\kappa$ -CN 1P and  $\beta$ -CN (Figure 7, panel a). 0.1% TFA produced simultaneous ionization of all the casein components, i.e.  $\kappa$ -CN 1P,  $\beta$ -CN A<sup>1</sup> and A<sup>2</sup> variant, 4P and 5P,  $\alpha_{s1}$ -CN 8P and 7P, and  $\alpha_{s2}$ -CN 11P and 12P (Figure 7, panel b). TFA concentration beyond 0.01 and 0.1% did not afford different protein recovery. Using 0.005% TFA,  $\kappa$ -CN 1P was almost exclusively desorbed distinctly from the more phosphorylated components (not shown). Using 0.5% TFA concentration in the MALDI matrix did not afford higher recovery of protein.






**Figure 7.** MALDI MS spectra of casein eluted with 0.01%TFA (a) and 0.1%TFA (b)



## Analysis of phosphopeptides

For the isolation of CPP, well rinsed HA-casein microgranules in suspension were submitted to hydrolysis *in situ* by overnight trypsin treatment. The resulting microgranules were separated by centrifugation and cleansed through mixing the equilibration/washing buffer to ensure that the enzyme action was stopped. The nonphosphorylated peptides were eliminated by washing buffers as illustrated in the Figure 8.




**Figure 8.** Schematic representation of the HAP-based CPP enrichment technique. HAP-bound phosphoproteins were hydrolyzed *in situ* by trypsin. Non phosphorylated peptides were washed out in the flow-through. The dried HAP-CPP microgranules included in the crystalline matrix were analysed by MALDI-TOF directly on the MALDI plate.

We raised the problem of determining which peptides remained tightly bound to the resin. Hence, a system of quality control of CPP preparation was developed, using mass spectrometry techniques such as MALDI/MS, LC-ESI/MS and LC-ESI-MS/MS. We demonstrated that each of these techniques allows to characterize the CPP bound to the resin. The study showed that the resin immobilizes a plethora of peptides, including CPP with multiple phosphorylation site of the type  $\alpha_{s1}$ -CN (f59-79) 5P (f2720.91 Da),  $\beta$ -CN (f1-25) 4P (3122.26 Da) and  $\alpha_{s2}$ -CN (f46-70) 5P (3087.99


Da), each containing the sequence cluster Ser(P)-Ser(P)-Ser(P)-Glu-Glu, functional to metal ion transport. A rapid analytical technique has been developed for the identification of the CPP. The HA-CPP microgranules were co-crystallised onto the well MALDI plate included into DHB matrix solution and phosphoric acid. Inclusion of 1% phosphoric acid allowed to achieve the maximum ionization efficiency by MALDI and minimize binding of CPP to HA. Kjellstrom, S and Jensen, O. N.<sup>139</sup> reported that phosphoric acid (PA) was proved to be the matrix additive chosen for the sensitive detection of phosphopeptides. PA actually worked well in enhancing the phosphopeptide signals.

The microscope images of HA-CPP on well MALDI plate before and after crystallisation are shown in Figure 9.



**Figure 9.** The microscopic images of HA-CPP on well MALDI plate before (a) and after crystallisation (b) of HA-CPP microgranules with DHB matrix in PA solution.

The MALDI spectrum of HA-CPP complexes is shown below (Figure 10). An enlargement in two spectra has been obtained for marking the corresponding CPP to every peak (Figure 10).



**Figure 10.** MALDI mass spectrum of HA-CPP complexes loaded directly on the well MALDI plate after enrichment. An enlargement in two spectra has been underlined.


The overnight incubation and high trypsin-to-substrate ratio (resin/enzyme=1/50) produced the maximum yield of tryptic peptides. Protein binding via Lys and Arg residues to negatively charged *P*-sites of HA would mask most of the casein sites to trypsin. In contrast, binding of phosphate groups to HA was chosen as

casein remained as susceptible to trypsin and produced tryptic CPP of ideal size for mass spectrometry analysis. The presence of basic amino acids Arg and Lys in C-terminal position also facilitates subsequent mass spectrometric analysis. In spite of this, from the proteolytic digests of casein about thirty CPP were identified, including some phosphopeptides with missed cleavages (Table 2). The list of the theoretical tryptic CPP annotated in the Swiss Prot archives and their molecular masses is shown in the Table 2. Tryptic phosphopeptides were identified by comparing the measured mass with that derived from the standard casein sample.

**Table 2.** Identification of CPP bound to the HA microgranules loaded directly on the well MALDI plate after enrichment.

Molecular Mass (Da)		Peptide identification	Missed cleavages CPP
NATIVE CPP			
Expected	Measured MH <sup>+</sup>		
1410.5	1411.6	$\alpha_{s2}$ (f126-136)2P	
1466.5	1467.6	$\alpha_{s2}$ (f138-149)1P	
1538.6	1540.3		$\alpha_{s2}$ (f126-137)2P
1594.7	1595.6		$\alpha_{s2}$ (f138-150)1P
1659.8	1661.6	$\alpha_{s1}$ (f106-119)1P	
1846.7	1847.1	$\alpha_{s1}$ (f43-58)1P	
1926.1	1928.3	$\alpha_{s1}$ (f43-58)2P	
1952.0	1952.3	$\alpha_{s1}$ (f104-119)1P	
2060.8	2062.8	$\beta$ (f33-48)1P	
2080.4	2079.4		$\alpha_{s1}$ (f103-119)1P
2539.4	2538.6	$\alpha_{s2}$ (f2-21)3P	
2598.0	2598.1		$\alpha_{s1}$ (f37-58)2P
2618.9	2619.3	$\alpha_{s2}$ (f2-21)4P	
2678.0	2678.3		$\alpha_{s1}$ (f37-58)3P
2703.9	2703.8	$\alpha_{s1}$ (f59-79)5P pyroQ	
2720.9	2720.9	$\alpha_{s1}$ (f59-79)5P	
2746.9	2747.6		$\alpha_{s2}$ (f1-21)4P
2855.2	2855.4		$\alpha_{s1}$ (f35-58)2P
2886.2	2886.0	$\beta$ (f2-25)3P	
2935.2	2935.2		$\alpha_{s1}$ (f35-58)3P
2966.2	2966.0	$\beta$ (f2-25)4P	
3088.0	3087.0	$\alpha_{s2}$ (f46-70)5P	
3007.9	3007.3	$\alpha_{s2}$ (f46-70)4P	
3122.3	3122.1		$\beta$ (f1-25)4P
3042.3	3043.8		$\beta$ (f1-25)3P
3132.1	3131.4		$\alpha_{s2}$ (f1-24)4P
3477.5	3477.0		$\beta$ (f1-28)4P
3605.6	3605.1		$\beta$ (f1-29)4P

LC/MS analysis of samples enriched in phosphopeptides was also carried out to verify purity of the preparation and the correctness of peptide assignment. The LC-ESI-MS TIC profile (Figure 11) and identification of the chromatographic peaks are reported in Table 3.



**Figure 11.** LC-MS chromatogram of CPP bound to the HA microgranules dissolved with an aqueous solution containing 0.5% PA

Dissolution of HA in 5% PA (w/v) solution has been carried out to ensure that all CPP bound were actually eluted from the resin.

**Table 3.** Peptide identification of each chromatographic peak of CPP bound to the HA microgranules dissolved with an aqueous solution containing 0.5% PA.

Peak Number	Theoretical mass (Da)	Measured mass (Da)	Peptide identification
1	1410.49	1410.82	$\alpha_{s2}$ -CN (f126-136)2P
2	1538.59	1538.04	$\alpha_{s2}$ -CN (f126-137)2P
3	1942.70	1943.00	$\alpha_{s1}$ -CN (f43-58)2P M(0)
4	2061.01	2061.59	$\beta$ -CN (f33-48)1P
	2720.90	2720.90	$\alpha_{s1}$ -CN (f59-79)5P
5	2720.90	2720.98	$\alpha_{s1}$ -CN (f59-79)5P
	3007.90	3008.04	$\alpha_{s2}$ -CN (f46-70)4P
6	3007.90	3008.04	$\alpha_{s2}$ -CN (f46-70)4P
7	3004.09	3004.26	$\alpha_{s2}$ -CN (f2-24)4P
	2618.89	2618.97	$\alpha_{s2}$ -CN (f2-21)4P




	2431.06	2431.86	$\beta$ -CN (f30-40)1P
8	1926.68	1927.32	$\alpha_{s1}$ -CN (f43-58)2P
9	1465.60	1465.40	$\alpha_{s2}$ -CN (f138-149)2P
	1846.70	1847.00	$\alpha_{s1}$ -CN (f43-58)1P
10	2935.19	2935.29	$\alpha_{s1}$ -CN (f35-58)3P
	2678.02	2678.03	$\alpha_{s1}$ -CN (f37-58)3P
11	2598.05	2598.10	$\alpha_{s1}$ -CN (f37-58)2P
	2855.19	2855.20	$\alpha_{s1}$ -CN (f35-58)2P
12	1659.80	1660.33	$\alpha_{s1}$ -CN (f106-119)1P
13	1951.95	1951.62	$\alpha_{s1}$ -CN (f104-119)1P
	3449.47	3448.64	$\beta$ -CN (f2-29)4P
14	3122.26	3122.42	$\beta$ -CN (f1-25)4P
15	3122.26	3122.42	$\beta$ -CN (f1-25)4P
16	2966.16	2966.22	$\beta$ -CN (f2-25)4P
	3122.26	3122.42	$\beta$ -CN (f1-25)4P
17	3477.48	3477.83	$\beta$ -CN (f1-28)4P
	3605.06	3605.30	$\beta$ -CN (f1-29)4P
18	3042.26	3043.32	$\beta$ -CN (f1-25)3P
	2966.16	2965.83	$\beta$ -CN (f2-25)4P
	3122.26	3121.13	$\beta$ -CN (f1-25)4P
19	3042.26	3042.34	$\beta$ -CN (f1-25)3P
	2886.16	2886.17	$\beta$ -CN (f2-25)3P
20	2886.16	2886.29	$\beta$ -CN (f2-25)3P

The results of the LC-MS analysis underline the presence of  $\alpha_{s2}$ -CN (f2-24)4P (3004.09 Da) which was masked by the more abundant signal of  $\alpha_{s2}$ -CN (f46-70)4P (3007.90 Da). It is possible to observe also the presence of the  $\beta$ -CN (f2-29)4P (3449.47 Da) peptide whose ionization was suppressed from that of the most abundant peptides in MALDI spectrum.

The fragmentation spectra obtained with ESI-MS/MS allowed to confirm the CPP bound to the HA and to identify the sites which underwent dephosphorylation. For example, the spectrum of Figure 12 shows the fragmentation of  $\alpha_{s1}$ -CN (f43-58)2P peptide having the amino acid sequence NH<sub>2</sub>-Asp-Ile-Gly-**p**Ser-**p**Ser-Glu-Thr-Glu-Asp-Gln-Ala-Met-Glu-Asp-Ile-Lys-COOH and molecular mass of 1926.7Da containing two serine residues (Ser<sub>46</sub> and Ser<sub>48</sub>) both phosphorylated while phosphorylatable Thr<sub>49</sub> was unphosphorylated.






**Figure 12.** MS/MS spectrum from fragmentation of the doubly charged precursor ion at  $m/z$  964.31. The product ions belonging to the y series is indicated. The fragmentation spectra were processed by the MaxEnt 3 program to a singly charged spectra and were elaborated using the ProteinLynx software.

The ions  $y_{10}$  (1179.51 Da) and  $y_{11}$  (1346.51 Da) with molecular mass variation ( $\Delta m$ ) of 167 Da (Ser + H<sub>3</sub>P<sub>0</sub><sub>4</sub>) indicate the fragmentation of phosphorylated Ser<sub>48</sub> (11<sup>th</sup> position from the C-terminal), the ions  $y_{12}$  (1475.55 Da) and  $y_{13}$  (1642.55 Da) with  $\Delta m$  of 167 Da (Ser + H<sub>3</sub>P<sub>0</sub><sub>4</sub>) indicate the fragmentation of phosphorylated Ser<sub>46</sub> (13<sup>th</sup> amino acids from the C-terminal).

The fragmentation of the peptide  $\alpha_{s1}$ -CN (f43-58)1P with amino acid sequence NH<sub>2</sub>-Asp-Ile-Gly-Ser-Glu-pSer-Thr-Glu-Asp-Gln-Ala-Met-Glu-Asp-Ile-Lys-COOH and molecular mass of 1846.74 Da included only one phosphate group on Ser<sub>48</sub>, whereas Ser<sub>46</sub> remained free (Figure 13).



**Figure 13.** MS/MS spectrum from fragmentation of the doubly charged precursor ion at  $m/z$  924.38. The product ions belonging to the  $y$  series is indicated. The fragmentation spectra were processed by the MaxEnt 3 program to a singly charged spectra and were elaborated using the ProteinLynx software.


The ions  $y_{10}$  (1179.51 Da) and  $y_{11}$  (1346.51 Da) with  $\Delta m$  of 167 Da (Ser +  $H_3PO_4$ ) indicate the fragmentation of phosphorylated Ser<sub>48</sub> (11<sup>th</sup> amino acids from the C-terminal), the ions  $y_{12}$  (1475.55 Da) and  $y_{13}$  (1562.59 Da) with  $\Delta m$  of 87Da (Ser) indicate the fragmentation of not phosphorylated Ser<sub>46</sub> residue (13<sup>th</sup> position from the C-terminal)

The ESI Q-TOF analysis of the phosphorylated mixture confirmed the presence of the peptide  $\alpha_{s1}CN$  (f43-58) with one degree of phosphorylation. Thus this peptide confirms the copresence of native casein  $\alpha_{s1}CN$  7P and  $\alpha_{s1}CN$  8P.

These experiments allowed to confirm the selectivity and specificity of the resin and the purity of the mixture obtained by applying the outlined analytical technique. At that time, it was assayed to transfer from the laboratory to pilot scale the HA-CPP complex for functional milk formulation.

## 11. Formulation of a functional drink in semi-industrial scale

The laboratory technique was transferred to semi-industrial scale. First at all the development of an industrial process implies the use of inexpensive raw materials. Thus, we planned the preparation of the complex HA-CPP in semi-industrial scale by de novo synthesizing HA, owing to the expensive commercial product. Therefore, HA was synthesized by wet-chemical precipitation reactions from  $\text{Ca}(\text{OH})_2$  and  $\text{H}_3\text{PO}_4$  solution, adopting temperature and pH optimum for obtaining pure crystals of apatite. The absorbent activity of the synthesized resin (HAS) was evaluated by comparing the binding capacity of CPP in 3 different proteins mixtures, e.g. isoelectric casein, milk proteins (casein + whey proteins) and raw milk. Milk proteins, commonly used in the dairy industry or raw milk were directly loaded on HA. After opportune washings, casein-HA and tryptic derived CPP were compared to those recovered by using isoelectric casein. We demonstrated that protein material loaded on HA could be variable depending on specific needs because the same CPP were linked to HAS from isoelectric casein, milk proteins and raw milk. For functional milk preparation, tryptic hydrolysis of *in situ* bound protein was operated on the HAS-casein suspension. There were CPP tightly bound to HA, and non-phosphorylated peptides removed from the resin by repeated washing buffers, until a washed product in milliQ water was obtained. The HA-CPP microgranules were then dried for the storage of the powder for times of the order of years at room temperature. Dried microgranules of HA-CPP complex were also analysed by MALDI. Then, dried microgranules were ground before addition to milk. The flow diagram of preparation of functional milk is shown below (Scheme 2).



**Scheme 2.** Flow diagram of functional milk preparation


## 12. Experimental procedure 2

### **Materials**

Raw whole milk was collected from local dairy farms. The skimmed pasteurized milk was supplied by YMA industry. Milk proteins powder were from Sacco industry (Milan, Italy). Calcium hydroxide was purchased from Carlo Erba (Milan, Italy). The source of the other raw materials has already been above indicated.

### **HA Synthesis**

HA was precipitated using this following reaction scheme.



12.5 mmol or 925 mg of  $\text{Ca}(\text{OH})_2$  powder in 125 mL of milliQ water and 7.5 mmol or 865 mg of 85 wt%  $\text{H}_3\text{PO}_4$  in 125 mL of milliQ water were used for the HA precipitation. The orthophosphoric acid solution was added in a dropwise manner to a dilute solution/suspension of calcium hydroxide. Prior to  $\text{PO}_4^{3-}$  ion addition to the  $\text{Ca}^{2+}$  ion solution, the latter was heated to 90°C and stirred for 1h at 400 rpm. The acid was added at a rate approximately equal to 3.5 mL/min using a peristaltic pump. The reaction was maintained under constant stirring to ~400 rpm at room temperature for 2h. The precipitation reaction was slow and proceeded at 4°C overnight. The precipitate was filtered, washed with milliQ  $\text{H}_2\text{O}$  for 3 times and dried in an oven at 60° C.

### **Application of the synthetic HAS to isoelectric casein, milk protein and raw milk**

The binding capacity of the synthesized HAS was evaluated by comparing the MALDI spectra of CPP from 3 different proteins mixture, e.g. isoelectric casein (sample 1), milk proteins (sample 2) and raw milk (sample 3).

Sample 1: 1 g casein was dissolved in 8 ml of buffer at pH 8.0 containing Tris-HCl 50 mM, KCl 0.2 M, urea 4.5 M, DTT 10 mM. The protein solution was loaded on 1 g of synthesized HA (ratio HA/protein=1/1), previously washed with loading buffer.

Sample 2: 1g milk proteins was dissolved in 8 ml of pH 8.0 buffer containing Tris-HCl 50mM, KCl 0.2 M, urea 4.5 M, DTT 10 mM. The protein solution was loaded on 1g of synthesized HA (ratio HA/protein=1/1), previously washed with loading buffer.

Sample 3: 31.2 ml of raw milk was loaded on 1 g of synthesized HAS (ratio HA/casein=1/1), previously washed with loading buffer.

The next steps and MALDI analysis conditions were the same as those already reported. The MALDI analysis of milk peptides was conducted by loading on the spot 1  $\mu\text{L}$  of milk solution diluted 1:100 with a solution containing  $\text{H}_2\text{O}/\text{ACN}$  (50/50). 1  $\mu\text{L}$  of the DHB solution (10 mg/mL) containing  $\text{H}_2\text{O}/\text{ACN}/\text{PA}$  (49/50/1) was loaded on dried sample and allowed to dry.

### ***Adding the suspension to skimmed pasteurized milk***


Aliquots of finely ground HAS-CPP microgranules (100 and 250 mg) could be derived from each of the above prepared samples. To avoid the immediate sedimentation of HAS-CPP in milk, grinding was carried out using the Ultra-Turrax T25 apparatus for 3 min at 24,000 rpm. 100  $\mu$ l (0.2% v/v) and 250  $\mu$ l (0.5% v/v) of the suspension aliquots were added to 50 ml of raw milk. The HAS-CPP microgranules added to the milk were recovered by centrifugation, washed and analyzed by MALDI-TOF to assess the residual binding capacity of the resin.

## **13. Results and discussion**

Hydroxyapatite [HA,  $\text{Ca}_5(\text{PO}_4)_3\text{OH}$ ] is a versatile biomaterial and when synthesized from wet-chemical precipitation reactions often forms nanoparticles with varying particle size and morphology, depending on the reactants and reaction conditions. Furthermore, the morphology, crystallite size, purity, stoichiometry, and structure of HA influence its bioactivity, bio-compatibility, chemical and physical stability, and mechanical properties, hence, its *in vitro* and *in vivo* performance after processing<sup>140</sup>.

The synthesis of HA can take place through a variety of processes. HA synthesis includes the sol-gel technique<sup>141</sup>, solid-state reactions at elevated temperatures<sup>142</sup>, and biosynthesis routes<sup>143</sup>. Among the different synthesis methods, the wet precipitation method for synthesizing HA was proved to be the most suitable to industrial application. Among the various syntheses, the wet-chemical precipitation reactions from  $\text{Ca}(\text{OH})_2$  and  $\text{H}_3\text{PO}_4$  were chosen for simplicity, rapidity of reaction and high level of repeatability. The morphology of the HA precipitates changed from needlelike to nearly spherical. The aspect ratio (length-to-diameter ratio) decreases as the reaction temperature is increased when it is synthesized using  $\text{Ca}(\text{OH})_2$  and  $\text{H}_3\text{PO}_4$ <sup>144,145</sup>. The crystallinity of apatites prepared at higher precipitation temperatures was higher than those prepared at lower precipitation temperatures (T). In particular  $T=90^\circ\text{C}$  produced a higher purity and crystallinity product.<sup>146</sup>. For this reason, the conditions described above were used.

To assess the binding capacity of the resin, three protein mixtures a) isoelectric casein, b) milk protein and c) raw milk were loaded on HAS. These proteins were linked to the resin, and *in situ* hydrolyzed by trypsin. The spectra of the three preparations are compared in Figure 14.




**Figure 14.** MALDI mass spectra of CPP recovered by HAS from isoelectric casein (a), milk protein (b) and raw milk (c).

Although the protein mixture loaded on HAS was of different complexity, the CPP profile revealed by MALDI-TOF analysis was similar, indicating that binding of the casein fractions to HAS was the same, with respect to the sample composition

and its form. This assays showed that the process was scalable for industrial purposes by using the most common protein source as ingredient depending on the specific industrial needs. Once obtained the HAS-CPP complexes on pilot scale, a functional food was formulated. It has been demonstrated that the addition of 2.0–5.0 g CPP-ACP<sup>1</sup> to milk increases its ability to remineralize enamel subsurface lesions<sup>147</sup> and the remineralizing effect of CPP-ACP in milk was dose-dependent with milk containing 0.2% CPP-ACP and 0.3% CPP-ACP producing an increase in mineral content of 81% and 164%, respectively, in comparison to the control milk<sup>148</sup>. The percentage of HAS-CPP was added to the functional milk. As the HAS-CPP suspension have greater density than milk, before addition to milk, the granules of HAS-CPP were finely ground to avoid their fast sedimentation. However, before drinking, functional milk should be shaken to homogenize the suspension.

Before analysis of microgranules recovered by milk, control CPP from skimmed pasteurized milk was carried out by MALDI analysis (Figure 15, panel a). This analysis disclosed the affinity of the milk proteins and peptides for the resin. The spectra of the HA-CPP showed casein in soluble sodium salts (not shown spectrum) and CPP bound HA (Figure 15, panel b).




**Figure 15.** MALDI spectra of peptides from skimmed pasteurized milk before HAS enrichment (a) and after HAS enrichment (b).

In the spectra of the untreated skimmed pasteurized milk, four non-phosphorylated peptides such as  $\beta$ -CN (f184-204),  $\alpha_{s1}$ -CN (f2-22),  $\alpha_{s2}$ -CN (f189-207) and  $\alpha_{s1}$ -CN (f179-199) together with a number of CPP (Figure 15, panel a) was detected in the wider mass range 2200-4200 Da. Sample treated with HAS microgranules specifically captured CPP, while those non-phosphorylated contaminating the resin were removed by extensive washings in batch with buffer as detailed in the experimental procedure 1.

Furthermore, the HAS-CPP microgranules added to milk were recovered by centrifugation and bound CPP were detected by MALDI-TOF, by loading microgranules on the well MALDI plate (Figure 16, panel c).

Comparison of the MALDI spectra amongst HA-CPP before addition to milk (a), peptides in untreated skimmed pasteurized milk (b) and HA-CPP fixed after addition to milk (c) are shown in Figure 16 (panel a-c). The microgranules of HAS-CPP added to milk (Figure 16, panel a) were able to chelate further free CPP in milk (Figure 16, panel b).





**Figure 16.** MALDI spectra of comparison between HA-CPP before addition to milk (a), peptides in untreated skimmed pasteurized milk (b) and HA-CPP after addition to milk and after recovery by centrifugation (c).

The HA-CPP microgranules added to milk were able to chelate further free CPP of milk as demonstrated in the spectrum (Figure 16, panel c) by the increased signals of peptides marked in purple. The number of CPP present in skimmed pasteurized milk sample (Figure 16, panel b) increased the level of CPP binding HAS-CPP complexes after addition to milk compared to the control (Figure 16, panel a). This means that some C-sites of HAS yet remained accessible to phosphate groups while the P-sites were able to chelate metal ions.

Finally, the same sensory characteristics of functional milk have been evaluated. Milk enriched with CPP showed the same sensory characteristics as starting milk, as CPP were neutralized by the calcium ions of the HAS crystals. The HAS-CPP complex is odourless and tasteless.

The HAS-CPP complex has been added to milk but it could be added to a wide range of products as toothpaste, toothpowder, topical gels, dental filling material, mouthrinse, chewing gum, lozenges, tablets, mineral drinks, nutritional supplements for children, confectionery, and products for dental care mouthrinse.

In conclusion, the preparation of a functional drink in semi-industrial settlement allowed to obtain a product with inexpensive raw materials and with nutraceutical ingredients (HAS-CPP) that could induce beneficial effects on human health especially for teeth.

#### 14. Quantification of CPP in HAS-CPP preparation to be added to milk

To understand the amount of CPP addition in the milk, the problem of quantitative determination of CPP linked to HAS has been faced.

Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) is used to obtain fast and accurate determination of molecular mass, but quantitative determinations are generally made by other techniques. While there have been reports of quantitative MALDI-TOFMS applications, there are many problems inherent to the MALDI ionization process that have restricted its widespread use<sup>149</sup>. These limitations primarily stem from factors as the limited dynamic range due to detector saturation, difficulties associated with coupling MALDI-TOFMS to on-line separation techniques as liquid chromatography and especially the sample/matrix heterogeneity that are believed to contribute to the large variability in observed signal intensities for analytes. A major issue is the non-homogeneous distribution of the analyte in the cocrystallite. For example, especially non homogeneous needle-shaped crystals were observed when DHB was used as a matrix. This leads to the observation that, at several points of the sample, no analyte signals can be found whereas at other positions strong signals can be monitored (hot-spot formation). The varying ion response on different positions on the sample spots leads to poor “shot-to-shot” reproducibility and poor “point-to-point” repeatability and this is therefore one of the main reasons hampering quantitative MALDI MS<sup>150</sup>. Because of these difficulties, practical examples of quantitative applications of MALDI-TOFMS have been limited. Internal standards have been used successfully to overcome these problems.<sup>151,152</sup> For quantification, in fact, internal standards are necessary to compensate for the poor shot-to-shot reproducibility inherent in the use of MALDI analysis. The selection of an appropriate internal standard (IS) for quantification is critical for the successful application of quantitative MALDI. There are several properties of the *ideal* internal standard<sup>153</sup>: 1) It must be completely resolved from the analyte; 2) It must be chemically stable during the analysis; 3) It should be chemically similar to the analyte (including ionization and extraction efficiencies) and should not react with the analyte; 4) It should be close to the analyte in mass and concentration to avoid instrumental errors. Ideal internal standards are substances showing a high physico-chemical similarity to the analyte. Standards labelled with stable isotopes like <sup>2</sup>H, <sup>13</sup>C, <sup>14</sup>N or <sup>18</sup>O deliver best results in terms of accuracy of the quantification<sup>154</sup>. Another strategy is the use of non-isotope labelled internal standards<sup>155</sup>, applying structurally modified compounds. For example, peptides with high molecular similarity<sup>156</sup> were successfully used as internal standards for the relative quantitation of peptides. Moreover, it has been reported that MALDI-TOF MS can be used for the quantification of proteins and other bioactive molecules by evaluating the ratio of the peak heights between the analyte and a correctly selected internal standard<sup>157,158</sup>.


In this PhD work, synthetic internal standards were used to quantify tryptic CPP enriched by HAS and used as ingredient for the functional milk. The synthetic peptide analogues which were chosen varied for a single amino acid in the peptide sequence to achieve a ionization efficiency equivalent to that of tryptic phosphopeptide in the CPP mixture.

Two CPP with different degree of phosphorylation as monophosphorylated peptide  $\alpha_{s1}$ -CN (f106-119) 1P (1659.8 Da) and diphosphorylated peptide,  $\alpha_{s1}$ -CN (f43-58) 2P (1926.7 Da) were chosen for the quantification. Four synthetic peptides were synthesized by solid-phase Fmoc synthesis without further purifications by Dr.


Olga Fierro (ISA CNR, Avellino) for the construction of calibration curve: the two said above natural peptides (PG<sub>N</sub>) and the modified peptides analogues (PG<sub>M</sub>). The modified were point-mutated peptides where leucine was replaced by a glycine ( $\Delta m=56$ ) in monophosphorylated peptide (PG<sub>1M</sub>) and isoleucine was replaced by a glycine ( $\Delta m=56$ ) in diphosphorylated peptide (PG<sub>2M</sub>):

Synthetic natural $\alpha_{s1}$ -CN (f106-119) (PG <sub>1N</sub> ):	VPQ <b>L</b> EIVPNpSAEER (1659.8 Da)
Synthetic modified $\alpha_{s1}$ -CN (f106-119) (PG <sub>1M</sub> ):	VPQ <b>G</b> EIVPNpSAEER (1603.7 Da)
Synthetic natural $\alpha_{s1}$ -CN (f43-58) (PG <sub>2N</sub> ):	D <b>I</b> GpSEpSTEDQAMEDIK (1926.7 Da)
Synthetic modified $\alpha_{s1}$ -CN (f43-58) (PG <sub>2M</sub> ):	D <b>G</b> GpSEpSTEDQAMEDIK (1870.6 Da)

As the two natural and analogue peptides had almost identical sequences, no significant difference in ionization efficiency was expected when mixtures of PG<sub>1N</sub> and PG<sub>1M</sub> and PG<sub>2N</sub> and PG<sub>2M</sub> were analyzed by MALDI-TOF. Measurements were made on the mixture containing PG<sub>1N</sub> and PG<sub>1M</sub> (Figure 17) and PG<sub>2N</sub> and PG<sub>2M</sub> (Figure 18) in 1:1(w/w) ratio.




**Figure 17.** MALDI spectrum of a solution containing PG<sub>1N</sub> and PG<sub>1M</sub> in 1:1 ratio




**Figure 18.** MALDI spectrum of a solution containing PG<sub>2N</sub> and PG<sub>2M</sub> in 1:1 ratio

It is worthy of note that, at this ratio, the peptide analogues showed different ionization even if the sequence varied in a single amino acid residue and concomitantly for the purity. This afforded different interaction with the matrix causing different ionization efficiency. It has experimentally been demonstrated that in order to have the same ionization the PG<sub>1N</sub>/PG<sub>1M</sub> ratio was 0.4/1 and PG<sub>2N</sub>/PG<sub>2M</sub> ratio was 0.9/1 as shown in the 'concentration ratio' column (Table 4 and 5). Taking into

account these ratios, three solutions containing concentrations of PG<sub>N</sub> and PG<sub>M</sub> in ratios of 1:1, 0.5:1 and 0.1:1 were compared (Figure 19 and 20).



**Figure 19.** MALDI spectra of solutions containing PG<sub>1N</sub> and PG<sub>1M</sub> in ratios of 1:1, 0.5:1 and 0.1:1 to detect the area of the underlying peak.



**Figure 20.** MALDI spectra of solutions containing PG<sub>1N</sub> and PG<sub>1M</sub> in ratios of 1:1, 0.5:1 and 0.1:1 to detect the area of the underlying peak.

The peptide mixture was analysed by MALDI-TOF, operating in reflector mode. The spectra were recorded by acquiring about 500 shots/spectrum to compensate for uneven ionization within the sample spots. Laser intensity was kept constant during the acquisition of data points. Each data point represents the average of five different spectra. The calibration curve was obtained by measuring the area of the underlying peak of synthetic natural peptide and its corresponding modified counterparts. The value of each area was obtained by the summation of areas of the whole isotopic cluster. For each ratio, the average area of different five spectra was considered (Table 4 and 5). In these tables, the concentrations of peptides were also reported.


**Table 4.** Measured values for the construction of the calibration curve using  $\alpha_{s1}$  (106-119) 1P and its modified peptide form PG<sub>1N</sub>

Expected N/M ratio	Peak Area <sub>N</sub>	Peak Area <sub>M</sub>	Area ratio	ng/ml of PG <sub>1N</sub>	ng/ml of PG <sub>1M</sub>	Concentration ratio
1/1	263792.25	276173.54	0.96	0.4	1	0.4
0.5/1	97657.95	194804.78	0.50	0.2	1	0.2
0.1/1	35621.34	234596.16	0.15	0.04	1	0.04


**Table 5.** Measured values for the construction of the calibration curve using  $\alpha_{s1}$  (43-58) 2P peptide (PG<sub>2N</sub>)

Expected N/M ratio	Peak Area <sub>N</sub>	Peak Area <sub>M</sub>	Area ratio	ng/ml of PG <sub>2N</sub>	ng/ml of PG <sub>2M</sub>	Concentration ratio
1/1	239694.67	226015.81	1.06	0.9	1	0.9
0.5/1	104187.91	149248.32	0.70	0.45	1	0.45
0.1/1	25628.06	174475.81	0.15	0.09	1	0.09

The peak area ratio (Area PG<sub>N</sub>/Area PG<sub>M</sub>) was proportional to the measured concentrations of the corresponding peptides as shown by equation of the calibration curve (Figure 21 and 22).




**Figure 21.** Calibration curve of  $\alpha_{s1}$  (43-58) 2P peptide




**Figure 22.** Calibration curve of  $\alpha_{s1}$  (43-58) 2P peptide

The combined data yielded the two linear calibration curves having the equation  $y = 0.4478x - 0.0267$  for  $PG_{1N}$  and  $y = 0.8674x - 0.071$  for  $PG_{2N}$ . A linear relationship (correlation  $R^2 = 0.9999$  for  $PG_{1N}$  and  $R^2 = 0.967$  for  $PG_{2N}$ ) was observed between the peak area ratio and the concentration ratio of peptides.

The calibration curve was used to measure the amount of CPP ( $PG_{1N}$  and  $PG_{2N}$ ) in a mixture containing HAS-CPP complexes to measure the amount of CPP added in functional milk. For this objective, known amounts of modified peptides were added to the phosphopeptide mixture.  $PG_{1M}$  (0.1 ng/ml) and  $PG_{2M}$  (1 ng/ml) were added to each solution containing HAS-CPP (1 mg/ml) dissolved in the minimum amount of acid (12  $\mu$ l 5% PA) and diluted to a final volume of 1 ml of  $H_2O/ACN$  (50/50). The MALDI spectra are shown below (Figure 23 and 24).



**Figure 23.** MALDI spectrum of HA-CPP mixture with PG<sub>1M</sub> added to the mixture for quantification PG<sub>1N</sub>.



**Figure 24.** MALDI spectrum of HA-CPP mixture with PG<sub>2M</sub> added to the mixture for quantification PG<sub>2N</sub>.

From areas detected by MALDI and applying the linear equation, it is possible to know the amount of PG<sub>1N</sub> and PG<sub>2N</sub> peptide bound to the HAS. In 1 mg of HAS, there are 0.07 ng (40% of 0.18) of  $\alpha_{s1}$  (106-119)1P and 1.26 ng (90% of 1.4) of  $\alpha_{s1}$  (43-58)2P. As 100 mg and 250 mg of HAS-CPP were added to the functional milk, 7 ng and 17.5 ng of  $\alpha_{s1}$  (106-119)1P and 126 ng and 315 ng of  $\alpha_{s1}$  (43-58)2P were added to 50 ml of milk.



## 15. Evaluation of the quality of used milk for CPP preparation

The third part of the PhD work has been dedicated to the study for the evaluation of milk quality for CPP preparation. If abnormal milk is used for the formulation of a functional drink, the quality of CPP preparation could substantially change.

Endogenous milk enzymes are technologically significant for the deterioration of milk through proteolytic modification of native casein. Many of these enzymes originate from somatic cells (neutrophils, macrophages, lymphocytes and a smaller number of epithelial cells)<sup>159</sup>. The neutrophils, also called polymorphonuclear leukocytes (PMN), dominate in milk during mastitis<sup>160</sup>. This pathology is an illness characterized by inflammation of the mammary gland and that causes the increase in somatic cell counts (SCC) and in proteolytic enzyme activities. Plasmin, the active enzyme derived from plasminogen activation, is usually considered as the principal proteolytic milk enzyme. Both plasmin and plasminogen-derived activities in milk increase with SCC and severity of mastitic infection, due to a weakened blood–milk barrier, and therefore contribute to the proteolytic systems in mastitic milk<sup>161</sup>. Plasmin activity was found to increase more than the plasminogen derived activity and it suggested that the increased plasmin activity in mastitic milk was due to both increased influx of plasminogen from blood to milk and increased activation<sup>162</sup>. In bovine milk, the proteose-peptone fraction was investigated in relation to health status of the animals<sup>163</sup>.  $\beta$ -CN-5P (f1-105/7) peptides should increase in subclinical mastitic milk because these components are breakdown products of  $\beta$ -casein by plasmin. Indeed, these peptides actually resulted a mixture of transient intermediate proteolytic products, as the  $\beta$ -CN5P (f1-105) also occurred in control milk. Therefore, they were considered as inappropriate indicators of subclinical mastitis. In contrast, the components  $\beta$ -CN (f29-105/7)1P as terminal products of plasmin-like activity were correlated with the plasmin activity as indicators of the endogenous proteolysis in milk from cows with subclinical mastitis. In addition to plasmin, there are also other native proteinases in milk that may be secreted from somatic cells or leaked out from damaged somatic cells<sup>164</sup>. Proteinases, including elastase and cathepsin G, are the predominant enzymes associated to somatic cells of mastitic milk<sup>165</sup> whose specificity towards  $\alpha_{s1}$ - and  $\beta$ -casein is well documented<sup>166,167,168</sup>. Other proteinases found in mastitic milk include cathepsin B and the acid protease cathepsin D<sup>169</sup>. Recently, the activity of alkaline phosphatase (ALP) in association with subclinical mastitis (SCM) has been evidenced. The mean activities of ALP were higher in the milk from udders with SCM than in the milk from healthy udders, since the blood–milk barrier is damaged with infection and it is possible that ALP could be transferred from blood to milk. In this study, results have shown that the ALP presence was consistent in the early diagnosis of subclinical mastitis<sup>170</sup>. The casein phosphorylation is the most important posttranslational modification which declines the effect of the increased activity of phosphatase, associated with the somatic cells. Hence, it is important to extend the knowledge on the phosphorylation level of casein to better understand the milk technological properties. According to the casein model, phosphorylation is important since phosphate groups are directly involved in the micelle-micelle interactions during coagulation and curd syneresis<sup>171</sup>. Moreover, casein breakdown in mastitic milk reduces the cheese yield as casein is partially lost in whey<sup>172</sup>. Furthermore, from a mastitic milk, CPP with lower degree of phosphorylation were obtained so that the Ser(P)-Ser(P)-Ser(P)-Glu-Glu cluster important for transporting minerals was altered.

The objective of the first part of this work was to study the phosphorylation kinetic of casein, via the dephosphorylation *in vitro* of bovine casein to understand the potential of the HA-based enrichment technique.

In the second part, the casein and milk phosphopeptides with high level of SCC were studied, applying the same enrichment procedure. As model was assumed ovine casein isolated from the same animal with left udder with low and right one with higher level of SCC. Another important difference between the casein samples was the different ALP activity. Furthermore, the identity of the casein fractions and tryptic derived casein phosphopeptides with the exact number of phosphate group was unambiguously determined by mass spectrometry (MS). At the end of the study, the conclusive remark is that testing the presence of partly dephosphorylated caseins directly or indirectly through derived CPP is a suitable indicator for mastitic milk.

## **16. Experimental procedure 3**

### ***Materials***

Raw ovine milk was collected from local dairy farms. Milk from the left udder showed low SCC, instead milk from right showed high level of SCC ( $4.6 \times 10^6$  cells/ml). Alkaline phosphatase (Grade I, 4,000U) from calf intestine was supplied by Roche (Roche Diagnostics, GmbH, Mannheim, Germany). Ammonium bicarbonate buffer (AMBIC) was from Carlo Erba (Milan, Italy). The other material have already been described above.

### ***Dephosphorylation kinetic***

3 samples with different degree of phosphorylation of casein fractions were prepared.

Sample1: Bovine casein (10 mg) was dissolved in 100  $\mu$ L 0.4% AMBIC at pH 8 and dephosphorylated by alkaline phosphatase (100  $\mu$ g) at an enzyme/substrate ratio of 1:100. The reaction was carried out at 37° C for 5 min.

Samples 2, and 3: Bovine casein (10 mg) was dissolved in 100  $\mu$ L 0.4% AMBIC at pH 8 and dephosphorylated by alkaline phosphatase (200  $\mu$ g) at an enzyme/substrate ratio of 1:50. The reaction was carried out at 37° C for 15 min (sample 2) and 24h (sample 3). Each solution was analysed by MALDI-TOF, loading on the spot 1  $\mu$ L of 1:100 dilution with a solution containing H<sub>2</sub>O/ACN (50/50). 1  $\mu$ L of the sinapinic acid solution (10mg/mL) containing H<sub>2</sub>O/ACN/PA (49.9/50/0.1) was loaded on dried sample and allowed to dry. The MALDI and ESI-MS analysis conditions are the same as those already reported above.

The three solutions were freeze-dried with a SpeedVac concentrator system, before loading on the HA. The partially dephosphorylated casein solutions were dissolved in 80  $\mu$ L buffer at pH 8.0 containing TrisHCl 50 mM, KCl 0.2 M, urea 4.5 M, DTT 10 mM and were loaded on 10 mg of HA. The next steps of phosphorylated protein enrichment and tryptic hydrolysis *in situ* were the same as those already reported. The rapid analysis of HA-phosphoprotein/CPP microgranules deposition was conducted for phosphoprotein/CPP enriched by HA. The microgranules were deposited onto the MALDI plate and covered by the SA matrix in presence of 0.1% TFA for proteins and by DHB solution in presence of 1% PA for CPP.

### ***HA-based phosphoprotein/peptide enrichment of milk mastitic***

Ovine casein (10 mg) from right udder with high level of SCC was dissolved in 80  $\mu$ l buffer at pH 8.0 containing TrisHCl 50 mM, KCl 0.2 M, urea 4.5 M, DTT 10 mM and loaded on HA (10 mg), previously washed with loading buffer. The next steps of phosphorylated protein enrichment and tryptic hydrolysis *in situ* were the same as those already reported. The MALDI analysis conditions are the same as those already reported.


## **17 Results and discussion**

### **17.1 Dephosphorylation kinetic**


The HA enrichment technique was applied to partially dephosphorylated casein. The objective was to understand the affinity of the resin for a protein mixture with different phosphorylation degree.

The enzyme-to-casein ratios and reaction time chosen were consistent with the optimum reaction kinetics.

After 24h, all proteins were dephosphorylated and no protein remained bound to the resin after loading on HA. From the comparison between the MALDI spectra of the casein fractions before (Figure 25 and 26, panel a) and after HA enrichment (Figure 25 and 26, panel b), it is evident that the resin has a greater affinity for proteins with a higher phosphorylation degree. In fact, the more phosphorylated proteins (green colored phosphoprotein) (Figure 25 and 26, panel b) appeared only after the HA enrichment. Before enrichment, the signals of more phosphorylated component were suppressed by that of the less phosphorylated components. Moreover,  $\alpha_{s2}$ -CN signals significantly increased (Figure 25 and 26, panel b) allowing a more correct identification of CPP.



**Figure 25.** Spectra MALDI of thecasein fractions (sample 1) after partially dephosphorylation at enzyme/substrate ratio of 1/100 for 5min (a) before and (b) after enrichment on HA. Signals of  $\alpha_{s2}$ CN have been indicated with a colour for a better visual identification of the fractions.



**Figure 26.** MALDI spectra of casein fractions (sample 2) after partially dephosphorylation at enzyme/substrate ratio of 1/50 for 15min (a) before and (b) after enrichment on HA.

The identification of totally and partially phosphorylated casein fractions at different dephosphorylation reaction time ( $t=0$ ,  $t=5$  min and  $t=15$  min) before and after casein enrichment are compared in Tables 6 and 7.


**Table 6.** Dephosphorylation kinetics before casein enrichment by HA

Phosphoprotein	Theoretical mass (Da)	$t_{AP}=0$ min	$t_{AP}=5$ min AP/protein=1/100	$t_{AP}=15$ min AP/protein=1/50
		Measured mass (Da)	Measured mass (Da)	Measured mass (Da)
k-CN 1P	19022.59	19028.54	19025.56	19026.89
k-CN 0P	18942.59	—	18943.56	18946.89
$\gamma_1$ -CN 1P	20562.01	20554.78	20514.38	20452.03
$\alpha_{S1}$ -CN 8P	23614.87	23627.56	—	—
$\alpha_{S1}$ -CN 7P	23534.87	23534.56	23525.10	—
$\alpha_{S1}$ -CN 6P	23454.87	—	23444.31	—
$\alpha_{S1}$ -CN 5P	23374.87	—	23363.95	—
$\alpha_{S1}$ -CN 4P	23294.87	—	23284.31	—
$\alpha_{S1}$ -CN 3P	23214.97	—	23205.13	23206.74
$\alpha_{S1}$ -CN 2P	23134.87	—	23124.54	23126.74
$\alpha_{S1}$ -CN 1P	23054.87	—	23044.85	23052.19
$\beta$ -CN 5P	24022.39	24036.26	—	—
$\beta$ -CN 4P	23942.39	24955.27	—	—
$\beta$ -CN 3P	23862.39	—	23891.92	—
$\beta$ -CN 2P	23782.39	—	23811.92	—
$\beta$ -CN 1P	23702.39	—	23733.73	23700.40
$\beta$ -CN 0P	23622.39	—	23651.73	23611.37
$\alpha_{S2}$ -CN 12P	25308.48	—	—	—
$\alpha_{S2}$ -CN 11P	25228.46	—	—	—
$\alpha_{S2}$ -CN 9P	25068.46	—	25050.02	—
$\alpha_{S2}$ -CN 6P	24828.46	—	24809.74	—
$\alpha_{S2}$ -CN 4P	24668.46	—	24656.68	24661.11
$\alpha_{S2}$ -CN 3P	24588.46	—	24576.68	24590.79
$\alpha_{S2}$ -CN 2P	24508.46	—	—	24510.79
$\alpha_{S2}$ -CN 1P	24428.46	—	—	24430.05
$\alpha_{S2}$ -CN 0P	24348.46	—	—	24353.04

**Table 7.** Dephosphorylation kinetics after casein enrichment by HA

Phosphoprotein	Theoretical mass (Da)	$t_{AP}=0$ min	$t_{AP}=5$ min AP/protein=1/100	$t_{AP}=15$ min AP/protein=1/50
		Measured mass (Da)	Measured mass (Da)	Measured mass (Da)
k-CN 1P	19022.59	19029.57	19037.40	19038.89
k-CN 0P	18942.59	—	—	—
$\gamma_1$ -CN 1P	20562.01	—	—	—
$\alpha_{s1}$ -CN 8P	23614.87	23626.52	23620.87	
$\alpha_{s1}$ -CN 7P	23534.87	23539.42	23542.28	23506.43
$\alpha_{s1}$ -CN 6P	23454.87	—	23464.34	23460.76
$\alpha_{s1}$ -CN 5P	23374.87	—	23379.45	23379.38
$\alpha_{s1}$ -CN 4P	23294.87	—	23307.89	23298.82
$\alpha_{s1}$ -CN 3P	23214.97	—	—	23219.78
$\alpha_{s1}$ -CN 2P	23134.87	—	—	23141.44
$\alpha_{s1}$ -CN 1P	23054.87	—	—	23068.08
$\beta$ -CN 5P	24022.39	24029.94	24024.78	—
$\beta$ -CN 4P	23942.39	23951.22	23945.14	—
$\beta$ -CN 3P	23862.39	—	23859.91	23870.20
$\beta$ -CN 2P	23782.39	—	23779.39	23791.09
$\beta$ -CN 1P	23702.39	—	—	23703.70
$\beta$ -CN 0P	23622.39	—	—	—
$\alpha_{s2}$ -CN 12P	25308.48	25292.5	—	—
$\alpha_{s2}$ -CN 11P	25228.46	25210.5	25231.05	—
$\alpha_{s2}$ -CN 10P	25148.46	25133.3	25153.52	—
$\alpha_{s2}$ -CN 9P	25068.46	—	25071.60	—
$\alpha_{s2}$ -CN 8P	24988.46	—	24987.32	—
$\alpha_{s2}$ -CN 7P	24908.46	—	24903.23	24909.14
$\alpha_{s2}$ -CN 6P	24828.46	—	24823.23	24830.17
$\alpha_{s2}$ -CN 5P	24748.48	—	24743.23	24753.69
$\alpha_{s2}$ -CN 4P	24668.46	—	—	24669.47
$\alpha_{s2}$ -CN 3P	24588.46	—	—	24589.87
$\alpha_{s2}$ -CN 2P	24508.46	—	—	24502.53
$\alpha_{s2}$ -CN 1P	24428.46	—	—	24426.37
$\alpha_{s2}$ -CN 0P	24348.46	—	—	—

The partially dephosphorylated casein fractions bound to the HA were hydrolyzed, *in situ*, under conditions indicated in Method section. By this means, peptides containing the Ser(P)-Ser(P)-Ser(P)-Glu-Glu cluster sequence were evaluated.



**Figure 27.** MALDI spectra of tryptic CPP hydrolyzed *in situ* from partially dephosphorylated casein bound to HA. The dephosphorylated reaction was conducted at the enzyme/substrate ratio of 1/100 for 5min (a) and with enzyme/substrate ratio of 1/50 for 15 min (b).

Comparing the MALDI spectra (Fig. 27, panel a and b), the following considerations can be made: 1) totally phosphorylated peptides were still present in



the mixtures after 5 and 15min of the dephosphorylation reaction but the intensity ratio between  $\beta$ -CN (f1-25)4P (3122.3 Da) and  $\beta$ -CN (f1-25) 3P (3042.3 Da) and between  $\alpha_{s1}$ -CN (f59-79)4P (2640.9 Da) and  $\alpha_{s1}$ -CN (f59-79)3P (2560.9 Da) tended to decrease; 2) after 5min dephosphorylation reaction,  $\alpha_{s2}$ -CN (f46-70) 3P (2927.8 Da) was already detectable 3) after 15min dephosphorylation reaction the  $\alpha_{s1}$ -CN (f59-79)3P (2560.1 Da),  $\alpha_{s2}$ -CN (f2-21)3P (2459.4 Da),  $\alpha_{s2}$ -CN (f46-70)2P (2848.7),  $\beta$ -CN (f1-25)2P (2963.0 Da) and  $\beta$ -CN (f1-25)1P (2883.0 Da) phosphopeptides were recorded. The partially phosphorylated peptides issued for different time of dephosphorylation (t=0, t=5 min and t=15 min) are compared in Table 8.


**Table 8.** Dephosphorylation kinetic of *in situ* hydrolyzed and enriched phosphopeptides. The peptides of new formation at  $t_{AP}=5$  min are marked in green and The peptides of new formation at  $t_{AP}=15$  min are marked in blue.

		$t_{AP}=0$ min	$t_{AP}=5$ min ratio=1/100	$t_{AP}=15$ min ratio=1/50
Monophosphopeptide	Theoretical mass (Da)	Measured mass (Da)	Measured mass (Da)	Measured mass (Da)
$\alpha_{s1}$ (f106-119)1P	1659.8	1661.6	1660.9	1660.2
$\alpha_{s1}$ (f104-119)1P	1952.0	1952.3	1952.8	1951.6
$\beta$ (f33-48)1P	2060.8	2062.8	2061.7	2061.3
$\alpha_{s1}$ (f103-119)1P	2080.4	2079.4	2081.6	2078.3
$\beta$ (f1-25)1P	2883.0	—	—	2883.9
Diphosphopeptide	Theoretical mass (Da)	Measured mass (Da)	Measured mass (Da)	Measured mass (Da)
$\alpha_{s2}$ (f126-136)2P	1410.5	1411.0	1411.9	1411.4
$\alpha_{s2}$ (f126-137)2P	1538.6	1540.3	1540.2	1539.7
$\alpha_{s1}$ (f43-58)2P	1926.1	1928.3	1927.7	1927.1
$\alpha_{s1}$ (f43-58)1P	1846.7	1848.2	1847.8	1847.1
$\alpha_{s2}$ (f2-21)2P	2459.4	—	—	2459.6
$\alpha_{s1}$ (f37-58)2P	2598.1	2598.1	2600.5	2595.8
$\alpha_{s2}$ (f46-70)2P	2848.7	—	—	2849.8
$\alpha_{s1}$ (f35-58)2P	2855.2	2855.3	2855.6	2852.9
$\beta$ (f1-25)2P	2963.0	—	—	2963.7
Triphosphopeptide	Theoretical mass (Da)	Measured mass (Da)	Measured mass (Da)	Measured mass (Da)
$\alpha_{s2}$ (f2-21)3P	2539.4	2538.6	2539.4	2540.0
$\alpha_{s1}$ (f59-79)3P	2560.1	—	—	2559.6
$\alpha_{s1}$ (f37-58)3P	2678.1	2677.8	2677.5	2676.7

$\beta$ (f2-25)3P	2886.2	2885.9	2885.1	2885.4
$\alpha_{s2}$ (f46-70)3P	2928.0	—	2927.9	2927.7
$\alpha_{s1}$ (f35-58)3P	2935.2	2935.0	2933.9	2932.6
$\beta$ (f1-25)3P	3042.3	3043.8	3044.0	3043.2
<b>Tetraphosphopeptide</b>	<b>Theoretical mass (Da)</b>	<b>Measured mass (Da)</b>	<b>Measured mass (Da)</b>	<b>Measured mass (Da)</b>
$\alpha_{s2}$ (f2-21)4P	2618.9	2619.2	2619.9	—
$\alpha_{s1}$ (f59-79)4P pyroQ	2623.9	—	2621.0	2621.4
$\alpha_{s1}$ (f59-79)4P	2640.9	2640.7	2640.5	2639.4
$\beta$ (f2-25)4P	2966.2	2965.9	2965.0	
$\alpha_{s2}$ (f46-70)4P	3007.9	3007.2	3006.8	3005.8
$\beta$ (f1-25)4P	3122.3	3122.1	3122.1	3121.0
<b>Pentaphosphopeptide</b>	<b>Theoretical mass (Da)</b>	<b>Measured mass (Da)</b>	<b>Measured mass (Da)</b>	<b>Measured mass (Da)</b>
$\alpha_{s1}$ (f59-79)5P pyroQ	2703.9	2703.7	2703.3	2701.9
$\alpha_{s1}$ (f59-79)5P	2720.9	2720.7	2720.4	2719.0
$\alpha_{s2}$ (f46-70)5P	3088.0	3086.7	3086.8	3085.0

## 17.2. Analysis of proteins and CPP occurring in mastitic milk

The enrichment of mixtures dephosphorylated *in vitro* has confirmed the ability of the resin to bind phosphoproteins and CPP with different degrees of phosphorylation. At this point, to evaluate the milk quality, our method for the phosphoprotein/phosphopeptide enrichment was tested on mastitic casein. In order to examine whether the phosphorylated proteins were enriched by HA, MALDI analysis was carried out on the casein sample before and after resin treatment (Figure 28)



**Figure 28.** MALDI spectra of casein sample before (a) and after (b) resin treatment in the mass range of 10-13 kDa.

The partial MALDI-TOF spectrum of the original casein sample (Figure 28, panel a) was compared to the same sample after the enrichment cycle by HA (Figure 28, panel b). Original casein sample signals could be assigned to  $\gamma_2$ -,  $\gamma_3$ -CN, and  $\beta$ -CN (f98-207). These non-phosphorylated plasmin-mediated peptides of  $\beta$ -CN were washed out when native casein sample was treated with HA. HA-treated samples did not contain these peptides consistently with the function of HAP in capturing phosphopeptides. In contrast, HA allowed phosphoproteins/phosphopeptides be enriched from high SCC casein as clearly shown in Figure 28, panel b. Here, in the partial view of the MALDI spectra, the m/z 10-13 kDa range contained a series of phosphopeptides with various degree of phosphorylation. In particular, together with the intact  $\beta$ -CN (not shown), the derived peptides  $\beta$ -CN (f1-97) (6P÷2P) and  $\beta$ -CN (f1-105) (6P÷2P) occurred. The signals of the peptide  $\beta$ -CN (f1-107) formed simultaneously with the  $\beta$ -CN (f1-105) counterpart were slightly detectable as  $\beta$ -CN (f1-107) (6P÷4P). The  $\beta$ -CN (f29-105/7)1P fragments considered by Le Roux Y. *et al.*<sup>163</sup> as possible indicators of the endogenous proteolysis in milk from cows with subclinical mastitis were not found perhaps because of the dephosphorylation activity. It must be remembered that unphosphorylated fragments didn't bind to the

HA. In contrast, the new fragment  $\beta$ -CN (f1-97) was released when the plasmin activity increased in mastitic milks. Consistently, the presence of the partly dephosphorylated fragments is connected to the higher ALP activity of mastitic milk. The casein derived from high SCC milk was also analysed using LC-ESI-MS to confirm the identity of proteins and phosphopeptides of mastitic milk. Four phosphorylated  $\beta$ -CN (6P÷3P) were detected in high SCC milk instead of the two, i.e.  $\beta$ -CN 6P and 5P occurring in control milk. Four phosphorylated  $\alpha_{s1}$ -CN (10P÷7P) were detected in high SCC instead of the two, i.e.  $\alpha_{s1}$ -CN 10P and 9P of control milk. In contrast,  $\alpha_{s1}$ -CN (f141-148) (10P÷8P) and  $\alpha_{s1}$ -CN (Gln<sub>78</sub>) (10÷8P) deleted forms occurred at similar degree of phosphorylation as shown in Table 9. Moreover, we recorded that  $\alpha_{s1}$ -CN (f141-148) was the prominent internally deleted form consistently with that occurs in milk from healthy animal for which (110-117) form was found. This is in agreement with the previous results<sup>173</sup>.  $\alpha_{s2}$ -CN shows the highest number of possible phosphorylation sites compared to the other casein fractions and naturally occurs under two molecular species both plasmin-sensitive substrates, a major full-length, and an internal 9-residue domain deleted. Both proteins show the same phosphorylation degree (Table 9).

**Table 9.** Identification of casein fractions in mastitic ovine milk obtained by HA enrichment and ESI-MS analysis

Measured molecular mass (Da)	Calculated molecular mass (Da)	Protein
<b><math>\alpha_{s2}</math>-Casein</b>		
25623.09± 4.7	25621.71	$\alpha_{s2}(1-208)12P$
25542.38± 1.2	25541.73	$\alpha_{s2}(1-208)11P$
25466.38± 6.2	25461.75	$\alpha_{s2}(1-208)10P$
25378.64± 3.6	25381.77	$\alpha_{s2}(1-208)9P$
25304.80± 5.0	25301.79	$\alpha_{s2}(1-208)8P$
25224.71± 3.9	25221.81	$\alpha_{s2}(1-208)7P$
24546.7±0.8	24546.6	$\alpha_{s2}(1-208)-(34-42)11P$
24466.1±0.5	24466.6	$\alpha_{s2}(1-208)-(34-42)10P$
24386.2±0.8	24386.6	$\alpha_{s2}(1-208)-(34-42)9P$
24305.5±0.3	24306.7	$\alpha_{s2}(1-208)-(34-42)8P$
24225.9.7±0.1	24226.7	$\alpha_{s2}(1-208)-(34-42)7P$
<b><math>\alpha_{s1}</math>-Casein</b>		
23564.2± 3.0	23561.6	$\alpha_{s1}(1-199)10P$
23481.3± 0.8	23481.7	$\alpha_{s1}(1-199)9P$
23400.7± 1.8	23401.7	$\alpha_{s1}(1-199)8P$
23323.2±2.8	23321.7	$\alpha_{s1}(1-199)7P$
23435.0±0.8	23433.5	$\alpha_{s1}(1-199)-(Gln_{78}) 10P$
23354.7±0.8	23353.5	$\alpha_{s1}(1-199) -(Gln_{78}) 9P$
23275.4±0.4	23273.6	$\alpha_{s1}(1-199)-(Gln_{78}) 8P$
22546.70±3.5	22549.5	$\alpha_{s1}(1-199)-(141-148)10P$
22466.53±3.1	22469.5	$\alpha_{s1}(1-199)-(141-148)9P$
22386.15±3.5	22389.5	$\alpha_{s1}(1-199)-(141-148)8P$
22306.20±3.5	22309.5	$\alpha_{s1}(1-199)-(140-148)7P$
<b><math>\beta</math>-Casein</b>		
23830.98±1.1	23831.14	$\beta(1-207)6P$
23747.04±4.7	23751.16	$\beta(1-207)5P$
23667.23±3.7	23671.18	$\beta(1-207)4P$
23587.32±4.2	23591.19	$\beta(1-207)3P$


The ESI-MS analysis allowed the identification of a wide variety of phosphorylated peptides of different size and wide phosphorylation degree derived from the intense enzymatic degradation associated with high SCC (Table 10).

**Table 10.** Identification of peptides in mastitic milk obtained by HA enrichment and LC-ESI-MS analysis. *N*-terminal and *C*-terminal cleavage sites are highlighted. The degree as well as maximum degree of phosphorylation are compared.

Fragment	<i>N</i> -terminal cleavage site	<i>C</i> -terminal cleavage site	Degrees of Phosphorylation	Maximum degree of phosphorylation
<b><math>\beta</math>-Casein (1-207)</b>				
$\beta$ (f1-29)	—	Lys <sub>29</sub> -Ile <sub>30</sub>	5P, 4P, 3P, 2P	5P
$\beta$ (f29-60)	Lys <sub>28</sub> -Lys <sub>29</sub>	Tyr <sub>60</sub> -Pro <sub>61</sub>	1P	1P
$\beta$ (f30-60)	Lys <sub>29</sub> -Ile <sub>30</sub>	Tyr <sub>60</sub> -Pro <sub>61</sub>	1P	1P
$\beta$ (f1-97)	—	Lys <sub>97</sub> -Val <sub>98</sub>	6P, 5P, 4P, 3P, 2P	6P
$\beta$ (f1-105)	—	Lys <sub>105</sub> -His <sub>106</sub>	6P, 5P, 4P, 3P, 2P	6P
$\beta$ (f1-107)	—	Lys <sub>107</sub> -Glu <sub>108</sub>	6P, 5P, 4P	6P
<b><math>\alpha_{s2}</math>-Casein (1-208)</b>				
$\alpha_{s2}$ (f1-25)	—	Lys <sub>25</sub> -Asn <sub>26</sub>	4P, 3P	4P
$\alpha_{s2}$ (f36-69)	Lys <sub>35</sub> -Leu <sub>36</sub>	Glu <sub>69</sub> -Val <sub>70</sub>	4P, 3P, 2P	4P
$\alpha_{s2}$ (f36-71)	Lys <sub>35</sub> -Leu <sub>36</sub>	Lys <sub>71</sub> -Ile <sub>72</sub>	3P, 2P	4P
$\alpha_{s2}$ (f36-77)	Lys <sub>35</sub> -Leu <sub>36</sub>	Lys <sub>77</sub> -His <sub>78</sub>	3P, 2P	4P
$\alpha_{s2}$ (f1-53)	—	Tyr <sub>53</sub> -Ser <sub>54</sub>	4P, 3P, 2P, 1P	4P
$\alpha_{s2}$ (f54-115)	Tyr <sub>53</sub> -Ser <sub>54</sub>	Arg <sub>115</sub> -Asn <sub>116</sub>	4P, 3P	4P
$\alpha_{s2}$ (f54-204)	Tyr <sub>53</sub> -Ser <sub>54</sub>	Tyr <sub>204</sub> -Val <sub>205</sub>	7P, 6P, 5P, 4P	7P
$\alpha_{s2}$ (f54-208)	Tyr <sub>53</sub> -Ser <sub>54</sub>	—	7P, 6P, 5P, 4P	7P
$\alpha_{s2}$ (f116-204)	Arg <sub>115</sub> -Asn <sub>116</sub>	Tyr <sub>204</sub> -Val <sub>205</sub>	3P, 2P, 1P	3P
$\alpha_{s2}$ (f116-208)	Arg <sub>115</sub> -Asn <sub>116</sub>	—	3P, 2P, 1P	3P
$\alpha_{s2}$ (f115-151)	Lys <sub>114</sub> -Arg <sub>115</sub>	Lys <sub>151</sub> -Thr <sub>152</sub>	3P, 2P	3P
<b><math>\alpha_{s1}</math>-Casein (1-199)</b>				
$\alpha_{s1}$ (f4-58)	Lys <sub>3</sub> -His <sub>4</sub>	Lys <sub>58</sub> -Gln <sub>59</sub>	3P, 2P, 1P	3P
$\alpha_{s1}$ (f1-60)	—	Met <sub>60</sub> -Lys <sub>61</sub>	3P, 2P, 1P	3P
$\alpha_{s1}$ (f2-60)	Arg <sub>1</sub> -Pro <sub>2</sub>	Met <sub>60</sub> -Lys <sub>61</sub>	3P, 2P, 1P	3P
$\alpha_{s1}$ (f61-174)	Met <sub>60</sub> -Lys <sub>61</sub>	Thr <sub>174</sub> -Asp <sub>175</sub>	6P, 5P, 4P	7P
$\alpha_{s1}$ (f62-174)	Lys <sub>61</sub> -Ala <sub>62</sub>	Thr <sub>174</sub> -Asp <sub>176</sub>	6P, 5P, 4P	7P
$\alpha_{s1}$ (f62-199)	Lys <sub>61</sub> -Ala <sub>62</sub>	—	7P, 6P	7P
$\alpha_{s1}$ (f62-90)	Lys <sub>61</sub> -Ala <sub>62</sub>	Arg <sub>90</sub> -Tyr <sub>91</sub>	4P, 3P, 2P	6P
$\alpha_{s1}$ (f43-102)	Lys <sub>42</sub> -Asp <sub>43</sub>	Lys <sub>102</sub> -Lys <sub>103</sub>	5P, 4P, 3P, 2P	8P
$\alpha_{s1}$ (f43-103)	Lys <sub>42</sub> -Asp <sub>43</sub>	Lys <sub>103</sub> -Tyr <sub>104</sub>	5P, 4P, 3P, 2P	8P

The specific cleavage of Lys-X and Arg-X at C-terminal position was clearly due to the increased activity of plasmin. In complement with other bonds, Tyr-X cleavage was caused by cathepsin G. All peptides showed a wide phosphorylation range, suggesting that proteolytic cleavage occurred concurrently with the intense dephosphorylation enzyme correlated with increased phosphatase activity.

Additionally, the tryptic *in situ* hydrolysis of mastitic casein bound to HA provided additional information about the milk quality to be used as nutraceutical. The identification of these CPP could represent easier indicators about the nature of milk, mastitic or not-mastitic. As dephosphorylation produces a characteristic mass decrease of 80 Da or multiple of 80 Da, CPP with this mass variation confirmed the phosphatase activity. This procedure was found very effective and actually represents one of the most powerful tool for the identification of parent phosphorylated proteins. The partial view of the MALDI spectra in two mass ranges taken by direct analysis of the crystallized matrix containing HA and phosphoric acid is shown in Figure 29 (panel a and b).



**Figure 29.** MALDI spectrum of tryptic CPP HA-enriched from mastitic milk in different mass range: 1-2.9 kDa (a) and 2.8-3.7 kDa (b). Adducts of CPP with  $K^+$  are encircled in green.

All the tryptic phosphopeptides identified in the HA-enriched fraction are listed in Table 11.



**Table 11.** Tryptic CPP enriched from mastitic ovine milk

User mass (Da)	DB mass (Da)	Peptide	Position	Modifications
<b><math>\beta</math>-Casein</b>				
3542.83	3544.27	REQEELNVVGETVESLSSE ESITHINK/(K)	$\beta$ -CN (f1-28)	PHOS PHOS PHOS PHOS PHOS
3462.83	3465.28	REQEELNVVGETVESLSSE ESITHINK/(K)	$\beta$ -CN (f1-28)	PHOS PHOS PHOS PHOS PHOS
3385.43	3385.30	REQEELNVVGETVESLSSE ESITHINK/(K)	$\beta$ -CN (f1-28)	PHOS PHOS PHOS
3306.42	3304.33	REQEELNVVGETVESLSSE ESITHINK/(K)	$\beta$ -CN (f1-28)	PHOS PHOS
3226.04	3225.34	REQEELNVVGETVESLSSE ESITHINK/(K)	$\beta$ -CN (f1-28)	PHOS
2062.01	2062.99	(K)/FQSEEQQTDELQDK/(I)	$\beta$ -CN (f33-48)	PHOS
<b><math>\alpha_{s1}</math>-Casein</b>				
2905.49	2905.78	(K)/ENINELSKDIGSESIEDQAM EDAK/(Q)	$\alpha_{s1}$ -CN (f35-58)	PHOS PHOS PHOS
2825.08	2826.79	(K)/ENINELSKDIGSESIEDQAM EDAK/(Q)	$\alpha_{s1}$ -CN (f35-58)	PHOS PHOS
1898.54	1898.78	(K)/DIGSESIEDQAMEDAK/(Q)	$\alpha_{s1}$ -CN (f43-58)	PHOS PHOS
1818.40	1798.92	(K)/DIGSESIEDQAMEDAK/(Q)	$\alpha_{s1}$ -CN (f43-58)	PHOS
2158.69	2155.97	K)/DIGSESIEDQAMEDAKQM/(K)	$\alpha_{s1}$ -CN (f43-60)2P	PHOS PHOS Aspecific cleavage
1239.82	1238.50	(K)/ SAEQLHSMK /(E)	$\alpha_{s1}$ -CN (f115-124)	PHOS
2287.34	2287.75	(K)/AGSSSSSEEIVPNSAEQK/(Y)	$\alpha_{s1}$ CN (f62-79)	PHOS PHOS PHOS PHOS PHOS PHOS
2208.60	2207.77	(K)/AGSSSSSEEIVPNSAEQK/(Y)	$\alpha_{s1}$ -CN (f62-79)	PHOS PHOS PHOS PHOS PHOS
2127.85	2127.79	(K)/AGSSSSSEEIVPNSAEQK/(Y)	$\alpha_{s1}$ -CN (f62-79)	PHOS PHOS PHOS PHOS
<b><math>\alpha_{s2}</math>-Casein</b>				
3187.93	3192.10	(K)/HKMEHVSSSEEPINISQEIY KQEK/(N)	$\alpha_{s2}$ -CN (f2-25)	PHOS PHOS PHOS PHOS
3105.60	3111.13	(K)/HKMEHVSSSEEPINISQEIY KQEK/(N)	$\alpha_{s2}$ -CN (f2-25)	PHOS PHOS PHOS
3031.89	3032.14	(K)/HKMEHVSSSEEPINISQEIY KQEK/(N)	$\alpha_{s2}$ -CN (f2-25)	PHOS PHOS

2951.98	2952.16	(K)/HKMEHVSSEEPINISQEIY KQEK/(N)	$\alpha_{s2}$ -CN (f2-25)	PHOS
2934.22	2934.85	KHKMEHVSSEEPINISQEI YK/(Q)	$\alpha_{s2}$ -CN (f1-22)	PHOS PHOS PHOS PHOS
2854.40	2854.87	KHKMEHVSSEEPINISQEI YK/(Q)	$\alpha_{s2}$ -CN (f1-22)	PHOS PHOS PHOS
2775.72	2774.89	KHKMEHVSSEEPINISQEI YK/(Q)	$\alpha_{s2}$ -CN (f1-22)	PHOS PHOS
2693.81	2694.91	KHKMEHVSSEEPINISQEI YK/(Q)	$\alpha_{s2}$ -CN (f1-22)	PHOS
2540.45	2541.36	(K)/MEHVSSEEPINISQEIYK/(Q)	$\alpha_{s2}$ -CN (f4-22)	PHOS PHOS PHOS PHOS
2461.48	2461.38	(K)/MEHVSSEEPINISQEIYK/(Q)	$\alpha_{s2}$ -CN (f4-22)	PHOS PHOS PHOS
1540.62	1540.41	(R)/EQLSTSEENSKK/(T)	$\alpha_{s2}$ -CN (f126-137)	PHOS PHOS
1412.48	1412.24	(R)/EQLSTSEENSK/(K)	$\alpha_{s2}$ -CN (f126-136)	PHOS PHOS
<b><math>\alpha_{s2}</math>-Casein aspecific cleavage of tryptic CPP</b>				
2806.00	2806.68	KHKMEHVSSEEPINISQEI Y(K)	$\alpha_{s2}$ -CN (f1-21) C-termin. Tyr <sub>21</sub> - Lys <sub>22</sub>	PHOS PHOS PHOS PHOS
2677.00	2678.50	(K)HKMEHVSSEEPINISQEIY(K)	$\alpha_{s2}$ -CN (f2-21) C-termin. Tyr <sub>21</sub> - Lys <sub>22</sub>	PHOS PHOS PHOS PHOS
2412.00	2413.19	(K)MEHVSSEEPINISQEIY(K)	$\alpha_{s2}$ -CN (f4-21) C-termin. Tyr <sub>21</sub> - Lys <sub>22</sub>	PHOS PHOS PHOS PHOS
2254.42	2253.97	(Y)SIRSSSEESA EVAPEEVK/(I)	$\alpha_{s2}$ -CN (f54-71) N-termin. Tyr <sub>53</sub> - Ser <sub>54</sub>	PHOS PHOS PHOS PHOS
2174.12	2174.99	(Y)SIRSSSEESA EVAPEEVK/(I)	$\alpha_{s2}$ -CN (f54-71) N-termin. Tyr <sub>53</sub> - Ser <sub>54</sub>	PHOS PHOS PHOS

It is possible to note the absence of non-phosphorylated peptides confirming the specificity of the HA-based procedure while the presence of partially dephosphorylated forms validated casein from high SCC.

From native  $\beta$ -casein, five partly dephosphorylated CPP species were identified, corresponding to loss of 1, 2, 3, 4 and 5 phosphate groups. The presence of  $\beta$ -CN (f1-28) (5P÷1P) is an additional indicator to the previous finding. A lower phosphorylation degree (6P÷3P) was observed before tryptic hydrolysis (Table 9). This means the partial dephosphorylation of  $\beta$ -casein in the presence of anomalous SSC.

From the native  $\alpha_{s1}$ -casein, tryptic hydrolysis produced  $\alpha_{s1}$ -CN (f62-79)6P (6P÷4P) and CPP as  $\alpha_{s1}$ -CN (f43-60)2P due to aspecific cleavage.

From  $\alpha_{s2}$ -casein,  $\alpha_{s2}$ -CN (f2-25)4P (4P÷2P) and aspecific  $\alpha_{s2}$ -CN (f54-71)4P (4P÷3P) were released. Three CPP having different N-terminal extension, i.e. 1-22, 4-22 and 2-25, raise from  $\alpha_{s2}$ CN (Table 11). All CPP containing the cluster Ser(P)-Ser(P)-Ser(P)-Glu-Glu, essential to bind minerals, showed a wide degree of phosphorylation due to the loss of phosphate groups.

In conclusion, high plasmin (or other proteases) activity associated with high cell count, and especially alkaline phosphatase activity may represent mastitis indicator. The enrichment by HA of phosphoproteins and CPP is fundamental for evaluating milk quality.

## 18. Use of CPP as process markers

CPP can also represent process markers. Proteolysis and casein and phosphopeptide dephosphorylation is of utmost interest in the cheese ripening. We considered Grana Padano (GP) cheese where the biochemical changes which occur during ripening are caused by the synergistic action of a variety of enzymes, such as chymosin, indigenous milk enzyme proteinase, starter bacteria enzymes, and secondary microorganisms enzymes<sup>174</sup>. Then, it has been suggested that acid phosphatases from both milk and lactic acid bacteria contribute to dephosphorylation of phosphopeptides in cheese, which are produced from casein by enzymatic activity during cheese ripening<sup>175</sup>. In cheese made from pasteurized milk, indigenous acid phosphatase or bacterial phosphatases are probably responsible for dephosphorylation of caseins, but in raw milk cheese, e.g. Parmigiano Reggiano or Grana Padano, ALP may play an important role<sup>176</sup>. Hence, in a cheese made from raw milk, the enzymatic activity is more intense than that occurring in a cheese made from pasteurized milk. Pasteurization, in fact, inactivates several enzymes in milk, including lipase and alkaline phosphatase. Lack of alkaline phosphatase activity indicates that the milk has been properly pasteurized. As Grana Padano is a D.O.P. cheese and its Production Disciplinary states that it must be produced with raw milk, it is important to have a technique for controlling the use of raw milk. It has been demonstrated that a centripetal temperature gradient and a consequent gradient of alkaline phosphatase inactivation between the outer part and the core of GP cheese takes place during moulding. The traditional cheesemaking technology also includes milk clotting at 32° C, curd cooking up to 55° C, and cheese moulding at room temperature for 48 h. It has been able to note that the temperature decreases rapidly to 35-40° C at the surface, but because of the slow heat-transfer within the cheese, the core remains at 52-56 °C for 8-10 h. Such condition promotes the formation of a centripetal gradient of ALP inactivation which remains unmodified in moulded forms at room temperature throughout ripening<sup>177</sup>. The outside of the Grana contain levels of residual phosphatase about 10-100 times higher than the core of cheese. Moreover, the significant heat load on the inner zones of the cheese together with the low pH value may reduce the activity of other indigenous and heat-sensitive enzymes, like acid protease<sup>178</sup>. Also an increased proteolytic activity was observed mainly in the outer zone of cheese. More free amino acids (FAA) were detected in the outer parts of GP cheese<sup>179</sup> just caused by the higher enzyme activities than in the cheese core. The peptide degradation involves firstly dephosphorylation of the SerP N-terminal and then release of Ser by aminopeptidases<sup>177</sup>. This mechanism was confirmed by the extremely low levels of SerP found in the free amino acid (FAA) containing fraction of GP whereas free Ser accumulated as a consequence of the simultaneous presence of both active phosphatase and aminopeptidase. As well known, constitutive alkaline phosphatase is inactivated by milk pasteurization which can affect splitting of SerP during cheese ripening: If SerP wasn't dephosphorylated by residual phosphatase, free Ser cannot be released by the bacterial aminopeptidase activity. Hence, milk pasteurization originates an equal distribution of FAA between the outer and the core part of the ripened cheese form. In fact, no free Ser gradient depending on the unequal activity of ALP within the cheese was observed but FAA content was depressed in comparison to control raw-milk cheese<sup>177</sup> together with longer size CPP.

In conclusion, the detection of a different peptide profile associated to the thermal gradient can be diagnostic for the use of raw milk as stated by the Decree of the Regulatory Production.

## **19. Experimental procedure 4**

### ***Materials***

0.1N Hydrochloric acid solution was Carlo Erba. 3 samples of Grana Padano cheese, at 15 months ripening, were supplied from GranBiraghi factory obtained according to the traditional cheesemaking technology. For the cheese samples, a cylindric portion with 5cm diameter from the round side near the outer layer and from the core of the cheese was recovered. Each portion was grated to obtain an uniform sample. The other materials have been already reported.

### ***Preparation of pH 4.6-soluble fraction of cheese***

Finely grated cheese (10 mg) was suspended in 45 mL of 0.1 N HCl. The suspension was homogenized for 1 min by an Ultra Turrax T50 and then centrifuged at 4,000 rpm for 30 min at 4° C. The resulting supernatant solution was freeze dried (Lyolab A, LSL Secfroid, Aclens, Switzerland).

### ***HA-based CPP enrichment of the pH 4.6 soluble fraction***

Lyophilized soluble fraction (10 mg) was dissolved in 80 µl buffer at pH 8.0 containing TrisHCl 50 mM, KCl 0.2 M, urea 4.5 M, DTT 10 mM and loaded on HA (10mg), previously washed with loading buffer. The next steps of phosphorylated protein enrichment and tryptic hydrolysis *in situ* were the same as those already reported above.

### ***LC/MS Analysis***

The LC-MS analysis was carried out under the conditions above reported. The only difference was that, instead of TFA, formic acid (FA) was used in the elution buffer to reduce signal suppression.

## **20. Results and discussion**

After enrichment by HA of the pH 4.6-soluble fraction of the GP inner and outer part, a lot of phosphopeptides bound to HA, while nonphosphorylated compounds were washed out with buffers. From the analysis of recovered CPP, it is possible to note that, during cheese ripening, several CPP derived by a intense enzymatic hydrolysis were present in the core and the inner part of the ripened cheese (Tables 12 and 13). All peptides had in common the *N*-terminal or *C*-terminal residues. Plasmin appeared to be the main responsible enzyme for casein degradation during hard cheese ripening.  $\beta$ -Casein was extensively degraded by this enzyme with the concomitant formation of plasmin-derived peptides as  $\beta$ -CN (f1-28),  $\beta$ -CN (f1-29),  $\beta$ -CN (f1-32), found only in the inner part of GP (Table 12).

**Table 12.** Identification of CPP by LC-ESI-MS from the inner part of a 15-month-old cheese.

Measured mass (Da) (MH <sup>+</sup> )	Measured mass (Da) (MH <sup>2+</sup> )	Measured mass (Da) (MH <sup>3+</sup> )	Measured mass (Da) (MH <sup>4+</sup> )	Amino acid sequence	CPP identification
<b>β-casein</b>					
1348.4	674.7			LpSpSpSEESITR	β-CN (f16-25)3P
1435.4	718.2	479.1		pSLpSpSpSEESITR	β-CN (f15-25)3P
1591.1	796.1	531.0		pSpSpSEESITRINK	β-CN (f17-28)4P
1644.6	822.8	548.9		EpSLpSpSpSEESITR	β-CN(f14-25)4P
1704.1	852.6	568.7		LpSpSpSEESITRINK	β-CN (f16-28)3P
1743.4	872.2	581.8		VEpSLpSpSpSEESITR	β-CN (f13-25)4P
1790.6	895.8	597.5		pSLpSpSpSEESITRINK	β-CN(f15-28)3P
1857.1	929.1	619.7		IVEpSLpSpSpSEESITR	β-CN(f12-25)4P
1870.0	935.5	624.0		pSLpSpSpSEESITRINK	β-CN (f15-28)4P
1871.0	936.0	624.3		EpSLpSpSpSEESITRIN	β-CN (f14-27)4P
1999.0	1000.0	667.0		EpSLpSpSpSEESITRINK	β-CN (f14-28)4P
2098.0	1049.5	700.0		VEpSLpSpSpSEESITRINK	β-CN(f13-28)4P
2211.5	1106.3	737.8		IVEpSLpSpSpSEESITRINK	β-CN (f12-28)4P
2341.0	1171.0	781.0		EIVEpSLpSpSpSEESITRINK	β-CN (f11-28)4P
2594.2	1297.6	865.4		VPGEIVEpSLpSpSpSEESITRINK	β-CN (f8-28)4P
2708.8	1354.9	903.6	678.0	NVPGEIVEpSLpSpSpSEESITRINK	β-CN (f7-28)4P
2967.0	1484.0	989.7	742.5	ELEEL NVPGEIVEpSLpSpSpSEESITR	β-CN (f2-25)4P
3079.0	1540.0	1027.0	770.5	EEL NVPGEIVEpSLpSpSpSEESITRINK	β-CN (f4-28)4P
3123.5	1562.3	1041.8	781.6	RELEEL NVPGEIVEpSLpSpSpSEESITR	β-CN (f1-25)4P
3193.0		1065.0	799.0	LEEL NVPGEIVEpSLpSpSpSEESITR INK	β-CN (f3-28)4P
3322.0		1108.0	831.3	ELEEL NVPGEIVEpSLpSpSpSEESITR INK	β-CN (f2-28)4P
3450.0		1150.7	863.3	ELEEL NVPGEIVEpSLpSpSpSEESITRINKK	β-CN (f2-29)4P
3478.6		1160.2	870.4	RELEEL NVPGEIVEpSLpSpSpSEESITRINK	β-CN (f1-28)4P
3607.0		1203.0	902.5	RELEEL NVPGEIVEpSLpSpSpSEESITRINKK	β-CN (f1-29)4P
3978.0		1326.7	995.3	RELEEL NVPGEIVEpSLpSpSpSEESITRINKK IEK	β-CN (f1-32)4P
<b>α<sub>s1</sub>-casein</b>					
1314.2	657.5			IpSpSpSEEVIPN	α <sub>s1</sub> -CN (f65-74)3P
1401.4	701.2	467.8		pSlpSpSpSEEVIPN	α <sub>s1</sub> -CN (f64-74)3P
1481.2	741.1	494.4		pSlpSpSpSEEVIPN	α <sub>s1</sub> -CN (f64-74)4P
1610.6	805.8	537.5		EpSlpSpSpSEEVIPN	α <sub>s1</sub> -CN (f63-74)4P
1681.4	841.2	561.1		AEpSlpSpSpSEEVIPN	α <sub>s1</sub> -CN (f62-74)4P
1810.6	905.8	604.2		EAEpSlpSpSpSEEVIPN	α <sub>s1</sub> -CN(f61-74)4P
1965.3	983.2	655.8		IpSpSpSEEVIPNpSVEQK	α <sub>s1</sub> -CN (f65-79)4P
2132.0	1066.5	711.3		pSlpSpSpSEEVIPNpSVEQK	α <sub>s1</sub> -CN (f64-79)5P

2261.0	1131.0	754.3		EpSlpSpSpSEEVNpSVEQK	$\alpha_{s1}$ -CN(f63-79)5P
2333.5	1167.3	778.5		AEpSlpSpSpSEEVNpSVEQK	$\alpha_{s1}$ -CN (f62-79)5P
2462.0	1231.5	821.3		EAEpSlpSpSpSEEVNpSVEQK	$\alpha_{s1}$ -CN(f61-79)5P
<b><math>\alpha_{s2}</math>-casein</b>					
1515.4	758.2	505.8		pSpSpSEESIlpSQE	$\alpha_{s2}$ -CN (f8-18)4P
1614.4	807.7	538.8		VpSpSpSEESIlpSQE	$\alpha_{s2}$ -CN (f7-18)4P
2006.6	1003.8	669.5		VpSpSpSEESIlpSQETYK	$\alpha_{s2}$ -CN(f7-21)4P

In the outer parts of cheese, the higher intense enzymatic hydrolysis with respect to the core caused the degradation of these precursors and their disappearance (Table 13).

**Figure 13.** Identification of CPP by LC-ESI-MS from the outer portion of a 15-month-old cheese sample.

Measured mass (Da) (MH <sup>+</sup> )	Measured mass (Da) (MH <sup>2+</sup> )	Measured mass (Da) (MH <sup>3+</sup> )	Measured mass (Da) (MH <sup>4+</sup> )	Amino acid sequence	CPP identification
<b><math>\beta</math>-casein</b>					
1192.2	596.8			LpSpSpSEESIT	$\beta$ -CN (f16-24)3P
1348.4	674.8	450.2		LpSpSpSEESITR	$\beta$ -CN (f16-25)3P
1359.2	680.2			SLpSpSpSEESIT	$\beta$ -CN (f15-24)4P
1435.4	718.0	479.0		SLpSpSpSEESITR	$\beta$ -CN (f15-25)3P
1703.8	852.4	568.6		LpSpSpSEESITRINK	$\beta$ -CN (f16-28)3P
1742.0	872.2	582.0		VEpSLpSpSpSEESITR	$\beta$ -CN (f13-25)4P
1870.6	935.8	624.0		pSLpSpSpSEESITRINK	$\beta$ -CN (f15-28)4P
1871.0	936.0	624.4		EpSLpSpSpSEESITRIN	$\beta$ -CN (f14-27)4P
1999.0	1000.4	667.4		EpSLpSpSpSEESITRINK	$\beta$ -CN (f14-28)4P
2211.8	1106.6	738.0	553.8	IVEpSLpSpSpSEESITRINK	$\beta$ -CN (f12-28)4P
2341.6	1171.3	781.2		EIVEpSLpSpSpSEESITRINK	$\beta$ -CN (f11-28)4P
2708.8		903.6	677.8	NVPGEIVEpSLpSpSpSEESITRINK	$\beta$ -CN (f7-28)4P
<b><math>\alpha_{s1}</math>-casein</b>					
1314.2	657.8			lpSpSpSEEVN	$\alpha_{s1}$ -CN (f65-74)3P
1320.4	660.8			EpSlpSpSpSEEV	$\alpha_{s1}$ -CN (f63-72)3P
1401.4	701.2	468.0		pSlpSpSpSEEVN	$\alpha_{s1}$ -CN (f64-74)3P
1481.4	741.2	494.4		pSlpSpSpSEEVN	$\alpha_{s1}$ -CN (f64-74)4P
1610.6	805.5	537.3		EpSlpSpSpSEEVN	$\alpha_{s1}$ -CN (f63-74)4P
1681.4	841.0	561.0		AEpSlpSpSpSEEVN	$\alpha_{s1}$ -CN (f62-74)4P
1965.4	983.4	656.0		lpSpSpSEEVNpSVEQK	$\alpha_{s1}$ -CN (f65-79)4P
2132.4	1067.0	711.6		pSlpSpSpSEEVNpSVEQK	$\alpha_{s1}$ -CN (f64-79)5P
2333.0	1166.8	778.4		AEpSlpSpSpSEEVNpSVEQK	$\alpha_{s1}$ -CN (f62-79)5P
<b><math>\alpha_{s2}</math>-casein</b>					
1515.4	758.2	505.6		pSpSpSEESIlpSQE	$\alpha_{s2}$ -CN (f8-18)4P
1614.4	807.8	538.8		VpSpSpSEESIlpSQE	$\alpha_{s2}$ -CN (f7-18)4P

Plasmin hydrolysed  $\alpha_{s1}$ -casein producing the  $\alpha_{s1}$ -CN (f61-79) peptide further attacked at the Met<sub>60</sub>-Glu<sub>61</sub> peptide bond, originated by action of an unknown

endopeptidase. The consequent formation of the three peptides such as  $\alpha_{s1}$ -CN(f1-60)2P,  $\alpha_{s1}$ -CN (f23-60)2P and  $\alpha_{s1}$ -CN (f61-79) 5P<sup>182</sup> was recorded.

Plasmin hydrolysed  $\alpha_{s2}$ -casein producing the  $\alpha_{s2}$ -CN (f1-21) fragment. Then, several shorter CPP were released from this precursor through the combined action of proteases and phosphatases; each peptide was devoid of one or more residues at the *N*- and/or *C*-terminus (Table 12 and 13). Following the specific cleavage of plasmin-derived CPP, it is possible to deduce the activity of general and specific aminopeptidases (which release the *N*-terminal amino acid from oligopeptides), phosphatase and carboxypeptidases A and B (which release the *C*-terminal amino acid from oligopeptides). In particular, the synergistic activity of phosphatase and aminopeptidases allows to obtain shorter CPP with cleavage in the cluster Ser(P)-Ser(P)-Ser(P)-Glu-Glu, otherwise resistant to any enzymatic activity<sup>180</sup>. As already mentioned, the presence of CPP such as  $\alpha_{s1}$ -CN (f65-74)3P,  $\alpha_{s1}$ -CN (f65-79)4P and  $\beta$ -CN (f16-25)3P is possibly due to the formation of dephosphorylated intermediate peptides such as  $\alpha_{s1}$ -CN (f64-74)3P and  $\beta$ -CN (f15-25)3P. This synergistic enzyme activity was also present in the inner part of GP. Here, the residual activity of phosphatases was very low as demonstrated by the higher number of CCPs in the GP core. This was sign of a lower enzyme activity than in the outer part of cheese form. All larger CPP such as  $\beta$ -CN (f2-25)4P,  $\beta$ -CN (f4-28)4P,  $\beta$ -CN (f1-25)4P,  $\beta$ -CN (f3-28)4P,  $\beta$ -CN (f2-28)4P,  $\beta$ -CN (f2-29)4P,  $\beta$ -CN (f1-28)4P,  $\beta$ -CN (f1-29)4P,  $\beta$ -CN (f1-32)4P,  $\alpha_{s1}$ -CN(f61-79)5P,  $\alpha_{s1}$ -CN(f63-79)5P,  $\alpha_{s2}$ -CN(f7-21)4P were absent in the outer parts of the cheese form while they occurred in the inner one. In GP made using pasteurized milk, the different peptide profile was not observed owing to the phosphatase inactivation and lower proteolytic activity. Peptides as  $\alpha_{s1}$ -CN (f65-74)3P,  $\alpha_{s1}$ -CN (f65-79)4P and  $\beta$ -CN (f16-25)3P were absent because CPP were not dephosphorylated by alkaline phosphatase (data not shown). Since indigenous ALP is fully inactivated in pasteurized milk, no gradient in free Ser depending on the unequal activity of the enzyme within the cheese form was observed and a diminutive amount of FAA was found in the core cheese form. In conclusion, the analysis of CPP of the inner and outer parts of the GP cheese form has provided some comprehensive information on the nature of the milk used in processing.



## 21. Conclusions

In conclusion, during the PhD work, a technique for selective enrichment of phosphorylated components has been developed starting from complex mixtures of proteins and peptides. The high selectivity technique of CPP enrichment based on hydroxyapatite (HA) chromatography was then transferred in semi-industrial scale for the formulation of a functional milk containing HA-CPP microgranules. HAS was synthesized by wet-chemical precipitation reactions from  $\text{Ca(OH)}_2$  and  $\text{H}_3\text{PO}_4$  to reduce production costs and 3 different protein mixtures as casein, milk proteins and raw milk were used to recover tryptic CPP. It was thus possible to use several initial raw materials for preparing the new ingredient, according to the specific industrial needs.

Once CPP were bound to the resin, the complex HAS-CPP was finely ground and added to milk. The sensory characteristics of this new formulation were compatible for milk fortification. Hence, in this PhD work, a new drink enriched with functional components of high biotechnological interest as phosphopeptides has been created. CPP preparation was useful for the treatment of dental caries and vehiculing trace elements (copper, iron, selenium, etc).

The quality of the CPP preparation was also important. The evaluation of milk quality was conducted through the study of phosphoproteome of a mastitic milk sample. In this kind of milk, the developed analytical technique revealed new phosphorylated components in a wide range of dephosphorylation due to the increased phosphatase(s) activity associated to the high somatic cells and a number of plasmin-derived casein peptides. Dephosphorylation of proteins and CPP correlated well to high SCC having a negative impact on the functionality of the bioactive peptides.

Furthermore, the study of CPP dephosphorylation in the inner and outer parts of a 15-month-old cheese has allowed to find CPP as process markers. In a milk made by raw milk, a gradient of alkaline phosphatase and protease inactivation was associated to a thermal gradient between the core and outer parts of GP, while no gradient of inactivation was evident for a cheese made by pasteurized milk. In this direction, the analytical method is suitable to provide detailed information on the evaluation of the genuineness of liquid milk and cheese. The development of such a specific strategy opens up the possibility for further application in phosphoproteomics and structure-function studies.

---

## 22. References

- <sup>1</sup> Hans Meisel 1997, *Livestock Production Science* 50, 125-138
- <sup>2</sup> Clare DA, Swaisgood HE 2000 *J Dairy Sci* 83, 1187-1195
- <sup>3</sup> Korhonen H, Pihlanto-Leppala A, Rantamaki P, Tupasela T 1998. *Trends in Food Science and Technology* 9, 307-319.
- <sup>4</sup> Hilliam M 2003. *Australian Journal of Dairy Technology* 58, 98-103.
- <sup>5</sup> Kitts DD, Weiler K 2003 *Current Pharmaceutical Design* 9, 1309-1323.
- <sup>6</sup> Latham, PW 1999. *Nature Biotechnology* 17, 755-758
- <sup>7</sup> Dziuba M, Darewicz M. 2007 *Food Science and Technology International* 13; 393-404.
- <sup>8</sup> FitzGerald RJ, Meisel H 2003. In: P.F. Fox, & P.L.H. McSweeney Eds., *Advanced dairy chemistry*, Vol. 1: Proteins (3rd ed.) 675-698.
- <sup>9</sup> Korhonen H, Pihlanto-Leppala A 2003. *Current Pharmaceutical Design* 9, 1297-1308.
- <sup>10</sup> Shimizu M 2004. *BioFactors* 21, 43-47.
- <sup>11</sup> Jollès P, Henschen A 1982. *Trends Biochem. Sci.* 7, 325-328.
- <sup>12</sup> Jollès P, Loucheux-Lefebvre MH, Henschen A 1978. *J. Mol. Evol.* 11, 271-277.
- <sup>13</sup> Fiat AM, Jollès P 1989. *Mol. Cell. Biochem.* 87, 5-30.
- <sup>14</sup> Jollès P, Levy-Toledano S, Fiat AM, Soria C, Gillesen D, Thomaidis A, Dunn FW, Caen J 1986. *European Journal of Biochemistry* 158(2), 379-382.
- <sup>15</sup> Bouhalla S, Mollè D, Leonil J 1992. *Biotechnology Letters* 14, 805-810.
- <sup>16</sup> Schlimme E, Meisel H 1995. *Die Nahrung* 39(1), 1-20.
- <sup>17</sup> Fiat AM, Migliore D, Jollès P 1993. *Journal of Dairy Science* 76(1), 301-310.
- <sup>18</sup> Chabance B, Jollès P, Izquierdo C, Mazoyer E, Francoual C, Drouet L 1995. *British Journal of Nutrition* 73(4), 583-590.
- <sup>19</sup> Ondetti MA, Rubin B, Cushman DW 1977. *Science*, 196, 441-444.
- <sup>20</sup> Fyhrquist F, Metsarinne K, Tikkanen I 1995 *J Human Hypertens*; 9 (Suppl. 5):S19-S24
- <sup>21</sup> Pihlanto-Leppälä A, Rokka T, Korhonen H 1998. *International Dairy Journal*, 8, 325-331.
- <sup>22</sup> Vermeirssen V, Van Camp J, Decroos K, Van Wijmelbeke L, Verstraete W 2003. *Journal of Dairy Science* 86(2), 429-438.
- <sup>23</sup> Maeno M, Yamamoto N, Takano T 1996. *Journal of Dairy Science* 79(8), 1316-1321.
- <sup>24</sup> Matsufuji H, Matsui T, Seki E, Osajima K, Nakashima M, Osajima Y. 1994. *Biosci Biotechnol. Biochem.* 58(12) 2244-2245.
- <sup>25</sup> Vermeirssen V, Van Camp J 2004. *Br J Nutr.* 92(3), 357-366.
- <sup>26</sup> Yamamoto N, Ejiri M, Mizuno S 2003. *Current Pharmaceutical Design* 9, 1345-1355.
- <sup>27</sup> Webb KE, Jr 1990 *J Anim Sci.* 68, 3011-3022.
- <sup>28</sup> Masuda O, Nakamura Y, Takano T. 1996. *J Nutr.* 126, 3063-3068.
- <sup>29</sup> Nakamura Y, Yamamoto N, Kumi S, Takano T 1995. *Journal of Dairy Science*, 78:1253-1257.
- <sup>30</sup> Gobbetti M, Ferranti P, Smacchi E, Goffredi F, Addeo F 2000. *Applied and Environmental Microbiology* 66, 3898-3904.
- <sup>31</sup> FitzGerald RJ, Murray BA, Walsh GJ 2004. *Journal of Nutrition* 134, 980S-988S.
- <sup>32</sup> Meisel H 1997. *Biopolymers* 43, 119-128
- <sup>33</sup> Meisel H 1997. *Livestock Production Science* 50, 125-138.
- <sup>34</sup> Rohrbach MS, Williams EB, Jr Rolstad RA 1981. *J. Biol. Chem.* 256, 225-230.
- <sup>35</sup> Cheung HS, Wang FL, Ondetti MA, Sabo EF, Cushman DW 1980. *J. Biol. Chem.* 255, 401-407.
- <sup>36</sup> Gómez-Ruiz JA, Recio I, Belloque J 2004. *J. Agric. Food Chem.* 52, 6315-6319.
- <sup>37</sup> Del Mar Contreras M, Carron R, Montero MJ, Ramos M, Recio I 2009. *International Dairy Journal* 19(10) 566-573.
- <sup>38</sup> Brantl V, Teschemacher H, Hemschem A, Lottspeich F 1979. *Hoppe Seylers Z. Physiol. Chem.* 360, 1211-1216
- <sup>39</sup> Smacchi E, Gobbetti M 2000. *Food Microbiology* 17(2), 129-141.
- <sup>40</sup> Teschemacher H, Brantl V 1994. In V. Brantl, & H. Teschemacher (Eds.),  $\beta$ -Casomorphin and related peptides: Recent developments 3-17. Weinheim, VCM, Germany
- <sup>41</sup> Meisel H, Schlimme E 1990. *Trends Food Sci. Technol.* 1, 41-43.
- <sup>42</sup> Paroli E 1988. *World Rev. Nutr. Diet* 55, 58-97.
- <sup>43</sup> Zioudrou C, Streaty RA, Klee WA 1979. *J. Biol. Chem.* 254, 2446-2449.
- <sup>44</sup> Greenberg R, Groves ML, Dower HJ 1984. *J. Biol. Chem.* 259, 5132-5138.

- <sup>45</sup> Yoshikawa M, Tani F, Shiota H, Usui H, Kurahashi K, Chiba H 1994. In V. Brantl, & H. Teschemacher (Eds.),  $\beta$ -Casomorphins and related peptides: Recent developments 43–48. Weinheim, VCH, Germany
- <sup>46</sup> Chang, KJ, Killian A, Hazum E, Cuatrecasas P 1981. *Science* 212, 75-77.
- <sup>47</sup> Mierke DF, Nobner G, Shiller PW, Goodman M 1990. *Int. J. Peptide Res.* 35, 34-45
- <sup>48</sup> Chabance B, Marteau P, Rambaud JC, Migliore-Samour D, Boynard M, Perrotin P, Guillet R, Jollès P, Fiat AM 1998. *Biochimie* 80(2), 155-165
- <sup>49</sup> Meisel H 1986. *FEBS Lett.* 196, 223-227.
- <sup>50</sup> Svedberg J, de Haas J, Leimenstoll G, Paul F, Teschemacher H 1985. *Peptides* 6, 825-830.
- <sup>51</sup> Schulte-Frohlinde E, Schimid R, Brantl V, Schusdzarra V 1994.  $\beta$ -Casomorphins and Related Peptides: Recent Developments 155-160
- <sup>52</sup> Teschemacher H, Koch G, Brantl V 1997. *Biopolymers* 43(2), 99-117.
- <sup>53</sup> Sturner RA, Chang KJ 1988. *Pediatric Research* 23, 4-10.
- <sup>54</sup> Gill HS, Doull F, Rutherford KJ, Cross ML 2000. *British Journal of Nutrition* 84(Suppl. 1), S111–S117.
- <sup>55</sup> Jollès P, Parker F, Floch F, Migliore D, Alliel P, Zerial A, Werner GH 1981. *Journal of Immunopharmacology* 3(3–4), 363–369.
- <sup>56</sup> Parker F, Migliore-Samour D, Floch F, Zerial A, Werner GH, Jollès J, Casaretto M, Zahn H, Jollès P 1984. *European Journal of Biochemistry* 145(3), 677-682.
- <sup>57</sup> Minkiewicz P, Slangen CJ, Dziuba J, Visser S, Mioduszevska H 2000. *Milchwissenschaft*, 55(1), 14-17.
- <sup>58</sup> Matar C, LeBlanc JG, Martin L, Perdigón G. 2003. In E. R. Farnworth (Ed., *Handbook of fermented functional foods. Functional foods and nutraceuticals series* 177-201.
- <sup>59</sup> Hata I, Ueda J, Otani, H 1999. *Milchwissenschaft*, 54(1), 3-7.
- <sup>60</sup> Silva SV, Malcata FX 2005. *International Dairy Journal* 15, 1-15.
- <sup>61</sup> Lahov E, Regelson W 1996. *Food and Chemical Toxicology*, 34(1), 131-145.
- <sup>62</sup> Zucht HD, Raida M, Adermann K, Magert HJ, Forssman WG 1995. *FEBS Lett.* 372, 185-188
- <sup>63</sup> Recio I, Visser S 1999. *Biochimica et Biophysica Acta*, 1428(2-3), 314-326
- McCann KB, Shiell BJ, Michalski WP, Lee A, Wan J, Roginski H 2006. *International Dairy Journal* 16, 316–323..
- <sup>65</sup> Malkoski M, Dashper SG, O'Brien-Simpson NM, Talbo GH, Macris M, Cross KJ 2001. *Antimicrobial Agents and Chemotherapy* 45, 2309-2315.
- <sup>66</sup> Matin MA, Monnai M, Otani H 2000. *Animal Science Journal* 71, 197-207.
- <sup>67</sup> Minervini F, Algaron F, Rizzello CG, Fox PF, Monnet V, Gobetti M 2003. *Applied and Environmental Microbiology* 69, 5297-5305.
- <sup>68</sup> Baranyi M, Thomas U, Pellegrini A 2003. *Journal of Dairy Research* 70, 189-197.
- <sup>69</sup> Epand RM, Vogel HJ 1999. *Biochimica et Biophysica Acta* 1462, 11-28.
- <sup>70</sup> Manso MA, López-Fandino R 2004. *Food Reviews International* 20, 329-355
- <sup>71</sup> Bezkorovainy A, Grohlich D, Nichols JH 1979. *American J. Clin.Nutri.* 32(7), 1428-1432
- <sup>72</sup> Otani H, Monnai M, Kawasaki Y, Kawakami H, Tanimoto M 1995 *Journal of Dairy Research*, Volume 62(2), 349-357
- <sup>73</sup> Guilloteau P, Le Huërou-Luron I, Chayvialle JA, Toullec R, Legeas M, Bernard C, Roger L, Mendy F 1994. *Reproduction nutrition Development* 34, 612-613.
- <sup>74</sup> Yvon M, Beucher S, Guilloteau P, Le Huerou-Luron I, Corring T 1994. *Reproduction, Nutrition & Development* 34, 527-537.
- <sup>75</sup> Stan Stan EI, Ekimovskii AP, Aleinik SI, Zhuravlev BV 1988. *Voprosy Pitaniia* 1, 39-43.
- <sup>76</sup> Fosset S, Fromentin G, Gietzen DW, Dubarry M, Huneau JF, Antoine JM 2002. *Peptides* 23, 1773-1781.
- <sup>77</sup> Chabance B, Marteau P, Rambaud JC, Migliore-Samour D, Boynard M, Perrotin P 1998. *Biochimie*, 80, 155-165.
- <sup>78</sup> Ajit V 1997. *FASEB J.*, 11, 248-255.
- <sup>79</sup> Nakajima K, Tamura N, Kobayashi-Hattori K, Yoshida T; Hara-Kudo Y; Ikedo M, Sugita-Konishi Y, Hattori M 2005. *Biosci. Biotechnol. Biochem.*, 69(12), 2294-2301.
- <sup>80</sup> Mellander O 1950. *Acta of the Society of Medicine (Uppsala)*, 55, 247-255.
- <sup>81</sup> Kasai T, Honda T, Kiriyaama S 1992. *Bioscience, Biotechnology and Biochemistry* 56, 1150-1151.
- <sup>82</sup> Chabance B, Marteau P, Rambaud JC, Migliore-Samour D, Boynard M, Perrotin P, Guillet R, Jollès P, Fiat AM 1998. *Biochimie*, 80(2), 155–166.
- <sup>83</sup> Meisel H, Bernard H, Fairweather-Tait S, FitzGerald RJ, Hartmann R, Lane CN, McDonagh D, Teucher B, Wal JM 2003. *British Journal of Nutrition* 89(3), 351-359.

- <sup>84</sup> Meisel H, Frister H 1989. *J. Dairy Sci.* 56, 343-349.
- <sup>85</sup> Meisel H. 1998. *International Dairy Journal* 8(5-6), 363-373.
- <sup>86</sup> Meisel H, Olieman C 1998. *Anal. Chim. Acta* 372, 291-297.
- <sup>87</sup> Meisel H 1997. *Biopolymers* 43(2), 119-128.
- <sup>88</sup> Sato R, Naguchi T, Naito H 1986. *Journal of Nutritional Science and Vitaminology*, 32(1), 67-76.
- <sup>89</sup> FitzGerald RJ 1998. *Int. Dairy J.* 8, 451-457.
- <sup>90</sup> Kitts DD, Yuan YV 1992 Caseinophosphopeptides and calcium bioavailability. *Trends Food Sci. Technol.* 3: 31-35
- <sup>91</sup> Ferraretto A, Signorile A, Gravaghi C, Fiorilli A 2001. *Journal of Nutrition* 131(6), 1655-1661.
- <sup>92</sup> Ferraretto A, Gravaghi C, Fiorilli A, Tettamanti G 2003. *FEBS Letters*, 551(1-3), 92-98.
- <sup>93</sup> Cross KJ, Huq NL, Bicknell W, Reynolds EC 2001 *Biochem. J.* 356, 277-286.
- <sup>94</sup> Huq NL, Cross KJ, Reynolds EC 1995 *Biochim. Biophys. Acta* 1247, 201-208
- <sup>95</sup> Bernard H, Meisel H, Creminon C, Wal JM 2000. *FEBS Lett.* 467, 239-244.
- <sup>96</sup> Ferraretto A, Gravaghi C, Fiorilli A, Tettamanti G 2003. *FEBS Letters*, 551(1-3), 92-98.
- <sup>97</sup> Farrell Jr., HM Qi PX, Wickham ED, Unruh JJ 2002. *J. Protein Chem.* 21, 307-321.
- <sup>98</sup> Cosentino S, Gravaghia C, Donetti E., Donida BM, Lombardi G, Bedonic M, Fiorilli A, Tettamanti G, Ferraretto A 2009. *Journal of Nutritional Biochemistry* article in press.
- <sup>99</sup> Ait-Oukhtar N, Bouhalla S, Arhan P, Maubois JL, Drosdowsky M, Bougle D 1999. *Journal of Agricultural and Food Chemistry*, 47(7), 2786-2790.
- <sup>100</sup> Peres JM, Bouhalla S, Petit C, Bureau F, Maubois JL, Arhan P, Bougle D 1998. *Reproduction, Nutrition & Development* 38(4), 465-472.
- <sup>101</sup> Holt C, Wahlgren NM, Drakenberg T 1996. *Biochem. J.* 314, 1035-1039.
- <sup>102</sup> Holt C, Timmins PA, Errington N, Leaver J 1998. *Eur. J. Biochem.* 252, 73-78.
- <sup>103</sup> Reynolds EC, Black CL, Cai F, Cross KJ, Eakins D, Huq NL 1999. *J Clin Dent* X(2):86-88.
- <sup>104</sup> Reynolds EC 2009. *Advances in Dental Research* 21; 25-29.
- <sup>105</sup> Reynolds EC, Cai F, Shen P, Walker GD 2003. *J Dent Res* 82, 206-211.
- <sup>106</sup> Rose RK 2000. *Caries Res* 34, 427-431.
- <sup>107</sup> Rose RK 2000. *Arch Oral Biol* 45, 569-575.
- <sup>108</sup> Shaw JH, Ensfield BJ, Wollman DH 1959. *J. Nutr.* 67, 253-273.
- <sup>109</sup> Papas AS, Joshi A, Belanger AJ, Kent RL, Palmer CA, DePaola PF 1995. *Am. J. Clin. Nutr.* 61, 417S-422S.
- <sup>110</sup> Rasić JL, Kurmann JA 1983. *Experientia Suppl.* 39, 1-295.
- <sup>111</sup> Ferrazzano GF, Cantile T, Quarto M, Ingenito A, Chianese L, Addeo F 2008. *Australian Dental Journal* 53, 314-319.
- <sup>112</sup> Donida BM, Mrak E, Gravaghi C, Villa I, Cosentino S, Zacchi E, Perego S, Rubinacci A, Fiorilli A, Tettamanti G, Ferraretto A 2009. Peptides article in press.
- <sup>113</sup> Scholz-Ahrens KE, Schrezenmeir J 2000. *British Journal of Nutrition*, 84, S147-S153.
- <sup>114</sup> Grenby, TH, Andrews AT, Mistry, M, Williams, RJH 2001. *Journal of Dentistry*, 29, 83-92.
- <sup>115</sup> Reynolds EC, Cai F, Shen P, Walker GD. 2003. *J Dent Res.* 82, 206-211.
- <sup>116</sup> Iijima Y, Cai F, Shen P, Walker G, Reynolds C, Reynolds EC. 2004. *Caries Res.* 38, 551-556.
- <sup>117</sup> Luo SJ, Wong LL 2000. *International Patent Application* No. PCT/US00/02142.
- <sup>118</sup> Craig AG, Hoeger CA, Miller CL, Goedken T, Rivier JE, Fischer WH. 1994. *Biol Mass Spectrom* 23, 519-528.
- <sup>119</sup> Krause E, Wenschuh H, Jungblut PR 1999. *Anal Chem* 71, 4160-4165.
- <sup>120</sup> Manson W, Annan WD 1971. *Archives of Biochemistry and Biophysics* 145, 16-26.
- <sup>121</sup> Gygi SP, Corthals GL, Zhang Y, Rochon Y, Aebersold R 2000. *PNAS*, 97(17), 9390-9395.
- <sup>122</sup> Oda Y, Nagasu T, Chait, BT 2001. *Nat. Biotechnol.* 19, 379-382.
- <sup>123</sup> Zhou H, Watts, JD, Aebersold R 2001. *Nat. Biotechnol.* 19, 375-378.
- <sup>124</sup> Posewitz MC, Tempst P 1999. *Anal. Chem.* 71, 2883-2892.
- <sup>125</sup> Kokubu M, Ishihama Y, Sato T, Nagasu T, Oda Y 2005. *Anal. Chem.* 77, 5144-5154.
- <sup>126</sup> Moser K, White FM 2006 *J. Proteome Res.* 5, 98-104.
- <sup>127</sup> Pinkse MW, Uitto PM, Hilhorst MJ, Ooms B, Heck AJ 2004. *Anal. Chem.* 76, 3935-3943.
- <sup>128</sup> Rinalducci, S.; Larsen, M. R.; Mohammed, S.; Zolla, L. 2006. *J. Proteome Res.* 5, 973-982.
- <sup>129</sup> Thingholm TE, Jorgensen TJ, Jensen ON, Larsen MR 2006. *Nat Protoc.* 1 (4), 1929-1935.
- <sup>130</sup> Larsen MR, Thingholm TE., Jensen ON, Roepstorff P, Jorgensen TJD 2005. *Mol. Cell. Proteomics* 4, 873-886.
- <sup>131</sup> Bodenmiller B, Mueller LN, Mueller M, Domon B, Aebersold R 2007. *Nat. Methods* 4, 231-237.
- <sup>132</sup> Sugiyama N, Masuda T, Shinoda K, Nakamura A, Tomita M, Ishihama Y 2007. *Mol. Cell. Proteomics* 6 (6), 1103-1109.

- 133 Zhang X, Ye J, Jensen ON, Roepstorff P 2007. *Mol. Cell. Proteomics* 6(11), 2032-2042.
- 134 Guanghui Han G, Ye M, Zou H 2008. *Analyst* 133, 1128-1138.
- 135 Schmidt SR, Schweikart F, Andersson ME 2007. *Journal of Chrom. B* 849, 154-162.
- 136 Kawasaki T 1991. *J Chromatogr.* 544, 147-184.
- 137 Tashima Y, Terui M, Itoh H, Mizunuma H, Kobayashi R, Marumo F 1990. *J. Biochem.* 108 (2) 271-217.
- 138 Zhang X, Shi L, Shu S, Wang Y, Zhao K, Xu N, Liu S, Roepstorff P 2007. *Proteomics* 7, 2340-2349.
- 139 Kjellstrom S, Jensen ON 2004. *Anal. Chem.* 76, 5109-5117.
- 140 Suchanek W, Yoshimura MJ 1998. *Mater. Res.* 13, 94-117.
- 141 Chai CS, Ben-Nissan, B 1999. *J Mater. Sci. Mater. Med.* 10, 465-469.
- 142 Xu Y, Wang D, Yang L, Tang H 2001. *Mater. Charact.* 47, 83-87.
- 143 Yadav KL, Brown PW 2003. *J. Biomed. Mater. Res.* 65A, 158-163.
- 144 Asaoka N, Best S, Knowles JC, Bonfield W 1995. *Bioceramics* 8, 331-337.
- 145 Kumar R, Prakash KH, Cheang P, Khor KA 2004. *Langmuir* 20, 5196-5200.
- 146 Jha LJ, Best SM, Knowles JC, Rehman I, Santos JD, Bonfield W 1997. *Journal of materials science: materials in medicine* 8, 185-191.
- 147 Walker G, Cai F, Shen P 2006. *J Dairy Res.* 73, 74-78.
- 148 Walker GD, Cai F, Shen P, Bailey DL, Yuan Y, Cochrane NJ, Reynolds C, Reynolds EC 2009. *Australian Dental Journal* 54, 245-249.
- 149 Kazmaier T, Roth S, Zapp J, Harding M, Kuhn R 1998. *Fres. J. Anal. Chem.* 361, 473-478.
- 150 Gusev AI, Wilkinson WR, Proctor A, Hercules DM 1993. *Appl. Spectrosc.* 47(8), 1091-1092.
- 151 Wilkinson WR, Gusev AI, Proctor A, Houalla M, Hercules DM 1997. *J. Anal Chem.* 357, 241-248.
- 152 Tang K, Allman SL, Jones RB, Chen CH 1993. *Anal. Chem.* 65, 2164-2166.
- 153 Boyd RK 1993 *Rapid Commun Mass Spectrom.* 7, 257-271.
- 154 Kang MJ, Tholey A, Heinzle E. 2001. *Rapid Commun Mass Spectrom.* 15, 1327-1333.
- 155 Bungert D, Heinzle E, Tholey A 2004. *Anal Biochem.* 326, 167-175.
- 156 Helmke SM, Yen CY, Cios KJ, Nunley K, Bristow MR, Duncan MW, Perryman MB 2004. *Anal. Chem.* 76 1683-1689.
- 157 Jespersen S, Niessen, WMA, Tjaden, UR, van der Greef J 1995 *J. Mass Spectrom.* 30, 357-364.
- 158 Bucknall M, Fung KY, Duncan MW 2002. *J. Am. Soc. Mass Spectrom.* 13, 1015-1027.
- 159 Sordillo LM, Shafer-Weaver K, DeRosa D 1997. *Journal of Dairy Science* 80, 1851-1865.
- 160 Azzara CD, Dimick PS 1985 *Journal of Dairy Science* 68, 3171-3175.
- 161 Politi I, Lachance E, Block E, Turner JD 1989. *Journal of Dairy Science* 72, 900-906.
- 162 Heegaard CW, Christensen T, Rasmussen MD, Benfeldt C, Jensen NE, Sejrsen K, Petersen TE, Andreasen PA 1994. *Fibrinolysis* 8, 22-30.
- 163 Le Roux Y, Girardet JM, Humbert G, Laurent F, Linden G 1995 *J Dairy Sci* 78, 1298-1305.
- 164 Larsen LB, McSweeney PLH, Hayes MG, Andersen JB, Ingvarsen KL, Kelly AL 2006. *International Dairy Journal* 16, 1-8.
- 165 Travis J 1988. *The American Journal of Medicine* 84(6A) 37-42.
- 166 Considine T, Healy A, Kelly AL, McSweeney PLH 1999. *Food Chemistry* 66, 463-470.
- 167 Considine T, Healy A, Kelly AL, McSweeney PLH 2000. *Food Chemistry* 69 19-26.
- 168 Considine T, Geary S, Kelly AL, McSweeney PLH 2002. *Food Chemistry* 76, 59-67.
- 169 Baggiolini M, Bretz U, Dewald B 1978. In K. Havemann, A. Janoff (Eds., Neutral proteases of human polymorphonuclear leucocytes. 3-17. Baltimore, MD: Urban and Schwarzenburg Inc).
- 170 Babaei H, Mansouri-Najand L, Molaei MM, Kheradmand A, Sharifan M 2007. *Veterinary Research Communications* 31, 419-425.
- 171 Muir DD, Griffiths WM, Phillips JD, Sweetsur AWM, West IG 1986. *J. Soc. Dairy Technol.* 39, 115-118.
- 172 Fox PF, Kelly AL 2006. *Int. Dairy J.* 16, 500-516.
- 173 Mamone G, Cairra S, Garro G, Nicolai A, Ferranti P, Picariello G, Malorni A, Chianese L, Addeo F 2003. *Electrophoresis* 24, 2824-2837
- 174 Fox PF 2002. In: Roginski H, Fuquay JW, Fox PF (eds, *Encyclopedia of Dairy Sciences*, 252-268. Academic Press, London).
- 175 Akuzawa R, Fox PF 2004. *Animal Science Journal* 75, 385-391.
- 176 De Noni I, Pellegrino L, Resmini P, Ferranti P 1997. *Nahrung* 41(5), S268 -273.
- 177 Pellegrino L, Battelli G, Resmini P, Ferranti P, Barone F, Addeo F 1997 *Lait* 77, 217-228.
- 178 Kaminogawa S, Mizobuchi H, Yamauchi K 1972 *Agric Biol. Chem.* 36, 2163-2167.

- 
- <sup>179</sup> Resmini P, Hogenboom JA, Pazzaglia C, Pellegrino L 1993. *Scienza e Tecnica Lattiero-Casearia* 44, 7-19.
- <sup>180</sup> Ferranti P, Barone F, Chianese L, Addeo F, Scaloni A, Pellegrino L, Resmini P 1997. *Journal of Dairy Research* 64, 601-615.

---

*Ringrazio di cuore il Prof. Addeo per avermi affettuosamente accolta nel suo gruppo di ricerca e per il suo prezioso apporto scientifico. Un grazie per il per il supporto sperimentale e didattico alle dottoresse con cui ho lavorato ed in particolare modo a Simonetta Caira, Marina Cuollo, Letizia Petrucci, Sabrina De pascale e Maria Adalgisa Nicolai. Infine, ringrazio la Dott.ssa Olga Fierro e il dott. G. Picariello dell'ISA (CNR Avellino) per la loro disponibilità e il loro sostegno scientifico.*

---

## **Publications**

1. Caputo R, Capone S, Della Greca M, Longobardo L, Pinto G.  
Novel selenium-containing non-natural diamino acids (2007).  
Tetrahedron Letters 48, 1425–1427.
2. Caputo R, Capone S, Della Greca M, Longobardo L, Pinto G.  
Chiral Aminoalkyl Cation Equivalents. Part 2. Novel Selenium-Containing Non-Natural Diamino Acids (2007).  
ChemInform 38, (22).



# Novel selenium-containing non-natural diamino acids<sup>☆</sup>

Romualdo Caputo,<sup>\*</sup> Stefania Capone,<sup>†</sup> Marina Della Greca,  
Luigi Longobardo and Gabriella Pinto

*Dipartimento di Chimica Organica e Biochimica, Università di Napoli Federico II, Via Cynthia 4, I-80126 Napoli, Italy*

Received 21 November 2006; revised 12 December 2006; accepted 15 December 2006

Available online 20 December 2006


**Abstract**—The general synthesis of a new class of non-natural diamino acids, 2-amino-3-[(2'-aminoalkyl)seleno]propanoic acids, or Se-(aminoalkyl)selenocysteines, is reported. Under the conditions devised, enantiopure *N*-Boc-protected β-L-iodoamines, which are readily generated from proteinogenic α-amino acids, were treated with the selenolate anion obtained from NaBH<sub>4</sub> splitting of the Se–Se bond in commercial L-selenocystine. The Se-alkylation products were enantiomerically pure and the reaction is high yielding (92–98%), without any detectable traces of accompanying by-products.  
© 2007 Elsevier Ltd. All rights reserved.

Selenium is an essential micronutrient for animals and humans: to date, its bio-availability seems to depend upon the naturally occurring selenium-containing amino acids selenocysteine (Sec) and selenomethionine, although other selenoamino acids, such as Se-methyl-selenocysteine, selenohomocysteine and selenocystathionine, are also involved in selenoamino acid metabolic pathways.<sup>1</sup>

In recent years, organoselenium chemistry has emerged as an exceptional class of structures, due to its pivotal role in the synthesis of a large number of biological compounds and important therapeutic products ranging from antiviral and anticancer agents to naturally occurring food supplements.<sup>2</sup>

Simple organochalcogenide compounds have been reported to display antioxidant activity *in vitro* and *in vivo*. It has been suggested that the exploitation of the redox activity of selenium, as in the case of tellurium, could provide antioxidants of considerable potency, which would be suitable tools in free radical biology, as the scavengers of reactive oxidizing agents.<sup>3</sup>

Exciting areas of research using chiral organoselenium compounds also include catalytic asymmetric reactions to provide enantiomerically enriched compounds, representing a new trend in this field of organometallic chemistry. In this context, chiral selenide- and diselenide-containing ligands have been employed as useful catalysts in various asymmetric transformations including enantioselective addition of diethylzinc to aldehydes,<sup>4,5</sup> the 1,4-addition of Grignard reagents to enones,<sup>6</sup> and palladium-catalyzed asymmetric allylic substitution.<sup>7</sup>



Here we report the synthesis of new enantiopure non-natural diamino acids (**1**) containing selenium. They represent a new family of chalcogenide diamino acids paralleling their sulfurated analogues that we have recently reported.<sup>8</sup> The interest of both classes of such novel non-natural diamino acids depends essentially upon their structural similarities with natural *meso*-lanthionine (**2a**), key-residue of lanthibiotic peptides and *meso*-selenolanthionine (**2b**), respectively. Even more interesting is their inclusion in peptides<sup>8</sup> that performs formal ‘bioconjugation’ processes,<sup>9,10</sup> mimicking the results of the alkylation, by proteinogenic α-amino acid moieties, at the chalcogen atom of selenocysteines (Sec), or cysteines (Cys) already present in peptide

**Keywords:** Organoselenium; Selenolanthionine; Selenocystine; β-Iodoamines; Diamino acids.

<sup>☆</sup> Chiral aminoalkyl cation equivalents, 2.

<sup>\*</sup> Corresponding author. Tel.: +39 081 674117; fax: +39 081 674 102; e-mail: rocaputo@unina.it

<sup>†</sup> Present address: Laboratorium für Organische Chemie, ETH Zürich, HCI Hönggerberg, Wolfgang-Pauli-Strasse 10, CH-8093 Zürich, Switzerland.

chains. An illustrative example of the use of *N*(Boc)- $\beta$ -iodoamines, obtained from aspartic and glutamic acids, to alkylate a pre-existing cysteine in a solid-phase growing peptide was already reported.<sup>11</sup>

The synthesis of compounds **4a–c** (Scheme 1) was accomplished in a very simple, clean and high yielding synthetic route starting from commercial L-selenocystine and *N*(Boc)- $\beta$ -L-iodoamines as Se-alkylation species. The procedure reported for the synthesis of their sulfur-containing analogues<sup>8</sup> could not be adapted, due to the high tendency of L-selenocystine to undergo oxidation. Hence, L-selenocystine was refluxed with NaBH<sub>4</sub> in dry EtOH, under argon atmosphere, to produce in situ (*R*)-2-amino-2-carboxyethaneselenolate anion. The formation of the latter could be observed by the disappearance of the initial intense yellow colour of selenocystine ethanolic solution.<sup>12</sup> The corresponding<sup>13,14</sup> *N*(Boc)- $\beta$ -L-iodoamine **3a–c** (obtained from Phe, Pro and Val, respectively) was then added to the solution to alkylate the anion and after refluxing the reaction mixture for a few more minutes, the Boc mono-protected selenodiamino acids **4a–c** were observed as sole products (TLC, LC–MS). Attempts to use cystine under the same conditions to prepare sulfur analogues of **4a–c** were disappointing, due to the poorest reaction yields.


Diamino acids **4a–c** were not isolated as such,<sup>15</sup> but were converted into N,N-protected compounds, ready for peptide coupling, bearing either a second Boc group (**5a–c**) or orthogonal Boc/Fmoc (**6a–c**) protection (Scheme 1).

We propose for any of these new chalcogen-containing diamino acids an acronym to avoid cumbersome systematic names in the current laboratory practice and in order to readily recognize their presence in peptide sequences as well. The proposed acronym is composed of 'Se' (from 'Sec') [as well as 'Cy' (from 'Cys') for the terms containing the sulfur atom] and the italicized 'one-letter code' denoting the  $\alpha$ -amino acid whose side chain (R in formula **3** and others therefrom) is present in it. Accordingly, the selenodiamino acids reported in this Letter are shown in Table 1 with their acronyms and the whole family should be referred to as 'SeX' fam-

ily [as well as 'CyX' family for the sulfur-containing terms].


The stereochemical integrity of the final products was assessed by RP-HPLC, <sup>1</sup>H and <sup>13</sup>C NMR.

Selenium nucleophiles have been reported<sup>16</sup> to react with aziridines that act as chiral aminoalkyl cation equivalents. In our experience, chiral  $\beta$ -iodoamines appear to be strongly competitive with aziridines: as an illustrative example, we obtained almost quantitative formation of (*S*)-*tert*-butyl 1-phenyl-3-(phenylselenenyl)propan-2-ylcarbamate (**7**), in only a few minutes using the protected  $\beta$ -iodoamine **3a**, from *N*(Boc)-L-phenylalanine, and benzeneselenolate anion generated in situ from diphenyl diselenide and NaBH<sub>4</sub> in refluxing EtOH. The same product had been reported<sup>17</sup> to be formed in 24 h, 72% yield, using the same benzeneselenolate anion and *N*(Boc)-aziridine from *N*(Boc)-L-phenylalanine.



In conclusion, these new, non-natural selenylated diamino acids can be obtained enantiopure, in good yields and if required, in orthogonally protected forms ready for insertion into peptide sequences. The synthesis is very simple and the starting materials are generally inexpensive and easily accessible as well. All the mentioned observations highlight the synthetic value of the enantiomerically pure *N*(Boc)- $\beta$ -iodoamines as aminoalkyl cation equivalents.

It is also worth noting that the lysine-like configuration of our diamino acids, associated with a proteinogenic side chain, prompts their exploitation as branching diamino acids to build up chalcogen-containing peptide-bond based new dendrimeric structures. Work is already in progress in our lab to produce enzyme-mimicking dendrimeric scaffolds including proteinogenic  $\alpha$ -amino



**Scheme 1.** Synthesis of N,N-protected SeX diamino acids from L-selenocystine and  $\beta$ -L-iodoamines.

**Table 1.** New N,N-protected SeX diamino acids

N(Boc)- $\beta$ -L-Iodoamine	SeX diamino acid	Yield <sup>a</sup> (%)	Mp (°C)	$[\alpha]_D^{25}$ (CHCl <sub>3</sub> )
<b>3a</b>	Boc–SeF(Boc)–OH ( <b>5a</b> )	98	132–133	45.1
<b>3a</b>	Fmoc–SeF(Boc)–OH ( <b>6a</b> )	95	138–139	40.2
<b>3b</b>	Boc–SeP(Boc)–OH ( <b>5b</b> )	92	Foam	23.8
<b>3b</b>	Fmoc–SeP(Boc)–OH ( <b>6b</b> )	94	97–98	31.3
<b>3c</b>	Boc–SeV(Boc)–OH ( <b>5c</b> )	97	Foam	35.7
<b>3c</b>	Fmoc–SeV(Boc)–OH ( <b>6c</b> )	95	88–89	38.5

<sup>a</sup> Yield of diprotected selenodiamino acid, referred to the starting  $\beta$ -iodoamine.

acids, such as Ser, His and Asp, that are commonly involved in the enzymatic active sites.<sup>18</sup>

## References and notes

1. *Kyoto Encyclopedia of Genes and Genomes*, KEGG, Release 40.0, October 2006. <<http://www.genome.jp/kegg/>>.
2. (a) Mughesh, G.; du Mont, W.-W.; Sies, H. *Chem. Rev.* **2001**, *101*, 2125–2180; (b) Nogueira, C. W.; Zeni, G.; Rocha, J. B. T. *Chem. Rev.* **2004**, *104*, 6255–6286.
3. Rossato, J. I.; Ketzer, L. A.; Centurião, F. B.; Silva, S. J. N.; Lüdtke, D. S.; Zeni, G.; Braga, A. L.; Rubin, M. A.; Rocha, J. B. T. *Neurochem. Res.* **2002**, *27*, 297–303.
4. (a) Wirth, T. *Tetrahedron Lett.* **1995**, *36*, 7849–7852; (b) Wirth, T.; Kulieke, K. J.; Fragale, G. *Helv. Chim. Acta* **1996**, *79*, 1957–1966; (c) Santi, C.; Wirth, T. *Tetrahedron: Asymmetry* **1999**, *10*, 1019–1023.
5. Braga, A. L.; Paixão, M. W.; Lüdtke, D. S.; Silveira, C. C.; Rodrigues, O. E. D. *Org. Lett.* **2003**, *5*, 2635–2638.
6. Braga, A. L.; Silva, S. J. N.; Lüdtke, D. S.; Drekenner, R. L.; Silveira, C. C.; Rocha, J. B. T.; Wessjohann, L. A. *Tetrahedron Lett.* **2002**, *43*, 7329–7331.
7. Braga, A. L.; Paixão, M. W.; Marin, G. *Synlett* **2005**, *11*, 1675–1678.
8. Bolognese, A.; Fierro, O.; Guarino, D.; Longobardo, L.; Caputo, R. *Eur. J. Org. Chem.* **2006**, 167–173.
9. Davis, B. G. *Curr. Opin. Biotechnol.* **2003**, *14*, 379–386.
10. Qi, D. F.; Tann, C. M.; Haring, D.; Distefano, M. D. *Chem. Rev.* **2001**, *101*, 3081–3112.
11. Campiglia, P.; Gomez-Monterrey, I.; Longobardo, L.; Lama, T.; Novellino, E.; Grieco, P. *Tetrahedron Lett.* **2004**, *45*, 1453–1456.
12. Block, E.; Birringer, M.; Jiang, W.; Nakaodo, T.; Thompson, H. J.; Toscano, P. J.; Uzar, H.; Zhang, X.; Zhu, Z. *J. Agric. Food Chem.* **2001**, *49*, 458–470.
13. Caputo, R.; Cassano, E.; Longobardo, L.; Palumbo, G. *Tetrahedron Lett.* **1995**, *36*, 167–168.
14. Caputo, R.; Cassano, E.; Longobardo, L.; Palumbo, G. *Tetrahedron* **1995**, *51*, 12337–12550.
15. Commercial L-selenocystine (0.3 g, 1 mmol) was suspended in anhydrous EtOH (10 mL) under argon atmosphere. Solid NaBH<sub>4</sub> (0.2 g, 5 mmol) was added in one portion and the mixture refluxed for 5 min, until clear and colourless. *tert*-Butyl (S)-1-iodo-3-methylbutan-2-ylcarbamate **3c** (0.6 g, 2 mmol) dissolved in anhydrous THF (4 mL) was then added. After 10 min under reflux, the reaction mixture was cooled to room temperature and split in two portions. The first one, after evaporation of the solvents under vacuum, was redissolved in THF (10 mL) and treated with FmocOSu (0.3 g, 1 mmol) under standard conditions to afford eventually (R)-2-[(9H-fluoren-9-yl-methoxy]carbonylamino-3-[(S)-2-(*tert*-butoxycarbonylamino)-3-methylbutylselenyl]propanoic acid, Fmoc–SeV(Boc)–OH (**6c**), (96%). An analytical sample: mp 88–89 °C (from CH<sub>2</sub>Cl<sub>2</sub>–hexane),  $[\alpha]_D^{25}$  +38.5 (c 1.0, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD, *J* in Hz):  $\delta$  = 0.87 (d, 3H, *J* = 6.8), 0.90 (d, 3H, *J* = 6.8), 1.44 (s, 9H), 1.77 (dq, 1H, *J* = 6.8), 2.67 (dd, 1H, *J* = 9.3 and 12.2), 2.82 (dd, 1H, *J* = 4.4 and 12.2), 2.97 (dd, 1H, *J* = 7.8 and 12.7), 3.03 (dd, 1H, *J* = 4.9 and 12.7), 3.50 (m, 1H), 4.25 (t, 1H, *J* = 6.8), 4.34 (m, 2H), 4.44 (m, 1H), 7.31 (t, 2H, *J* = 7.8), 7.39 (t, 2H, *J* = 7.8), 7.69 (d, 2H, *J* = 7.8), 7.79 (d, 2H, *J* = 7.8); <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD):  $\delta$  = 18.8, 20.5, 27.0, 29.3, 29.9, 33.9, 48.7, 56.3, 58.0, 68.7, 80.4, 121.4, 126.8, 128.6, 129.3, 142.9, 145.6, 158.8, 174.6. HR-MS (EI): calcd for C<sub>28</sub>H<sub>36</sub>N<sub>2</sub>O<sub>6</sub>Se [M+H<sup>+</sup>] 576.5626, found 576.5630.
16. The second portion, after evaporation of the solvents under vacuum, was also redissolved in THF (10 mL) and treated with Boc<sub>2</sub>O (0.2 g, 1 mmol) under standard conditions to afford (R)-2-(*tert*-butoxycarbonylamino)-3-[(S)-2-(*tert*-butoxycarbonylamino)-3-methylbutylselenyl]propanoic acid, Boc–SeV(Boc)–OH (**5c**) (97%). An analytical sample: foam,  $[\alpha]_D^{25}$  +35.7 (c 1.6, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD, *J* in Hz):  $\delta$  = 0.89 (d, 3H, *J* = 6.8), 0.92 (d, 3H, *J* = 6.8), 1.45 (s, 18H), 1.78 (dq, 1H, *J* = 6.8), 2.65 (dd, 1H, *J* = 12.7 and 8.9), 2.83 (dd, 1H, *J* = 12.7 and 3.9), 2.93 (dd, 1H, *J* = 12.7 and 6.8), 3.0 (dd, 1H, *J* = 12.7 and 4.9), 3.50 (m, 1H), 4.37 (br t, 1H); <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD):  $\delta$  = 18.7, 20.5, 27.1, 29.3, 29.7, 34.0, 58.5, 80.3, 81.2, 158.2, 158.9, 174.5. HR-MS (EI): calcd for C<sub>18</sub>H<sub>34</sub>N<sub>2</sub>O<sub>6</sub>Se [M+H<sup>+</sup>] 454.4397, found 454.4402.
17. (a) Braga, A. L.; Lüdtke, D. S.; Paixão, M. W.; Alberto, E. E.; Stefani, H. A.; Juliano, L. *Eur. J. Org. Chem.* **2005**, 4260–4264; (b) Braga, A. L.; Schneider, P. H.; Paixão, M. W.; Deobald, A. M.; Peppe, C.; Bottega, D. P. *J. Org. Chem.* **2006**, *71*, 4305–4307.
18. Mp 81–82 °C (from Et<sub>2</sub>O–hexane),  $[\alpha]_D^{25}$  15.5 (c 1.0, CH<sub>2</sub>Cl<sub>2</sub>); lit.<sup>16</sup> <sup>1</sup>H NMR spectrum consistent with the structure; mp 80.7–81.3 °C,  $[\alpha]_D^{25}$  14.
19. Darbre, T.; Reymond, J.-L. *Acc. Chem. Res.* **2006**, *39*, 925–934.